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GENERAL INTRODUCTION
The lysosomal enzyme acid α-glucosidase (GAA), also called acid maltase, is responsible 
for the breakdown of the intra-lysosomal glycogen into glucose, which represents 
approximately 10-15% of the cellular glycogen content [1]–[3]. Pompe disease (OMIM 
232300), also known as glycogen storage disease type II, is an inborn error of metabolism 
caused by the deficiency of GAA and is transmitted in an autosomal recessive manner. 
The GAA gene is considered to be a housekeeping gene since it is expressed in every cell 
type [4]. However, skeletal and cardiac muscles are mainly affected. Disease-associated 
variants in the GAA can lead to dysfunctional or absent GAA production causing excessive 
glycogen accumulation within lysosomes resulting in structural damage of cells and tissues 
[5]–[8].
CLINICAL FORMS
The primary Pompe disease classification was based on the age at start of symptoms, 
and/or the presence of cardiomyopathy. The classic infantile form is characterized by age 
at symptom onset before 1 year old and the presence of hypertrophic cardiomyopathy 
(cardiomegaly). The non-classic forms may start at any age [9]. In most of these cases, 
the heart is not involved. Based on the age of symptom onset, further subdivisions have 
been made in childhood and adult Pompe disease, but in fact the disease presents as a 
continuous spectrum [7], [10], [11]. In general, early onset of symptoms precludes a more 
severe form of disease. Due to the deficiency of GAA in Pompe disease, the initial idea 
was to treat the disease by administering functional GAA intravenously, known as enzyme 
replacement therapy (ERT) [12]. The clinical trials of ERT with recombinant human GAA 
(rhGAA) in classic infantile Pompe patients showed improvement on survival for these 
patients [13], [14]. In 2006, the first treatment of Pompe disease with ERT was approved by 
the Food and Drug Administration (FDA). ERT results in substantial clinical improvement 
for classic infantile patients, eliminating the cardiac symptoms and improving the motor 
function [13], [15]. The features of classic infantile, childhood and adult Pompe disease are 
described below.
Classic infantile Pompe disease
Patients with the classic infantile form, the most severe type of the disease develop 
symptoms within the first months of life. They completely lack GAA enzyme activity. Classic 
infantile patients can be further subdivided into two groups: patients that do not produce 
any GAA protein so called cross- reactive immunological material (CRIM) negative patients 
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and patients who produce catalytically inactive GAA so called CRIM positive patients [16], 
[17]. CRIM negative patients have a higher likelihood of forming anti-rhGAA antibodies 
when treated with ERT since their immune system does not recognize the GAA protein. 
The primary phenotypic features of classic infantile patients are progressive general muscle 
weakness (floppy baby appearance) and hypertrophic cardiomyopathy. When patients do 
not receive ERT, they will die within the first year of life due to cardiorespiratory failure [18]. 
Additional common symptoms of untreated infants are feeding problems, failure to thrive, 
and respiratory problems including airway infections and respiratory insufficiency [19]. Early 
postmortem studies have shown that glycogen storage in infants is not limited to muscle. 
The glycogen stores in other organs and tissues as well, such as in the nervous system 
[20], [21]. 
Childhood and Adult Pompe disease
Patients with the childhood form of the disease experience the first symptoms from early 
infancy (some patients within the first 6 months of life) up to 16 years of age, but mostly 
without developing progressive hypertrophic cardiomyopathy. They show some residual 
GAA enzymatic activity, and the disease progression is slower than in classic infantile 
Pompe disease. Childhood patients present with a slowly progressive proximal skeletal 
muscle weakness (limb-girdle weakness). This leads to mobility problems and children often 
show delayed motor development [22], [23]. Other features related to muscle weakness are 
scapular winging, scoliosis and increased lumbar lordosis [24]. The respiratory muscles 
are also affected, which may cause respiratory complications and may also contribute to 
the fatigue that most patients experience. Without treatment, the life expectancy of these 
children is variable. They can survive from several years to several decades [25]. In a 
long-term follow-up study of 17 childhood patients, ERT had a positive effect by increasing 
muscle strength and stabilizing muscle function. However, the effects on lung function were 
more variable [26].
Patients with adult onset Pompe disease usually present with slowly progressive 
proximal myopathy and/or reduced pulmonary function [22], [27]. Cardiac involvement is 
rarely seen [28]. As in childhood Pompe disease, the respiratory muscles, in particular the 
diaphragm, are involved. This results in reduced pulmonary function and hypoventilation 
especially when patients are in supine position. Most patients ultimately require mechanical 
ventilation [29]. Respiratory insufficiency is the leading cause of death [30]. Adult patients 
can benefit from ERT. In a placebo controlled multicenter trial, ERT was shown to improve 
walking distance (assessed by the six-minute walk test) and to stabilize lung function. 
Further studies have shown that ERT changes the natural course when it comes to loss of 
pulmonary function and muscle strength [31]–[34]. 
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DISEASE PATHOLOGY
For understanding the pathology of Pompe disease it is easiest to start with explaining 
the function and processing of GAA. GAA is co-translationally imported in the endoplasmic 
reticulum (ER), folded and glycosylated, whereafter it is transported through the Golgi 
complex en route to the lysosomes. Phosphorylation of mannose residues provides the 
mannose 6-phosphate (M6P) recognition marker and directs transport to the lysosomes by 
binding to M6P-receptors in the trans Golgi network. Once GAA is inside the lysosome, it 
degrades lysosomal glycogen to glucose.
Lysosomes accumulate glycogen through autophagy. The autophagosome 
envelops cytoplasmic material, which contains glycogen, after which it fuses with the 
lysosome. Deficiency of GAA causes accumulation of glycogen in lysosomes since glycogen 
cannot cross the lysosomal membrane. Cellular pathology is mainly seen in muscle tissue 
but can be seen in other tissue as well [35], [36]. Glycogen accumulation increases the 
size and number of lysosomes. The increase of size causes susceptibility of the lysosomal 
membrane to rupture, releasing degradative enzymes and metabolites into the cytoplasm 
resulting in cellular damage [37]. Also, when the lysosomal function is compromised due to 
glycogen accumulation, autophagosomal dysfunction ensues as a consequence followed 
by total cellular dysfunction [38], [39]. These (secondary) cellular disturbances involve 
abnormal calcium homeostasis, mitochondrial abnormalities and accumulation of lipofuscin 
deposits, which has been associated with oxidative stress [40]–[43]. 
MOLECULAR ASPECTS OF POMPE DISEASE
  The GAA gene
In 1979, the human acid α-glucosidase gene with gene symbol GAA was discovered to reside 
on chromosome 17 [44]. Ten 10 years later, the GAA locus was determined to be on the 
distal portion of the long arm around position q23 [45]. The exact location is 17q25.2-q25.3 
[7]. The GAA gene was characterized in 1990 to consist of approximately 20kb containing 
20 exons [46]. The first exon is noncoding, and has recently been found to consist of exon 
1A and 1B, interspersed by a 195 bp long intron 1A [47]. The ATG translation start codon is 
located in exon 2 following 32 base pairs (bp) of untranslated sequence counting from the 
5’ end of exon 2. According to the conventional nomenclature, the base A of the ATG codon 
is c.1. GAA exon 2 contains the sequence for the signal peptide that directs the ribosome to 
the membrane of the ER [37].
The GAA protein
GAA mRNA is translated at the ER, emerging as a 110 kDa glycoprotein. Mannose 
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6-phosphate groups are acquired, the GAA protein is subsequently transported to the Golgi 
and transverses the cis- and trans-Golgi cisternae. At the exit of the trans-Golgi, GAA is 
captured by the mannose 6-phosphate receptor, whereby it is transported to the lysosomal 
system [48]. During transport, the 110 kD precursor form of GAA undergoes N and C terminal 
proteolytic processing and is activated, resulting in the formation of the 95 kD intermediate 
form and mature forms of 76 kD and 70kD [49].
The mature GAA protein contains several domains, including a trefoil Type-P 
domain, an N-terminal β-sheet domain, the catalytic GH31 (β/α)8 domain, and proximal 
and distal β-sheet domains [50]. A schematic representation of the GAA sequence and its 
domains is shown in Figure 1.
ENZYMATIC AND MOLECULAR DIAGNOSTIC OF POMPE DISEASE
The diagnosis of Pompe disease can be easily missed due to the rarity of the disease 
and the unawareness of the condition by general practitioners. Furthermore, the phenotypic 
features can be similar as in other neuromuscular disorders, particularly in affected children 
and adults [51]. Among the first indicative symptoms is limb-girdle weakness. Blood analysis 
may reveal high creatine kinase (CK) serum levels in symptomatic and presymptomatic 
patients [52], [53]. Non-invasive tests, such as the analysis of the tetrasaccharide GLc4 
in the urine, can also be performed [54]–[56]. However, Glc4 is not specific for Pompe 
Figure 1. Schematic representation of the GAA gene and GAA protein. Upper cartoon: the GAA gene located 
in chromosome 17, encompassing 18 kb. There are 20 exons, of which 19 (2-20) are coding. Dark brown regions 
indicate the 5’ and 3’ untranslated regions. The exonic regions corresponding to the predicted protein domains are 
indicated as follows: the trefoil-P domain (pink), the N-terminal β-sheet domain (blue), the catalytic GH31 domain 
(green), catalytic site 1 (yellow), catalytic site 2 (salmon), the proximal (dark yellow) and distal (emerald green) β-sheet 
domains. (*, start codon; T, stop codon; SP, signal peptide; PP, propeptide; TR, trefoil). Lower cartoon: the GAA 
protein encompassing 952 amino acids with the representation of the protein domains and the 7 glycosylation sites, 
some carrying the mannose 6-phosphate recognition marker (indicate as brown structures) (Based on [8], [50], [83]).
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disease as elevated Glc4 also occurs in other glycogen storage diseases, in some cases 
of Duchenne muscular dystrophy and after disease-unrelated muscle trauma [56], [57]. 
Electromyography may reveal a myopathic pattern [7]. Muscle or skin biopsies can be 
very useful for the diagnosis of metabolic myopathies. Biopsy specimens are tested for 
histology, immunohistochemistry, electron microscopy, and biochemistry. Patients with 
Pompe disease may show a higher concentration of intramuscular glycogen detected by 
periodic acid Schiff (PAS) in the biopsy. However, the absence of vacuolization is seen 
in some cases of childhood or adult Pompe disease [58]–[60]. In addition, the presence of 
PAS positive material may vary from fiber to fiber, and glycogen can easily be washed out 
when the material is not properly fixated. Increased staining of acid phosphatase may point 
to a positive diagnosis. To confirm the diagnosis of Pompe disease, GAA enzyme activity 
in leukocytes or fibroblasts are commonly used, preferably combined with DNA analysis, as 
described below. 
Enzymatic analysis
Lysosomal acid α-glucosidase (GAA) is present in all human tissues and is expressed 
e.g. in leukocytes and cultured skin fibroblasts, which sources can be used for enzymatic 
diagnosis [61]. Prenatal diagnosis in families at risk can be performed by GAA DNA analysis 
to identify known familial GAA variants combined with enzymatic assays using chorionic villi 
as a sample source [62], [63]. Since ERT became available in 2006 to treat Pompe disease, 
newborn screening (NBS) has become an option for neonatal patient detection. Biomarkers 
such as CK and Glc4 display low specificity and are mainly used for additional diagnostic 
purposes [64]. 
High throughput methods to quantify the GAA activity in dried blood spots (DBS) 
are based on Tandem Mass Spectrometry (MS/MS) and Fluorometric assays. MS/MS is 
a highly sensitive and specific technique. This technique is becoming more popular for 
the analysis of biomarkers for different types of lysosomal storage disorders [65]. In 2002, 
Chamoles and colleagues showed that many lysosomal enzymes remain active in dried 
blood spots [66]. Since this finding, DBS has been increasingly implemented as an NBS 
method for lysosomal storage disorders [67]. Nowadays, many NBS programs worldwide 
use DBS samples to perform enzymatic analysis using a glycogen-similar substrate that is 
quantified by MS/MS. The use of digital microfluidics (DMF) is also being performed. DMF 
is a multiplex advancement of the classical enzymatic fluorescent assay based on synthetic 
4-methylumbelliferyl-α-D-glucopyranoside (4MUG) that processes microdroplets. Droplets 
are dispensed, moved, stored, mixed, reacted and analysed in an automated manner, taking 
less than 4 hours with minimal crosstalk between analyses [68], [69]. A study reported the 
use of MS/MS to distinguish patients with Pompe disease from healthy individuals with the 
known Asian pseudodeficiency allele c.[ 1726G>A;2065G>A] [70]. However, the use of this 
technique requires in all cases a second tier enzyme assay to decrease the false-positive 
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rate [71]. Therefore, the final diagnosis is made by fluorometric GAA assay using mixed 
leukocytes and/or cultured primary skin fibroblasts combined with molecular analysis to 
detect the disease-associated variants in the GAA that cause the deficiency. The enzymatic 
activity can be measured using the natural substrate glycogen or the artificial substrate 
4MUG. The addition of acarbose to the reaction mixture is essential to inhibit the interfering 
glucoamylase activity when using leukocytes as an enzyme source. According to our recent 
analysis (Chapter 2), cultured skin fibroblasts provides the only source that enables us to 
distinguish between the different phenotypes of Pompe disease [72]–[74].
Molecular analysis and Pompe disease in a genomic era
As part of the diagnostic workup for Pompe disease, DNA analysis is usually performed 
to determine the causative GAA disease-associated variants after the diagnosis has been 
confirmed enzymatically. The diagnosis is confirmed when two disease-associated GAA 
variants are identified, one in each GAA allele. In some cases, the definitive diagnosis can 
be delayed when the pathogenicity of a variant is unknown, or when only one disease-
associated variant is detected. DNA analysis is advantageous because it can discriminate 
between carriers and affected individuals. However, there are cases that require more 
extensive analysis, such as deletions that are too big to be detected by Sanger sequencing 
[75], [76] or when complex situations are encountered as described in Chapter 3.
The past decades have seen the advent of powerful and innovative methods for the 
sequencing of nucleic acids (DNA and RNA). These Next Generation Sequencing (NGS) 
techniques provide new ways to analyze the genetic bases of diseases. NGS methods range 
from gene panel sequencing, as is the case in MotorPlex sequencing, and whole exome 
and genome sequencing [77], [78]. These sequencing techniques are so powerful that they 
have led to the discussion of whether NGS can replace conventional biochemical tests for 
newborn screening [79]. One of the major driving forces of this debate is the decreasing 
price of NGS techniques compared to the prices of more traditional diagnostic methodology 
[80]. There are many possible applications of utilizing NGS techniques for the diagnosis of 
Pompe disease and other disorders, which are shown in Table 1. 
However, the major challenge of NGS technology is the interpretation of the clinical 
significance of the DNA variants that are identified. The interpretation of a variant of unknown 
Table 1. Applica�ons  for the use of NGS in diagnos�cs 





Iden�fica�on of biomarkers or gene�c modifiers  
Screening when enzyma�c test is unavailable 
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significance (VUS) is discussed in Chapter 4, in which benign variants can be misinterpreted 
as disease-associated. The disease-associated genotype alone is not always sufficient to 
predict the disease phenotype. A deeper understanding of the effects of disease-associated 
variants is needed to clarify the correlation between the patient’s genotype and clinical 
phenotype in inherited diseases such as Pompe disease. The maintenance of databases 
that include both genotypic as well as phenotypic information of affected individuals is 
essential to obtain a better understanding of the link between genotype and phenotype and 
to investigate the role of modifying factors.
POMPE DISEASE GAA VARIANT DATABASE  
Databases
Many disease-associated GAA variants have been reported in the literature, and various 
different sources provide an overview of the discovered variants in the GAA gene. The 
Human Gene Mutation Database (HGMD) at http://www.hgmd.cf.ac.uk/ac/ currently lists 
658 variants distributed throughout the GAA gene. The HGMD collects variants present 
in published scientific articles using automated procedures and manual curation [81]. The 
Leiden Open Variation Database (LOVD) at www.lovd.nl/GAA reports 756 unique GAA 
sequence variants, of which 404 are classified as pathogenic. LOVD is a freely accessible 
gene-centered collection platform that allows for the inclusion of data at the individual 
level but can also accommodate data from NGS studies. The LOVD provides a public web 
interface in which registered users can submit sequence variants prior to publication. These 
submissions are subsequently reviewed by a curator to ensure the correct use of Human 
Genome Variation Society (HGVS) nomenclature [82].
Above mentioned databases provide a global overview of variants that have been 
described in the literature. However, these databases do not clearly define the impact of 
a specific variant on the disease severity in terms of clinical presentations. The Pompe 
disease GAA variant database at www.pompevariantdatabase.nl is a comprehensive 
disease-specific database that provides information on 911 variants that have been 
described in the literature. Furthermore, it provides the predicted clinical severity of the 
variant based on the phenotypes of patients carrying the variant and displays information 
regarding the effect of the sequence variants based on functional analysis and in silico 
predictions. Regular updates of the database are performed in which new variants are 
added and existing variants are curated in order to update variant severity scores. From 
the total of 911 variants, 336 variants could be linked to classic infantile, childhood or adult 
phenotypes when combined with a null allele [8], [83].
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Disease-associated variants in the GAA gene
Disease-associated variants in the GAA gene can affect the GAA protein production and/or 
activity in several ways. In some instances, the type of disease-associated variant can be 
used to predict the phenotype [7], [8], [84]. The most common types of disease-associated 
variants that cause Pompe disease are missense variants [8]. These variants often affect the 
structure of GAA, thereby destabilizing the protein structure, which can subsequently lead to 
endoplasmic-reticulum-associated protein degradation [8], [50], [85]. Exonic deletions are 
the second most common type of variants identified to cause Pompe disease. An example 
is the c.525del variant. This variant, which is the most common deletion in Dutch patients, 
is a severe variant that generates a premature stop codon in GAA exon 2 [86]. Variants that 
affect pre-mRNA splicing are also common in Pompe disease; they amount to 13% of the 
disease-associated GAA variants reported to date. The most common variant in Pompe 
disease, which occurs in 90% of Caucasian patients, is c.-32-13T>G (commonly referred 
to as IVS1). It is an intronic splicing variant that will be discussed in more detail below [87].
During the standard diagnostic screening of monogenic diseases, exonic 
sequences and exon-intron boundaries are analyzed for detection of disease-associated 
variants since they are most common. However, variants located deep into intronic regions, 
promoter regions and UTRs have also been identified and can be missed [47]. Although 
these variants are not located in the coding region of the gene, they may still have an impact 
on pre-mRNA splicing. An example of such a deep intronic variant that causes aberrant 
splicing was identified in GAA intron 15. The c.2190-345A>G variant generates a new splice 
acceptor site, leading to the production of three additional products that contain a premature 
stop codon [6]. The HGMD database reports a similar percentage (12.7%) of splice variants 
as the Pompe variant database (13%). The pathogenic effect of these variants has been 
analyzed previously [88]. One common disease-associated variant, which occurs in 50% 
of children and 90% of adults with Pompe disease in the Caucasian population, is the IVS1 
variant (c.-32-13T>G) [89]–[91]. This variant is located in the polypyrimidine tract of GAA 
intron 1B and causes partial or total skipping of exon 2, thereby removing the translation 
start site [89], [92]. Some residual normal splicing remains, which allows the production of 
10-15% of canonically spliced GAA mRNA, leading to a late-onset phenotype [93]. Patients 
that carry the IVS1 variant have been reported to have a broad clinical spectrum, indicating 
that modifying factors play a role in the Pompe disease phenotype [4], [87], [94], [95].
Extended molecular analysis
Traditional Sanger sequencing for the detection of disease-associated variants might fail 
to detect larger deletions. For example, two reports have described gross deletions in the 
GAA that were caused by the recombination of two Alu elements. Sanger sequencing was 
unable to identify these variants, which were only found after additional molecular analysis 
[76], [96]. Furthermore, uniparental disomy (UPD), which stands for the inheritance of two 
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homologous chromosomes from the same parent, was diagnosed in a patient with Pompe 
disease after extended diagnosis [97]. In another case report, an infant was presented with 
symptoms suggestive of Pompe disease, but with an uncertain diagnosis. The patient had 
left ventricular hypertrophy, consistent with the classic infantile form of Pompe disease, but 
did not have muscle weakness. In this case, the routine molecular diagnosis did not either 
provide a clear answer. Additional studies implementing extensive molecular screening and 
the use of SNP array (searching for single nucleotide polymorphisms (SNP)) established a 
chromosomal imbalance on chromosome 17, discussed in Chapter 3. This chromosomal 
imbalance was present in a mosaic pattern [47].
Common variants in the GAA gene
Many SNPs with minor allele frequencies (MAF) above 1% have already been reported 
to reside within the GAA and can be ruled out to cause Pompe disease due to their high 
MAF in healthy individuals [94], [98], [99]. Nonetheless, it cannot be excluded with certainty 
that these variants affect disease progression when present in cis with disease-associated 
variants [83]. Several in cis disease-modifying variants in the GAA have been reported. 
These variants cause a decrease in GAA enzymatic activity but do not cause Pompe disease 
by themselves. They cause GAA pseudodeficiency. An example is the Caucasian c.271G>A 
(p.Asp91Asn) variant (also termed GAA2), which is located in GAA exon 2 [100], [101]. 
This variant has a MAF of 3% in the European population. Alleles with this variant encode 
the GAA2 alloenzyme, which has reduced affinity for the glycogen substrate [100], [102]. 
Another well described pseudodeficiency allele is the combination c.[1726G>A;2065G>A] 
with MAFs of 15% and 24%, respectively, in East Asia. Homozygotes have an estimated 60-
80% reduction of acid α-glucosidase enzyme activity when tested in vitro [103]. However, 
considering the MAF and the effect on GAA activity, these variants are insufficiently 
deleterious to cause Pompe disease when no other disease-associated variants are present 
in cis [8], [83].
Is there an SNP signature for Pompe disease?
An allele can be described as a variant of a gene at a specific chromosomal location, 
termed a locus. A locus consisting of a combination of distinct alleles is called a haplotype. 
An important aim in the field of inherited diseases is to identify the relationship between 
alleles and/or haplotypes and their respective effect on the expression of genes that could 
result in a specific phenotype. Haplotypes are often defined by the presence of a specific 
combination of SNPs. Individual SNPs can affect the gene they reside in depending on their 
location (e.g. coding region, enhancer, silencer, promoter)[104], [105]. The combination 
of multiple SNPs can potentially influence certain traits [106], [107]. Often such traits are 
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specific to geographical regions and can differ by ethnicity since they are more likely to be 
inherited within such a population [108]. 
Many SNPs have been described in the GAA gene. However, little information 
about the potential impact of these variants on GAA protein production and/or activity is 
available [8], [99]. Understanding the effect of these SNPs can yield additional information 
for a specific phenotype. Some of these effects have already been established and are 
described as quantitative trait loci (QTLs). QTLs are sections of DNA that contain a specific 
combination of genetic variants that correlate with a specific trait. Sections of DNA that 
affect gene expression of certain genes are known as expression QTLs (eQTLs) [109]. 
eQTLs for the GAA can be found in the Genotype-Tissue Expression project (GTEx) (https://
www.gtexportal.org/home/). eQTLs in different tissues from post mortem healthy donors 
shows variants in cis that influence the expression of GAA in the lung, skeletal muscle, and 
other tissues. Therefore, common variants residing in the GAA itself and in the nearby (<250 
kilobases) surrounding area influence GAA expression (Figure 2). Moreover, variants that 
are located further away from the gene (>5 megabases) or on a different chromosome, 
could also affect gene expression. These variants are known as trans-eQTLs. However, to 
study the impact of trans-eQTLs, a considerable number of samples needs to be analysed, 
since the overall effects are usually small [109]. 























Skeletal Muscle (338 variants)
Tibial nerve (358 variants)




Figure 2. cis-eQTLs for GAA. Significant variants associated with GAA expression in lung, skeletal muscle and tibial 
nerve tissues. The strength of the eQTL is expressed as the -10 log of the p-value of the ratio between the expression 
of the alternative variant and the reference variant. The cis-eQTLs are present at both upstream and downstream 
locations relative to the GAA transcription start site. 
(* intergenic region) (source: GTExportal.org)
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to a null variant on the other allele present a broad spectrum of phenotypes with respect to 
ages at symptom onset and severity of clinical features. This suggests that modifying factors 
play a role [4], [87], [94], [95]. A comparative study performed among affected children and 
adults both carrying the IVS1 variant has identified the synonymous c.510C>T variant as a 
disease modifying factor [87]. Splice assays and RT-qPCR analyses have shown that this 
variant negatively influences the correct GAA pre-mRNA splicing when present in cis with 
IVS1.
Kroos et al 2007 published a major core GAA haplotype based on 17 variants (some 
of which are common (MAF >1%), while others are rare (MAF <1%)) in IVS1 haplotypes. 
This core haplotype was defined by the amino acids DHRGEIVT present in the majority of 
174 unaffected individuals from different ethnicities [94]. Analysis using samples from 71 
patients that carried the IVS1 variant showed that 68% of IVS1 haplotypes did not harbour 
any of the 17 variants analyzed. Just one patient carried the major GAA core haplotype [94]. 
It has been hypothesized that the IVS1 allele was propagated as a founder mutation through 
inheritance and migration, although other scenarios also are possible. Another haplotype 
study has been performed based on 10 GAA SNPs in which Taiwanese newborns with low 
GAA activity were screened [98]. Analysis in 93 unaffected Taiwanese individuals revealed 
two core GAA haplotypes, DRHGHEIVST (24% of the individuals) and DHRGHEVVST 
(41%). The IVS1 variant was not present in those individuals. Interestingly, newborns with 
Figure 3. Example of haplotype blocks and their combinations. The different colours in a block show alternative 
alleles. A) Within each block, there is little or no evidence for recombination. Recombination hotspots are represented 
as zigzag lines. In a specific population, a limited number of distinct alleles within a given haplotype block can occur. 
B) Most chromosomes are composed of a mosaic arrangement of haplotype blocks. Each population will differ in the 
frequency of those specific arrangements (adjusted from [112]).
Block 1 Block 3Block 2
A) Haplotype blocks
B) Mosaic chromosomes in a population
Block 1 2 3
*                                    *
 *             *
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low GAA activity had another haplotype (DRHSHKIVS), harbouring the common Asian 
pseudo-deficiency allele c.[1726G>A;2065G>A] in 81% of cases.
GAA haplotypes often vary between patients from different ethnicities. A common 
way to determine the ancestral chromosomal segment is through the analysis of haplotype 
blocks. Haplotype blocks are regions with high linkage disequilibrium (LD, nonrandom 
assortment of alleles at different loci in a population) and low variability in a certain population, 
passed from a shared ancestor [110] (Figure 3). Factors that affect LD are recombination, 
genetic drift, natural selection and how the population size changes over time. On average, 
haplotype blocks span from 5kb to 20kb, but they can reach up to 100kb [110]. Haplotype 
blocks have been used to identify tag SNPs, which can help to predict which other SNPs 
will be present in the block by calculating the LD [111]. Analyzing haplotypes of disease-
associated variants in Pompe disease could help to understand if the presence of certain 
variants (common or rare) within a haplotype interferes with GAA expression and/or activity.
Aims and scope of this thesis
Since the development of ERT for Pompe disease, substantial progress has been made with 
the identification of novel disease-associated variants in relation to the clinical phenotypes. 
A better understanding of the subjacent genetics of Pompe disease combined with the 
application of improved tools enables the molecular diagnosis of patients, the unravelling 
of complex cases, and the prediction of phenotypes. The aims of the research described in 
this thesis are two-fold: Firstly, to improve the enzymatic and molecular diagnosis of Pompe 
disease (Chapters 2 and 3); Secondly, to investigate and reveal the genotype-phenotype 
correlation in Pompe disease (Chapters 4-7). 
  Chapter 2 is a study on enzymatic diagnostic practice over a period of 28 years 
using different sample sources and methods with which the “gold standard” could be 
defined of how to diagnose Pompe disease enzymatically. Chapter 3 illustrates the need 
for additional analyses to detect new disease-associated GAA variants when conventional 
methods are insufficient. After a diagnosis of a patient with Pompe disease by enzymatic and 
molecular analysis, a broad spectrum of disease severity is observed in the childhood and 
adult onset forms. This stresses the need to collect data from many patients to understand 
the genotype-phenotype correlation. This relation is investigated in the second part of this 
thesis that is focused on the importance of maintaining a versatile and up-to-date version of 
the Pompe variant database (Chapters 4 and 5). Chapter 6 analyses the impact of disease-
associated variants in the context of GAA haplotypes. The research described in Chapter 
7 explores the genotype-phenotype correlation in Pompe disease by comparing mRNA 
expression levels of genes of affected children and adults with similar GAA genotypes. The 
overall results are discussed in the last chapter of this thesis (Chapter 8). 
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Abstract
Pompe disease is a lysosomal and neuromuscular disorder caused by deficiency of acid alpha-glucosidase (GAA), and
causes classic infantile, childhood onset, or adulthood onset phenotypes. The biochemical diagnosis is based on GAA
activity assays in dried blood spots, leukocytes, or fibroblasts. Diagnosis can be complicated by the existence of
pseudodeficiencies, i.e., GAA variants that lower GAA activity but do not cause Pompe disease. A large-scale comparison
between these assays for patient samples, including exceptions and borderline cases, along with clinical diagnoses has not
been reported so far. Here we analyzed GAA activity in a total of 1709 diagnostic cases over the past 28 years using a total
of 2591 analyses and we confirmed the clinical diagnosis in 174 patients. We compared the following assays: leukocytes
using glycogen or 4MUG as substrate, fibroblasts using 4MUG as substrate, and dried blood spots using 4MUG as substrate.
In 794 individuals, two or more assays were performed. We found that phenotypes could only be distinguished using
fibroblasts with 4MUG as substrate. Pseudodeficiencies caused by the GAA2 allele could be ruled out using 4MUG rather
than glycogen as substrate in leukocytes or fibroblasts. The Asian pseudodeficiency could only be ruled out in fibroblasts
using 4MUG as substrate. We conclude that fibroblasts using 4MUG as substrate provides the most reliable assay for
biochemical diagnosis and can serve to validate results from leukocytes or dried blood spots.
Introduction
Pompe disease is an autosomal recessive metabolic disorder
caused by acid α-glucosidase (GAA) deficiency, which
leads to intralysosomal accumulation of glycogen causing
progressive damage especially to cardiac and skeletal
muscles [1–3]. Pompe disease presents as a spectrum of
phenotypes. The classic infantile form is associated with
rapidly progressive general muscle weakness and hyper-
trophic cardiomyopathy, culminating in death within the
first year of life if left untreated. Less severe and less pro-
gressive forms can manifest at any age from infancy to late
adulthood and present with proximal muscle weakness and/
or respiratory problems with minimal or no cardiac invol-
vement [4–7]. These patients may eventually lose ambula-
tion and/or become ventilator dependent. Patients with less
severe forms and with the same GAA genotype can have
broad phenotypic variation, with symptom onset ranging
from early infantile to late adult [8]. This indicates the
presence of environmental, epigenetic, or genetic modifying
factors. Recently we identified the silent, cis-acting
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c.510C>T GAA variant as a genetic modifier of symptom
onset and splicing in Pompe disease [9]. Symptoms in other
tissues and organs also occur including in smooth muscle,
visceral organs, and, in the classic infantile form, the central
nervous system. Enzyme replacement therapy with recom-
binant human GAA is available and is often applied in
combination with immunomodulation in classic infantile
cases to reduce the chance of antibody formation [10–13].
Early diagnosis including phenotype prediction is required
to optimize counseling and to ensure a timely start of
treatment.
Current diagnostic guidelines recommend the establish-
ment of GAA enzyme deficiency with additional con-
firmation of two disease-associated GAA variants [14, 15].
Disease-associated variants, recently linked to clinical
phenotypes, are listed in the open access Pompe disease
GAA variant database [www.pompevariantdatabase.nl]
[16, 17]. Different enzymatic diagnostic assays are available
in which the biological material and the choice of substrate
are variables.
Biological materials can be leukocytes, dried blood spots
(DBSs), fibroblasts derived from skin biopsies, and muscle
tissue. Leukocytes and DBSs are easily obtained, which is
important for timely screening, diagnosis, and treatment of
classic infantile patients. Newborn screening (NBS) pro-
grams are based on DBS assays and positive cases require a
second-tier assay for confirmation [18]. Muscle biopsies can
be used for diagnosis however, these are not always avail-
able and involve a rather invasive and sometimes
painful procedure. In addition, in the case of fat replacement
of muscle, which can occur in Pompe disease, it can be
difficult to obtain muscle cells from a muscle biopsy.
Substrates include the natural substrate glycogen, and the
artificial substrates 4-methylumbelliferyl-α-D-glucopyrano-
side (4MUG) [19] and (GAA-S), a substrate used in tandem
mass spectrometry for NBS [20]. In certain assays such as
using leukocytes or DBSs, the neutral hydrolase glucoa-
mylase activity needs to be inhibited using acarbose as it
interferes with the measurement of GAA activity [21–23].
Additional evidence for the diagnosis of Pompe disease
can be obtained by measuring urine tetrasaccharide Glc4
(TGLC), which can be measured using HPLC with UV
detection or using mass spectrometry. This biomarker has
been found to be sensitive but it is not specific to Pompe
disease, as it is also elevated in liver abnormalities or in
response to food intake. In borderline cases, it might help to
establish the diagnosis [24–26].
For the interpretation of diagnostic outcome, it is
important to consider the following information on GAA
DNA variants. (1) At least two (combinations of) GAA
variants can lead to pseudodeficiency. In the Caucasian
population, the GAA2 (c.271G>A) pseudodeficiency variant
lowers the activity of GAA for the natural substrate
glycogen, but not for the artificial substrate 4MUG [27, 28].
In the Asian population, the common GAA pseudodefi-
ciency variants c.[1726G>A; 2065G>A] can lower GAA
activity to levels that come close to the disease threshold,
and their presence can lead to a false positive diagnosis in
certain assays [23, 29, 30]. (2) Standard DNA diagnostic
analysis may fail to identify GAA variants, in these cases
extended analysis is required as described [31–33].
Over the past 28 years, our laboratory has processed
1709 diagnostic cases and has diagnosed over 250 patients
with Pompe disease using various assays separately
and in parallel. In this article we are presenting
and reviewing all our test results of blood-based and
fibroblast-based assays from 1990 until 2018 allowing to
compare the various methods for enzymatic diagnosis and
their pitfalls.
Materials and methods
Nomenclature and Pompe variant database
The variant nomenclature is according to HGVS standards
[34]. The reference sequences used for the annotation of
GAA cDNA variants were NM_000152.5 and LRG_673t1.1.
Position c.1 represents the first nucleotide of the translation
start codon ATG located in exon 2. Exon numbering was
according to Niño et al., 2019 [17]. NP_000143.2 was used
for annotation of GAA protein variants. Variant information
was retrieved from the Pompe disease GAA variant database
at www.pompevariantdatabase.nl and the Leiden open var-
iation database (http://lovd.nl/gaa).
Diagnostic materials and assay procedures
GAA activity assays were performed when there was a
suspicion of Pompe disease based on clinical symptoms
(described below). Results were obtained over the period
1990–2018. Reference ranges reflect those of the Diagnostic
Department of the Erasmus MC and were established for
each assay based on at least 20 individuals per phenotype
(classic infantile, childhood, adulthood, healthy controls)
with a confirmed clinical diagnosis. Values in between these
ranges are specified as ‘gray zone’, which is defined as
GAA enzyme activities above the patient range but below
the control range. For fibroblasts, the reference ranges were
derived from data collected over a 40 years period. For the
other assays, including GAA activity in leukocytes and
bloodspots, and tetrasaccharide 6-α-D-glucopyranosyl-
maltotriose (Glc4) concentration in urine by mass spectro-
metry, data collection of at least 8-years was used [24]. All
reference ranges for patients, healthy controls, and the gray
zones are indicated in the legends of the figures. The study
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was conducted according to the Declaration of Helsinki.
The Medical Ethical Committee at Erasmus University MC
approved the study protocol, and all patients, or their par-
ents or legal guardians, provided written informed consent.
Activity assays were performed as previously described
[22, 24, 35–37]. A final concentration of 3 µmol/L acarbose
(in the reaction mixture) was used for the glycogen assay
and 8 µmol/L acarbose for the 4MUG assay to inhibit glu-
coamylase activity present in mixed leukocytes and which
interferes with GAA activity measurements. Performance of
the assays was determined for each individual assay by
including an internal standard sample. According to stan-
dard diagnostic procedures, a maximal deviation of less
than 10% of the internal standard was required to use values
as diagnostic values. For all assays, no false positive or false
negative values of the internal standard were obtained.
Typical standard deviations were: leukocytes/4MU: 5.1%
(n= 29); leukocytes/glycogen: 6.2% (n= 72); fibroblasts/
4MUG: 7.1% (n= 78); DBS (in our Diagnostic Center not
used as diagnostic assay): 11.3% (n= 7). The GAA activity
in DBS was determined in the presence of 8 µmol/L acar-
bose for glucoamylase inhibition and after precipitation of
hemoglobin as previously described [35, 36].
Clinical diagnosis
We classified patients with classic-infantile Pompe disease
when they presented symptoms at or under 12 months of age.
Symptoms in these patients consist of muscle weakness com-
bined with a hypertrophic cardiomyopathy. The phenotype of
childhood and adulthood onset Pompe disease is dominated by
a progressive limb-girdle myopathy that leads to severe func-
tional limitations, while respiratory muscle dysfunction limits
patients’ average life span. Childhood onset is here defined as
symptom onset before the age of 18 years, adult onset at 18
years or older. The diagnosis was established based on com-
bined evidence consisting of these clinical symptoms, GAA
enzyme deficiency, and DNA analysis.
Results
Over the past 28 years, we analyzed a total of 1709 indi-
viduals using a total of 2591 assays (Fig. 1 and Table S1).
In the majority of individuals, leukocytes were used with
both glycogen and 4MUG as substrate (n= 637). In 539
individuals, fibroblasts using 4MUG as substrate were used
as single assay, while in 375 individuals, leukocytes with
glycogen were used as single assay. Only one individual
was analyzed with leukocytes using 4MUG as substrate as
single assay. Eighty-eight individuals were analyzed with
all three assays, while 69 individuals were analyzed with
both leukocytes/glycogen and fibroblasts/4MUG. As part of
this study we traced back the clinical data of all patients
with a confirmed enzymatic diagnosis. The following
categories for the diagnoses were defined: ‘Classic Infan-
tile’, ‘Childhood onset’ (symptom onset before the age of
18 years), ‘Adult onset’ (symptom onset at 18 years and
older), ‘no Pompe disease’, and ‘Unknown’. For enzymatic
assays, the following additional categories were defined:
‘Unknown/Deficient’ (i.e., the value of the assay was defi-
cient but it was unknown whether the individual had Pompe
disease), ‘No Pompe/Deficient’ (i.e., the value of the assay
was deficient but Pompe disease was excluded based on
other assays), ‘Asymptomatic/Deficient’ (i.e., the value of
the assay was deficient but the individual was asympto-
matic), and ‘Gray Zone’ (the values above patient ranges
but below normal ranges).
GAA activity assay in leukocytes using glycogen as
substrate
Figure 2A shows GAA activities using glycogen as sub-
strate that were measured in 1169 individuals. Within
the range of 0–3.5 nmol/mg/h for classic infantile patients,
there were 20 classic infantile patients, 15 with childhood
onset, and 111 with adult onset Pompe disease. Two indi-
viduals were ‘unknown deficient’. Within the range of





       Leukocytes 
(AGLU-GN + 3ACB)
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Fig. 1 Venn diagram showing how many diagnostic cases were
processed with each of the three different enzymatic methods. The
figure shows the similarities and differences of individuals whereby
the GAA activity was measured in leukocytes with glycogen as well as
with 4MUG as substrate, and in fibroblast with 4MUG. Of note 11
assay results (five from leukocytes with glycogen four from leukocytes
with 4MUG, and two from fibroblast with 4MUG) were not included
in this comparison since they are biological replicates. DBS assays (20
assays from 18 individuals) are not shown.
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childhood/adult onset patients (range 0–10 nmol/h/mg),
there were 1 classic infantile patient, 6 with childhood
onset, 20 with adult onset, 7 ‘no Pompe/deficient’, and
3 ‘unknown/deficient’. This indicated that the range of
0–3.5 nmol/mg/h contained 95% of the classic infantile,
71% of the childhood onset, and 84% of the adulthood
onset patients. The 3.5–10 nmol/mg/h range contained 5%
of the classic infantile, 29% of the childhood onset, and
16% of the adulthood onset patients. In both ranges,
putative false positives were found to a total of 12 indivi-
duals. A subset of these false positives was followed up
using leukocytes/4MUG and fibroblasts/4MUG assays, and
these showed mainly gray zone (seven assays) and normal
(nine assays) values, while one assay in leukocytes/4MUG
showed an unknown/deficient value (see Table S1 for raw
data). Within the range of 10–40 nmol/mg/h, 52 individuals
were classified with gray zone (above the patient range but


























Acid α-glucosidase assay in leukocytes using glycogen as substrate
Total n = 1169
Ranges (nmol/hr/mg):
Classic Infantile: 0 - 3.5
Childhood/Adult: 0 - 10
Normal: >40 - 250
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Fig. 2 Distribution of GAA activity in leukocytes using. A Glyco-
gen as substrate in the presence of 3 µmol/L acarbose (AGLU-GN+
3ACB assay). A total of 1169 individuals suspected of Pompe disease
were included. B 4MUG as substrate in the presence of 8 µmol/L
acarbose (AGLU-4MUG+ 8ACB assay). A total of 726 individuals
suspected of Pompe disease were included in this series.
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patient was present. This patient showed values in
the patient range in leukocytes/4MUG (3.46 nmol/mg/h)
and in the classic infantile range in fibroblasts/4MUG
(0.2 nmol/mg/h). In the normal ranges above 40 nmol/mg/h,
a total of 921 healthy individuals were present. In conclu-
sion, the leukocytes/glycogen assay has limited ability to
discriminate between patients with classic infantile and late
onset phenotypes, has a considerable risk of false positive,
and a low risk of false negative outcomes.
GAA activity assay in leukocytes using 4MUG as
substrate
In Fig. 2B, the activities in leukocyte assays using 4MUG as
substrate, measured in 726 individuals, are shown. In the
patient range of 0.0–4.9 nmol/h/mg, there were 19 classic
infantile patients, 10 with childhood and 66 with adulthood
onset, 2 were no Pompe/deficient, and 17 were unknown/
deficient. The two individuals that were no Pompe/deficient
and the 17 individuals that were unknown/deficient showed
either gray zone and/or normal values when tested in leu-
kocytes/4MUG and/or fibroblasts/4MUG. This showed that
the leukocyte/4MUG assay did not distinguish classic
infantile from late onset phenotypes. The range
4.9–6.7 showed 1 childhood onset patient, 1 adult onset
patient, and 57 gray zone individuals. The childhood onset
patient had borderline activity just above the threshold (5.14
nmol/mg/h) and tested in the patient range (0.365 nmol/mg/h)
in the leukocyte/glycogen assay. The healthy range > 6.7
nmol/mg/h included 548 healthy individuals and 5 indivi-
duals with somewhat increased enzyme activities. This
indicated that the leukocyte/4MUG assay could faithfully
discriminate between healthy and diseased individuals but
could also result in false positive outcomes.
GAA activity assay in fibroblasts with 4MUG as
substrate
In Fig. 3, the activities in fibroblasts using 4MUG as
substrate are shown. In the range 0–3 nmol/h/mg for
classic infantile patients, there were 77 classic infantile
patients, 8 patients with childhood and 3 with adulthood
onset. One patient with childhood onset had an activity in
between 3 and 4.2. In the range 4.2–20 nmol/mg/h for
childhood/adult onset patients, there were 1 classic
infantile patient, 18 with childhood onset and 108 with
adulthood onset. There were six asymptomatic/deficient
individuals. These individuals may develop symptoms
later in life, as symptom onset in Pompe disease can be
highly variable. Two of these individuals were also tested
using leukocytes/glycogen and 4MUG, and in both indi-
viduals, these two assays yielded gray zone values. This
indicated that the fibroblasts/4MUG assay could distin-
guish classic infantile from childhood/adulthood onset
patients to a large extent, and between childhood and
adulthood patients to a lesser extent. There were 61
individuals with enzyme activities in the gray zone range
of >20–45 nmol/h/mg. All individuals with activities in




































n=91 n=137 n=61 n=394 n=13
Ranges (nmol/hr/mg):
Classic Infantile: 0 - 3
Childhood/Adult: 4.2 - 20
Normal: >45 - 180
Total (n) = 696




















Acid α-glucosidase assay in fibroblasts using 4MUG as substrate
Fig. 3 Distribution of GAA activity in fibroblast using the artificial substrate 4-methylumbelliferyl-α-D-glucoside (4MUG) (AGLU-4MUG
assay). A total of 695 individuals suspected of Pompe disease were included in this series.
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the healthy range >45 nmol/h/mg were healthy. This
showed that the fibroblast/4MUG assay can distinguish
both healthy from diseased individuals and classic
infantile from childhood/adulthood onset phenotypes.
GAA activity assay in DBS
Table 1 shows the results of DBS assays in 18 individuals
with Pompe disease. In 15 cases (12 classic infantile, 2
childhood, 1 with an unknown phenotype), GAA activity
was in the patient range of 11–56 pmol/17 h/punch, while
three individuals (patients 30–32, who had classic infantile
Pompe disease) were in the gray zone of 56–94 pmol/17 h/
punch. However, all individuals including individuals
30–32 tested in the patient range in leukocytes with gly-
cogen as substrate. One sample, from patient 32 was mea-
sured three times, of which one was in the patient range and
2 in the gray zone. Fibroblasts from this patient showed
activity in the patient range and DNA analysis of this
patient and patients 30 and 31 confirmed the presence of
two severe GAA disease-associated variants (Table 2 and
Fig S1). These results indicated that in this cohort the DBS
assay resulted in relatively frequent false negative outcomes
(16.7% in this analysis) although the number of DBS
samples analyzed here (n= 18) was low.
GAA2 pseudodeficiency
Individuals with pseudodeficiencies can give false positive
outcomes in GAA enzyme assays. To illustrate this, we
compared individuals with confirmed presence of the GAA2
(c.271G>A) and Asian c.[1726G>A; 2065G>A] pseudo-
deficiencies using different GAA activity assays.
In four individuals with the GAA2 variant at hetero-
zygous state without other known GAA disease-associated
variants, activities were in the gray zone (two cases) or in
the normal range (two cases) in leukocytes/glycogen
(Table 3). In leukocytes/4MUG, one case had activity in the
gray zone, and three in the normal range. In fibroblasts/
4MUG, three patients were tested, two of whom were in the
normal range and one (individual 4) in the patient range.
This indicated that the GAA2 allele at heterozygous state
can already lower GAA activity in leukocyte-based assays
to values in the gray zone. Individual 4 had a medical record
of hypertrophic cardiomyopathy. This individual underwent
metabolic screening as no cause for his hypertrophic car-
diomyopathy could initially be found. Genetic testing using
WES led to the identification of a disease-associated variant
in exon 19 (c.1831G>A, p.Gly611Ser) of the MYBPC1
gene (Myosin Binding Protein C, slow type), which plays
an important role in muscle contraction and cardiac con-
duction. No muscle biopsy or MRI was performed, CK was
normal (91 U/l). He had an incomplete traumatic cervical
spinal cord lesion; he can walk but suffers from spasms due
to this condition. General and neurological examination
showed no other abnormalities, and there were no signs or
symptoms of Pompe disease.
In individuals that were homozygous for GAA2 (number 5
and 6), GAA activities were in the patient range in leukocytes/
glycogen, but in the normal range in leukocytes/4MUG and in
fibroblasts/4MUG (Table 3). In individuals that were com-
pound heterozygous for GAA2 in combination with a second
disease-associated GAA variant (numbers 7–11), GAA activ-
ities were in the patient range in leukocytes/glycogen in all
cases (individual 11 contained an additional GAA variant
classified as childhood when combined with a null allele
according to www.pompevariantdatabase.nl) (Table 3). In
leukocytes/4MUG and fibroblasts/4MUG, values were either
in the gray zone or in the normal range. This highlights that
the GAA2 pseudodeficiency at homozygous or compound
heterozygous state can give false positive outcomes when
using the leukocyte/glycogen assay, while correct outcomes
can be obtained by using either the leukocytes/4MUG or
fibroblast/4MUG assays. Patient 12 contained 2 GAA disease-
Table 2 Follow up of three cases with inconclusive DBS data.
Patient Genotype DNA (protein) Predicted severity (Pompe








30 c.1460T>C p.(Phe487Ser); Potentially less severe Likely pathogenic 0.432 Classic infantile
c.1460T>C p.(Phe487Ser) Potentially less severe Likely pathogenic Pompe disease
31 c.379_380del p.(Cys127Leufs*18); Very severe Pathogenic 0.35 Classic infantile
c.525del p.(Glu176Argfs*45) Very severe Pathogenic Pompe disease
32 c.2481+102_2646+31del p.(Gly828_Asn882del); Very severe Pathogenic 0.415 Classic infantile
c.525del p.(Glu176Argfs*45) Very severe Pathogenic Pompe disease
Ranges (GAA activity) Normal range >45–180
Classic infantile 0–3
Childhood/Adult 4.2–20
DNA analysis and GAA activity in cultured fibroblasts left no doubt that all three patients had classic infantile Pompe disease.
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associated variants in addition to the GAA2 allele at hetero-
zygous state, and showed GAA values in the patient range in
all three assays consistent with the diagnosis of Pompe dis-
ease (adulthood onset).
Asian c.[1726G>A; 2065G>A] pseudodeficiency
Individual 13 was compound heterozygous and individual
14 homozygous for the Asian c.[1726G>A; 2065G>A]
pseudodeficiency (Table 4). In both cases, assays using
leukocytes, either with glycogen or with 4MUG as sub-
strate, resulted in activities in the patient range, while
activities in fibroblasts/4MUG were in the gray zone, just
above the patient range. Additional diagnostic analyses
showed that individual 13 had normal CK, ASAT, and
ALAT levels, but slightly elevated TGLC levels. Indivi-
dual 14 did have elevated CK, ASAT, and ALT levels but
normal TGLC levels. Both individuals were diagnosed not
to have Pompe disease based on the diagnostic informa-
tion and the lack of clinical signs associated with Pompe
disease. This indicated that the presence of the Asian
pseudodeficiency can seriously affect the diagnostic out-
come of enzymatic assays that are based on leukocytes,
independent of the substrate used.
 Skin fibroblasts







Individual with suspicion of Pompe disease
Perform GAA assay
and/or confirm by confirm by 
If outcome 
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Fig. 4 Flow chart for diagnosis
of Pompe disease. A General
flow chart. B Flow chart for
cases with pseudodeficiency.
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Discussion
We compared the outcome of different assay procedures for
measuring the GAA activity in various sample types using
different substrates measured at the Erasmus MC in the last
28 years. The pro’s and con’s of the different diagnostic
procedures are discussed below.
Blood-based assays
Leukocytes
We used leukocyte pellets for diagnostic purposes and applied
both glycogen as well as 4MUG as substrate [36]. The results
presented in Fig. 2A, B illustrate that a diagnosis can be
established in most cases and with both substrates if proper
cutoff values are chosen. As previously suggested by van
Diggelen et al. [36], our long-term data also demonstrate that
the dynamic range, i.e., the difference in values between
patients and healthy individuals, is broader with glycogen than
with 4MUG. None of the two assays fully discriminate
between classic and milder (childhood, adult) phenotypes, but
by using both assays in parallel, pseudodeficiencies caused by
the Caucasian GAA2 allele can be excluded (Fig. 4B) [27, 28].
Another pseudodeficiency that complicates the assay is the
Asian c.[1726G>A; 2065G>A] pseudodeficiency [23, 29, 30].
This problem applies to all enzymatic procedures used.
Bloodspots
In our small patient cohort, 3 (16.7%) of 18 patients (assays
30–32 in Fig. S1) came out as false negative in the DBS
assay but were correctly diagnosed with other diagnostic
methods. Analysis of the activity of a second lysosomal
enzyme (for instance BGAL) as reference enzyme may help
to judge the outcome of the assay. For example, a normal
GAA activity should not be trusted if the reference enzyme
shows activity outside of the normal ranges. In such an
event additional assays are required. In our diagnostic
center we do not use the DBS assay routinely as we have
fast and standard procedures for leukocyte-based assays.
DBS-based assays prove to be very valuable tools for NBS.
In both individual cases and in NBS, a second assay is
required to confirm the diagnosis.
Despite the ten times higher activity of GAA for glyco-
gen compared to 4MUG, the small sample size of the
bloodspot assay precludes the use of glycogen for DBS
testing due to the lower sensitivity of the colorimetric assay
used with glycogen compared to the fluorimetric detection
using 4MUG. The tandem mass spectrometry methodology,
employing GAA-S has proven to be a valuable alternative
[20]. A recent refinement of that method was reported to
separate 96% of the Taiwanese newborns with GAA
pseudodeficiency and all Pompe disease carriers from
patients with Pompe disease [38]. A recent study from
Japan supports this claim [39].
Skin fibroblast assays
Figures 2A, B and 3 clearly demonstrate that the combi-
nation of fibroblasts as diagnostic material and the fluori-
metric assay using 4MUG as artificial substrate provide the
most robust and reliable enzymatic assay for diagnosing
Pompe disease. In the majority of cases it distinguishes
classic infantile Pompe disease from childhood/adulthood
onset phenotypes on the basis of residual activity (although
exceptions exist), while none of the other methods do.
Assays with intermediate GAA activity were likely derived
from Pompe disease carriers. DNA analysis usually pro-
vides a clear answer in these cases, but some remained
unsolved. For instance, in individual 13, that carried the
Asian pseudodeficiency c.[1726G>A; 2065G>A] in com-
bination with the IVS1 variant, biochemical results sug-
gested Pompe disease while clinical signs did not, but it
leaves doubt whether adult/late onset Pompe disease can be
fully ruled out in this patient.
Conclusions and recommendations
We conclude from our data that cultured skin fibroblasts
provide the only sample source that can distinguish classic
infantile from childhood/adulthood phenotypes, although
exceptions can occur, as noted previously [40]. The labor-
ious procedure of biopsy and culturing makes this assay not
suitable for a fast diagnosis. Leukocytes isolated from
peripheral blood offer a fast diagnostic sample source,
provided that the reaction mixture contains acarbose to
inhibit glucoamylase. The use of glycogen as natural sub-
strate enhances the resolution between affected and unaf-
fected, but GAA2 pseudodeficiency occurs in the Caucasian
population and has to be excluded by also using 4MUG as
substrate in case of exceptionally low GAA activity
(Fig. 4B). The implementation of DBSs has enabled
(newborn) screening, and several analytical methods have
proven their value as first-tier test. There is general agree-
ment that additional tests remain necessary to finally
establish the diagnosis. For reasons mentioned in the text,
we advise to conduct genetic testing in addition to any type
of enzymatic testing, as recommended recently by the
EPOC consortium and others [18, 41].
The recommended enzymatic and molecular diagnostic
flow at our Center is as follows: (1) start with leukocytes
using 4MUG and glycogen as substrate; (2) confirm with
DNA analysis, in which two disease-associated variants
should be identified, while a pseudodeficiency does not
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qualify as disease-associated variant; (3) if there is doubt,
for example when values are close to the gray zone or when
a DNA variant is unidentified or novel with unknown sig-
nificance unknown, use fibroblasts as confirmation
(Fig. 4A, B).
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Pseudodeficiencies and borderline cases  
c.271G>A (GAA2): common Caucasian background 
Table 3 lists individuals that contained the GAA2 pseudodeficiency allele. In individuals 1-4, 
only the GAA2 variant was detected in heterozygous state but no other disease-associated GAA 
variant were detected. GAA enzyme activities were generally low and in some cases in the 
gray zone, but above the patient range in all three assays (leukocytes using 4MUG or glycogen 
as substrate and fibroblasts using 4MUG as substrate), except for individual 4. This person 
showed an activity that was within the patient range in fibroblasts using 4MUG a substrate 
(19.5 nmol/mg/hr, patient range 4.2-20), while the activity was slightly above the disease 
threshold in leukocytes using 4MUG as substrate. This individual was diagnosed not to have 
Pompe disease. The genetic testing led to the identification of a disease-associated variant in 
exon 19 (c.1831G>A, p.E611K) of the MYBPC1 gene (Myosin Binding Protein C, Slow 
Type). The GAA enzymatic diagnostic outcome remained enigmatic. 
Individual 5 and 6 were homozygous for GAA2. In both cases, the activity for glycogen 
was within the patients’ range, but for 4MUG in the normal range. Also based on the normal 
activity in cultured fibroblasts, both cases were diagnosed not to have Pompe disease.  
Individual 7-10 were compound heterozygous for GAA2 and c.-32-13T>G (IVS1). Also 
in these cases, the activities using glycogen as substrate were in the patient range, but activities 
using 4MUG as substrate were in the normal range or gray zone.  
Individuals 11 and 12 contained the GAA2 allele in heterozygous state in addition to 
two disease-associated variants. Case 11 concerned an unaffected of six children, two females 
of whom have the adult Pompe disease phenotype. DNA analysis of the mother revealed the 
presence of two disease-associated variants on one GAA allele c.[-32-13T>G; 1076-22T>G] 
and the GAA2 variant on the other. The activity in leukocytes was in the patient range when 
measured with glycogen as substrate, but in the gray zone (33.3 nmol MU/hr/mg) when 
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measured in fibroblasts with 4MUG as substrate. She was diagnosed not to have Pompe 
disease. Case 12 demonstrated GAA deficiency in all three assays and was diagnosed with 
adult onset of Pompe disease. She contained [c.271G>A; c.-32-13T>G on one allele, and the 
disease-associated variant c.1447G>A p.(Gly483Arg) on the other. This was supported by her 
clinical history, mentioning unbalanced walking at the age of 26 years, progressing to difficulty 
with running, respiratory involvement at the age of 43, and weak back and walking difficulties 
one decade later. She developed walking disability and started ERT at the age of 64 years.  
In conclusion, the pseudodeficiency GAA2 allele can lower GAA enzyme activity 
measurements when using glycogen as substrate, but not when using 4MUG as substrate. This 
can result in values within the patient range when using leukocytes with glycogen as substrate 
in patients that carry a disease-associated variant on one allele and GAA2 on the second allele.  
 
c.1726G>A and c.2065G>A: common Asian background 
Individual 13 was referred at the age of 73 and was compound heterozygous for c.[1726G>A, 
c.2065G>A] and c.-32-13T>G (IVS1) (Table 4). Activities in leukocytes were in the patient 
range, both when using glycogen and 4MUG as substrate. The activity in fibroblasts was just 
above the patient range in the gray zone. This individual also had elevated urinary glucose 
tetrasaccharide levels, but no pathology in a muscle biopsy. Individual 14 was referred at the 
age of 60 and was homozygous for c.[1726G>A, c.2065G>A]. GAA enzyme activity was in 
the patient range in leukocytes with 4MUG as substrate but not with glycogen as substrate; in 
fibroblasts the activity was just above the patient range. This case also had elevated CK, ASAT, 
and ALAT levels. Both cases did not display clinical signs of Pompe disease and were 
diagnosed not to have Pompe disease. They illustrate the difficulty of GAA diagnosis solely 
based on biochemical assays.  
 
Genetic analysis 
DNA sequence analysis has become an alternative or supportive diagnostic tool in Pompe 
disease. We recently extended the Pompe mutation database, now termed the Pompe disease 
GAA variant database, with clinical information [www.pompevariantdatabase.nl] [1]. There are 
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at least two reasons not to put DNA analysis first in line. First, two disease-associated GAA 
variants cannot always be identified by standard diagnostics, for example when the variant is 
located in an intron [2]. Second, it is not always known whether the variant is disease-
associated, despite the large number of variants listed at www.pompevariantdatabase.nl and at 
the LOVD. 
Our present studies focused on the performance of various enzymatic procedures for 
diagnosing Pompe disease. The pro’s and con’s of various genetic procedures are largely 
known and we mention them only briefly. Sequencing of only the GAA exons and adjacent 
regions bears the risk that disease-associated variants in the promoter sequences or deeper 
intronic sequences are missed. This may be approached using analysis at the mRNA level as 
shown by us previously [2, 3]. Another limitation is the identification of variants of uncertain 
significance (VUS) necessitating the performance of an expression assay [4, 5]. NGS 
procedures, developed for disease specific gene panels, are gaining field, but their application 
is expected to increase the number of VUSs. The great advantage of an enzymatic assay over 
DNA analysis is that the enzymatic assay captures in principle all disease-associated GAA 
variants in one. However, when it comes to carrier detection and genetic counseling in families 
with an index Pompe case, DNA analysis is essential since the activity ranges of carriers and 
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Supplementary Figure S1. Series of assays used for diagnosis of patient 32. DBSs, leukocytes and 
fibroblasts were analyzed as well as the Glc4 content of urine. 1 = pathogenic variant from the mother, 
2= pathogenic variant from the father, * a pilot study by DBS showed GAA activity in the grey zone, 
and BGAL activity higher than normal ranges. Technical replicates were therefore performed (**), as 
well as assays in leukocytes using glycogen or 4MUG (plus acarbose) as substrate and in fibroblast with 
4MUG as substrate. 
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Douglas O. S. de Faria
CHAPTER 3
Novel GAA Variants and Mosaicism in Pompe 
Disease Identified by Extended Analyses of 
Patients with an Incomplete DNA Diagnosis
Stijn L.M. in ’t Groen, Douglas O.S. de Faria, Alessandro Iuliano, Johanna 
M.P. van den Hout, Hannie Douben, Trijnie Dijkhuizen, David Cassiman, 
Peter Witters, Miguel-Ángel Barba Romero, Annelies de Klein, Galhana 
M. Somers-Bolman, Jasper J. Saris, Lies H. Hoefsloot, Ans T. van der 
Ploeg, Atze J. Bergsma, and W.W.M. Pim Pijnappel
Mol Ther Methods Clin Dev. 2020 Jan 13;17:337-348.
doi: 10.1016/j.omtm.2019.12.016
50 | Chapter 3
Original Article
Novel GAA Variants and Mosaicism in Pompe
Disease Identified by Extended Analyses
of Patients with an Incomplete DNA Diagnosis
Stijn L.M. in ’t Groen,1,2,3 Douglas O.S. de Faria,1,2,3 Alessandro Iuliano,1,2,3 Johanna M.P. van den Hout,1,3
Hannie Douben,2 Trijnie Dijkhuizen,4 David Cassiman,5 Peter Witters,5 Miguel-Ángel Barba Romero,6
Annelies de Klein,2 Galhana M. Somers-Bolman,2 Jasper J. Saris,2 Lies H. Hoefsloot,2 Ans T. van der Ploeg,1,3
Atze J. Bergsma,1,2,3 and W.W.M. Pim Pijnappel1,2,3
1Department of Pediatrics, Erasmus University Medical Center, 3015 GE Rotterdam, the Netherlands; 2Department of Clinical Genetics, Erasmus University Medical
Center, 3015 GE Rotterdam, the Netherlands; 3Center for Lysosomal and Metabolic Diseases, Erasmus University Medical Center, 3015 GE Rotterdam, the
Netherlands; 4Department of Genetics, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, the Netherlands; 5Center for Metabolic
Diseases, UZ and KU Leuven, 3000 Leuven, Belgium; 6Internal Medicine Department, Albacete University Hospital, 02006 Albacete, Spain
Pompe disease is a metabolic disorder caused by a deficiency of
the glycogen-hydrolyzing lysosomal enzyme acid a-glucosidase
(GAA), which leads to progressive muscle wasting. This auto-
somal-recessive disorder is the result of disease-associated
variants located in the GAA gene. In the present study, we per-
formed extended molecular diagnostic analysis to identify
novel disease-associated variants in six suspected Pompe
patients from four different families for which conventional
diagnostic assays were insufficient. Additional assays, such as
a generic-splicing assay, minigene analysis, SNP array analysis,
and targeted Sanger sequencing, allowed the identification of
an exonic deletion, a promoter deletion, and a novel splicing
variant located in the 50 UTR. Furthermore, we describe the
diagnostic process for an infantile patient with an atypical
phenotype, consisting of left ventricular hypertrophy but no
signs of muscle weakness or motor problems. This led to the
identification of a genetic mosaicism for a very severe GAA
variant caused by a segmental uniparental isodisomy (UPD).
With this study, we aim to emphasize the need for additional
analyses to detect new disease-associated GAA variants and
non-Mendelian genotypes in Pompe disease where conven-
tional DNA diagnostic assays are insufficient.
INTRODUCTION
Pompe disease (glycogen storage disease type II, OMIM 232300) is a
rare metabolic disorder that leads to progressive muscle wasting
caused by acid a-glucosidase (GAA) enzyme deficiency. This auto-
somal-recessive disorder is caused by disease-associated variants
located in the GAA gene.1 Classic infantile Pompe patients have a
complete deficiency of GAA enzymatic activity and present hypertro-
phic cardiomyopathy and severe muscle weakness shortly after birth.
Patients with residual GAA activity can be classified as childhood- or
adult-onset Pompe patients, based on the age at symptom onset, and
generally do not show cardiac involvement.
Enzyme replacement therapy (ERT) is currently the only available
treatment. Without treatment, classic infantile Pompe patients do
not survive the first year of life due to cardiorespiratory failure.2,3
In order to become eligible for ERT, a patient needs to present a clin-
ical phenotype related to Pompe disease and have a GAA deficiency,
and certain countries require the identification of two disease-associ-
ated variants in the GAA gene.4 GAA activity measurements are
performed using dried blood with spot sampling or with primary
fibroblasts or leukocytes using either glycogen or 4-methylumbellifer-
one-a-d-glucopyranoside (4MU) as a substrate.5 False-positive
results are known to occur using blood-based assays, for example,
those caused by known pseudodeficiency alleles; therefore,
DNA analysis is recommended in order to identify disease-associated
variants.5–7 Routine diagnostic DNA analysis usually focuses
only on the coding regions of GAA using PCR reactions and subse-
quent Sanger sequencing.6,8 This method detects variants in the
coding regions and in close proximity to splice sites but not in the
promoter, UTRs, and most of the intronic regions.4,9 Reported
variants are listed in the “Pompe disease GAA variant database”
(http://www.pompevariantdatabase.nl), which contains over 400 dis-
ease-associated variants in GAA and has4 recently been extended to
include clinical phenotypes.10 When the disease-associated variants
of both alleles are identified using DNA sequencing, a general predic-
tion of the patient phenotype is possible using the information in this
database. Recent findings indicate that analysis of the modifier
c.510C> T variant, which is silent but modulates splicing in patients
carrying the common c.-32-13T>G (IVS1) variants, is also
important.11
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Previously, we described an exon-flanking RT-PCR that can be used
to detect novel disease-associated variants that affect pre-mRNA
splicing, irrespective of their location.9,12 This assay is important
for diagnosis but also to allow the design of antisense oligonucleotides
that can restore splicing.12–15 Other work has shown single-nucleo-
tide polymorphism (SNP) array analysis to be capable of explaining
phenotypes by detecting large deletions or genomic copy number var-
iations (CNVs).16–18 In addition, SNP array analysis can be used to
elucidate homozygote variants incompatible with Mendelian inheri-
tance by detecting uniparental isodisomies (UPDs) and regions of ho-
mozygosity (RoHs).16,17
Here, we utilized the additional diagnostic assays described above to
identify the genetic cause of Pompe disease in six patients from four
families with incomplete DNA sequencing results. This resulted in the
identification of three novel disease-associated variants located in
non-coding regions of GAA. Additionally, we describe the genetic
analysis performed for a patient with an atypical Pompe phenotype,
first described in Labrijn-Marks et al.17 We provide the clinical symp-
toms and the series of experiments that were performed in order to
make this diagnosis and to strengthen the conclusion that this is a
mosaic patient.
RESULTS
The six patients (including three siblings) described here had symp-
toms that could be attributed to a GAA deficiency. Enzymatic activity
of GAA was found deficient in primary fibroblasts and indicated that
Pompe disease is a probable cause of symptoms. Genetic screenings of
the coding regions of GAA were insufficient to provide a genotype
that corresponds with the observed phenotype (Table 1).
Patient 1
The first indication of Pompe disease was observed during prenatal
ultrasound, which found evidence of cardiac hypertrophy. Muscle
weakness presented shortly after birth, and cultured primary fibro-
blasts showed no GAA enzyme activity (Table 1). Sanger sequencing
of the coding regions identified the heterozygous c.2331+2T>A
variant (Table 1; Figure 1A). The intronic c.2331+2T>A variant has
been classified as “very severe” and is associated with the classic infan-
tile phenotype when combined with a null allele.10,19 This variant is
located close to the exon 16 splice donor site and affects splicing of
intron 16, ultimately resulting in a frameshift, the generation of an
early stop codon, and mRNA degradation. The second disease-asso-
ciated variant was not identified by standard DNA sequencing.
Exon-flanking RT-PCR for all GAA exons was performed as previ-
ously described9 to test for the presence of a non-coding intronic
variant and revealed an aberrant product of exons 8, 9, and 10 (Fig-
ure 1B; product 2). Sanger sequence analysis of this product showed
the exclusion of exon 9 from the transcripts, but it failed to identify a
candidate splicing variant around the splice junctions (Figure 1C). To
test the possibility of a deletion that could have been obscured by the
presence of the other allele, we performed flanking exon PCR analysis
of exon 9 (ranging from exon 8 to exon 10) using genomic DNA as a
template (Figure 1D). This showed the presence of an additional band
in the patient DNA that was not found in the healthy control, one that
corresponded with the expected product ranging from exon 8 to 10
and one that contained a 343-bp deletion that spanned exon 9 and
parts of the neighboring introns (band A in Figure 1E).
The resulting c.1327-61_1437+171del variant explains the exclusion
of exon 9 at the RNA level and why the initial DNA sequencing anal-
ysis was unable to detect this variant, as the annealing sites for PCR
amplification were included in the deleted region. The deletion of
exon 9 has been shown to result in a total disruption of GAA
enzyme activity in previous work.9 The combination of c.1327-
61_1437+171del and c.2331+2T>A explains the lack of enzyme
activity and the classic infantile phenotype of the patient (Figure 1F).
Patient 2
The second patient presented mild muscle weakness at 15 years of
age. GAA activity in fibroblasts was found to be reduced to
13.7 nmol/h/mg (patient range: 0–20 nmol/h/mg). Sanger sequencing
analysis performed on the patient’s DNA identified the c.-32-13T>G
Table 1. Basic Information for All Patients at Start of Analysis
Age at Symptom
Onset
GAA Activity in Fibroblasts




Variant 2 Initial Symptoms
Patient 1 <1 month 0 nmol/h/mg
c.2331+2T>A
p.0?
? muscle weakness and cardiomyopathy















muscle weakness and general fatigue





muscle weakness and general fatigue
Patient 6 <1 month 8.1 nmol/h/mg
c.925G>A
p.(Gly309Arg)
? left ventricular hypertrophy
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(IVS1) variant in a heterozygous state but failed to identify a second
disease-associated variant (Table 1; Figure 2A)
Exon-flanking RT-PCR of cDNA, derived from the patient’s fibro-
blasts, showed no aberrant splicing products, except for those
caused by the IVS1 variant around exon 2 (Figure 2B).13,20,21
Next, we performed SNP array analysis to test for the presence of
large genomic aberrations. This analysis revealed a deletion on chro-
mosome 17 (GRCh37/hg19 [Chr17:78.059.821–78.076.592]) (Fig-
ure 2C). Further evaluation of this 17kb deletion indicated that it
starts upstream of GAA in the CCDC40 gene and included the pro-
moter, transcription start site (TSS), and non-coding exons 1A and
1B of GAA.
Formally proving the pathogenicity of this deletion was compli-













































Patient 1: 16 1715
c.2331+2T>A
Allele 1











Figure 1. Identification of a Disease-Associated Deletion in Patient 1 Using the Splicing Assay
(A) Genotype of patient 1 at the start of analysis. (B) Splicing assay for GAA exons 2–19 performed on cDNA obtained from fibroblasts. Bands marked 1. and 2. indicate two
different products detected around exon 9. (C) Cartoons of products 1 and 2 identified using Sanger sequencing of the PCR product. (D) PCR product from GAA exon 8 to
exon 10, performed on DNA. A., An additional band from patient 1 that was 343 bp smaller compared to the normal product; *, non-specific bands as a result of the PCR. (E)
Sanger sequencing of product A. The new junction resulting from the deletion is indicated. (F) Cartoon of both disease-associated variants identified in patient 1.
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from the IVS1 allele. To address this, the sequence of exon 3 in the
patient’s DNA and mRNA was analyzed for allele-specific SNPs
(Figure 2D). We identified the c.596A>G SNP (rs1042393, minor
allele frequency [MAF] in Dutch population: 75%) in a heterozy-
gous state in the patient’s DNA.22 With the use of an IVS1-specific
PCR (Figure S1), we found the c.596A>G SNP not to be present on
the allele containing the IVS1 variant. Sequence analysis of the
cDNA failed to detect transcripts that contained the c.596A>G
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Figure 2. Identification of a GAA Promoter Deletion in Patient 2 Using a SNP Array
(A) Genotype of patient 2 at the start of analysis. (B) Splicing assay forGAA exons 2–19 performed on cDNA obtained from fibroblasts. *Knownmis-spliced transcripts caused
by the IVS1 variant. (C) Cartoon of the genomic region spanning the CCDC40, GAA, and EIF4A3 genes in the chromosome (top) and the SNP array analysis (bottom)
visualized for Chr17:78,050,000–78,120,000. Zooms are also shown on the 50 and 30 ends of the 17-kb deletion. (D) Sanger sequencing results around the c.596A>G SNP
using a non allele-specific PCR of DNA (top), an IVS1 allele-specific PCR of DNA (middle), and a non allele-specific PCR of cDNA obtained from fibroblasts (bottom). (E)
Cartoon of both disease-associated variants identified in patient 2.
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In conclusion, the 17kb deletion, including the promoter and TSS,
completely abrogates GAA expression, and the combination with
the late-onset IVS1 variant on the other allele (Figure 2E) explains
the late-onset phenotype presented by the patient.
Patients 3, 4, and 5
Patients 3, 4, and 5 are siblings, all of whom showed progressive mus-
cle weakness later in life. Primary fibroblasts were only available for
patient 3. GAA activity in lymphocytes was deficient in all three sib-
lings; this was confirmed in the primary fibroblasts of patient 3 (Table
1). Sanger sequence analysis revealed the 2065G>A variant in a ho-
mozygous state for all three siblings but was unable to identify any
disease-associated variants (Figure 3A). Previous work has shown
that the c.2065G>A variant reduces GAA activity to 54% in a GAA
cDNA expression construct.23 This reduction is not sufficient for a
patient to present symptoms associated with Pompe disease but is
known to lead to a pseudodeficiency of GAA.23
Exon-flanking RT-PCR of cDNA derived from fibroblasts of patient
3 did not detect any aberrant splicing events but showed an overall
low expression of GAA (Figure 3B). Quantitative real-time PCR
(qRT-PCR) analysis confirmed this, showing a reduction of GAA
expression to 8% of healthy control values (Figure 3C). SNP array anal-
ysis showed several large RoHs in all siblings that were likely derived
from regions that were homologous in both parents, suggesting con-
sanguinity between the parents. Interestingly, all three siblings were
found to have a RoH ranging from 17q25.3 to the 17qter (including
GAA) but this was not present in the paternal DNA (Figure 3D; Fig-
ure S2). The consanguinity of the parents explains the presence of
the multiple RoHs in the three siblings via a combination of several
identical blocks. However, this finding does not explain the decreased
expression of GAA mRNA, and we hypothesized the presence of a
variant in the 50 UTR or the promoter. To this end, Sanger sequencing
was performed for the non-coding first exons and the GAA promoter
(Figure 3E). Sanger sequence analysis of this region revealed the pres-
ence of the homozygous variant c.-113+2T>C in patient 3. This variant
is located close to the splice acceptor of exon 1A, which is, according to
recent annotations, the 50 part of exon 1. Our unpublished RNA
sequencing (RNA-seq) data indicate that in agreement with the recent
annotations, exon 1 consists of two small exons (exon 1A and exon 1B)
that are spliced in cells from healthy individuals, as well as patients with
Pompe disease. The c.-113+2T>C variant was also found in a homozy-
gous state in the two siblings (patients 4 and 5) and in a heterozygous
state in paternal DNA. This variant has not been described previously.
DNA from the mother was unavailable.
To investigate the pathogenic nature of c.-113+2T>C, a previously
published minigene model was modified to include the genomic
region of exon 1A.12 Two new constructs were generated, one wild-
type and one carrying the c.-113+2T>C variant (Figure 3F). qRT-
PCR of cDNA obtained from transfected HEK293T cells using
primers located in exon 2 showed that c.-113+2T>C reduced GAA
expression to 35% of the wild-type minigene (Figure 3G). Exon-flank-
ing PCR for exons 1 to 3 showed that c.-113+2T>C lowered expres-
sion of mRNA containing exon 1B-exon 3 (Figure 3H, left panel).
An additional exon-flanking RT-PCR was performed to detect aber-
rant splicing events between exons 1A and 1B (Figure 3H). The wild-
type construct spliced both exons correctly, whereas the mutant
completely abolished expression of the mRNA transcript containing
the exon 1A-exon 1B splice junction (Figure 3H). We note that we
were unable to test these splicing events in patient fibroblasts due
to the low expression of GAA mentioned previously.
In summary, the c.-113+2T>C variant decreases expression of GAA.
We note that the reduction in the minigene was less strong (65%)
compared to the reduction in fibroblasts (92%). This difference might
be due to promoter-dependent effects of the c.-113+2T>C variant, as
in the patient’s fibroblasts, mRNA expression is regulated by the
endogenous GAA promoter, whereas expression from the minigene
model is regulated by the cytomegalovirus (CMV) promoter. Addi-
tionally, all three patients carry both the c.-113+2T>C and
c.2065G>A variants at a homozygous state (Figure 3I). The
c.2065G>A missense variant is known to decrease activity to
�50%.23 The combined action of both variants likely reduces endog-
enous GAA activity to pathogenic levels.
Patient 6
Indications for a superior vena cava syndrome were found during a
routine prenatal ultrasound. Further cardiac screening was performed
at the age of 2.5 months and revealed a left ventricular hypertrophy
(LVH) with cardiac ultrasound, whereas electrocardiography showed
a shortened PQ interval time without signs of pre-excitation (Table
2). At this time, the patient was normotonic with good psychomotor
development and showed no signs of muscle weakness. Exome
screening of cardiac genes was negative, and a metabolic examination
of plasma and urine showed mildly elevated creatine kinase (CK) and
transaminase levels. GAA activity was found to be only slightly
Figure 3. Identification of a RoH and a Novel Splicing Variant in Exon 1A in Patients 3–5
(A) Genotype of patient 3 at the start of analysis. (B) Splicing assay forGAA exons 2–19 performed on cDNAobtained from fibroblasts frompatient 3. (C) qRT-PCR results forGAA
performed on cDNA obtained from fibroblasts, normalized for GAPDH. Significance comparing healthy control and patient 3: p < 0.001. (D) SNP array result visualized for a
segment of chromosome 17 showing absence of deletions or duplications (top) and a RoH from17q25.3 to 17qter (bottom). (E) Sanger sequencing of exon 1, demonstrating the
presence of the c.-113+2T>C variant. (F) Cartoonof the generated constructs ranging fromGAA exon 1A to exon 3,with the c.-113+2T>C variant indicated. (G) qRT-PCRofGAA
exon 2 performed on cDNA obtained fromHEK293T cells after transfection with the minigenemodel. Results are normalized for neomycin. All comparisons were significant: p <
0.001. (H) RT-PCRs performed oncDNAobtained from transfectedHEK293T. RT-PCR ranging fromexon 1b to exon 3 (left) andRT-PCR for the exon1a–1b splice junction (right).
With an accompanying cartoon for the RT-PCRs, the location of the primers are indicated using arrows. (I) Cartoon of the disease-associated variant c.-113+2T>C and the
pseudodeficiency variant c.2065G>A, both at a homozygous state in patient 3. Error bars in C and G indicate standard deviation (S.D.)
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c.925G>A in cDNA from cultured fibroblasts




















c.925G>A in DNA from leukocytes
c.925G>A in DNA from cultured fibroblasts
AC GAC C CG GGG G G TTTT G
c.925G>A in DNA from skeletal muscle
AC GAC C CG GGG G G TTT TT G
AC GAC C CG GGG G G TTTT G
location probe
17p12 (green) 96% (400) 99.5% (200) 98% (200)
17q22 (red) 95% (200) 95.5% (200) 97.5% (200)
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decreased in leukocytes, whereas in primary fibroblasts, enzymatic ac-
tivity was within the range of late-onset Pompe disease (Table 2).17
Histochemical analysis of a muscle biopsy showed normal
morphology, but some enlarged lysosomes were visible using acid
phosphatase staining (Figure S3). In addition, periodic acid-Schiff
(PAS) staining showed minor glycogen accumulation (Figure S3).
These findings suggested that the patient might have late-onset
Pompe disease,24 but there were two inconsistencies: the lack of
GAA deficiency in lymphocytes and the LVH, a characteristic of
the classic infantile phenotype but not late-onset Pompe disease.
Sanger sequencing revealed only the disease-associated variant
c.925G>A at a heterozygous state (Figure 4A). This variant is associ-
ated with the classic infantile phenotype when combined with a null
allele.25,26 Sanger sequence analysis of the parents (both showed no
signs of Pompe disease) found the c.925G>A only in a heterozygous
state in paternal DNA. No other disease-associated variants were
identified in the patient nor in his parents (Table 2). Exon-flanking
RT-PCR of cDNA from primary fibroblasts of the patient did not
detect any splicing aberrations (Figure 4B). Sequence analysis of the
GAAmRNA transcripts showed that the majority of transcripts con-
tained the c.925G>A variant (Figure 4C). This indicated that the sec-
ond GAA allele was present but was expressed at reduced levels. SNP
array analysis identified a 39.5-Mb allelic imbalance, ranging from
17q21.31 to the 17qter (Figure 4D).17 The imbalance showed no
change in CNV but a change in chromosomal equilibrium (i.e., a
change in the B allele frequency of heterozygous SNPs) for SNPs
located in the affected segment.17 Within the imbalanced segment,
GAA was present, whereas all other genes present within this region
were unlikely to be the cause of the presented phenotype (Table S1).27
When analyzing the SNP array data, it became clear that the allelic
imbalance was more profound in fibroblasts compared to leukocytes.
We estimated a deviation in B allele frequency (DBAF) of ±25% in fi-
broblasts compared to ±17% in leukocytes (Figure 4D). This was
consistent with the GAA activity, which showed that activity in fibro-
blasts was lower compared to leukocytes (Table 2).
Additional Sanger sequence analysis of the patient’s tissues showed a
skewed contribution in favor of the c.925A variant in primary fibro-
blasts, leukocytes, and also in skeletal muscle tissue (Figure 4E).
Microsatellite analysis of chromosome 17 showed a skewed composi-
tion in favor of the paternal allele in the affected segment, whereas
markers located in the unaffected segmentwere distributed evenly (Fig-
ure S4). Fluorescence in situ hybridization (FISH), using probes located
on 17p12 and 17q22 to detect both ends of chromosome 17, showed a
normal karyotype in the patient’s fibroblasts (Figure 4F). Both ends of
the chromosome were present at equal numbers, confirming that this
imbalance is not the result of a change in genomic copy number.
The results are in line with a mosaic segmental UPD, in which
affected cells contain two copies of the paternal GAA that harbor
the c.925G>A variant. The patient’s tissue is comprised of two distinct
cell populations: one with the c.925G>A variant in a homozygous
state, resulting in a classic infantile Pompe genotype, and one with
Figure 4. Identification of a Mosaic Segmental UPD in Patient 6
(A) Genotype of patient 6 at the start of analysis. (B) Splicing assay for GAA exons 2–19 performed on cDNA obtained from fibroblasts. (C) Sanger sequencing around the
c.925G>A variant performed on cDNA obtained from fibroblasts. (D) SNP array analysis of chromosome 17 performed on DNA obtained from leukocytes (top) or fibroblasts
(bottom). DBAF indicates the estimated difference in BAF between the affected and unaffected segment. (E) Sanger sequencing around the 925G>A variant performed on DNA
obtained from leukocytes (top), fibroblasts (middle), or skeletal muscle tissue (bottom). (F) FISH analysis performed in fibroblasts showing probes located on 17p12 (green) and
17q22 (red) and 40,6-diamidino-2-phenylindole (DAPI) staining to highlight the cell nucleus. A representative image is shown, and a quantification is given below the figure. (G, top)
Biochemical quantification of GAA activity measured using 4MU as a substrate. Significance comparing patient 6 and all other samples: not significant. Significance comparing
classic infantile and healthy control: p = 0.01. (G, bottom)Measurements of intracellular glycogen. Significance comparing classic infantile versus the childhood, adult, and healthy
control samples: p < 0.01. Comparison of patient 6 and all other samples: not significant (patient 6 versus healthy control: p = 0.052). Both assays were performed on the same
protein extracts obtained from fibroblasts after culturing to confluence for 3 weeks, followed by a 24h starvation to clear intracellular glycogen. GAA activity is shown as a
percentage of the healthy control fibroblasts. (H) Cartoon of both disease-associated variants identified in patient 6. Error bars in G indicate S.D.
Table 2. Clinical and Molecular Information Accompanying Patient 6
Patient Information
Age at analysis 2.5 months to 4 years
Gender male
GAA Activity Patient Range
Fibroblasts 8.1 nmol/h/mg 0–20 nmol/h/mg
Leukocytes 26 nmol/h/mg 0–10 nmol/h/mg
Clinical Description
Left ventricular hypertrophy detected
No signs of respiratory insufficiency
No muscle weakness
Cardiac Muscle Measurements
Left ventricular mass 122.1 g (Z score +3.7)
Shortening fraction 37.1% (Z score +0.14)
CK levels 243 U/L (ref < 230 U/L)
Disease-Associated Variants
Allele 1 c.925G>A




Allele 2 no variant found
Mother (Asymptomatic)
Allele 1 no variant found
Allele 2 no variant found
SNP Array Result
Segmental abnormality range: Chr17:41.681.527–Chr17qter
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the c.925G>A variant in a heterozygous state, which results in a
healthy cell population. To confirm this further, two protein-based
assays were performed to examine the biochemical properties of the
patient’s cells. Figure 4G shows the results of the glycogen accumula-
tion and GAA activity assays, which were performed on the same
cellular extract. Patient fibroblasts accumulated intracellular
glycogen, a characteristic that normally only occurs in vitro in fibro-
blasts derived from classic infantile Pompe patients but not in late-
onset patients. However, GAA enzymatic activity (Figure 4G) was
present and in the range of late-onset Pompe disease. This is in agree-
ment with a genetic mosaicism with the sample consisting of two cell
populations: one that accumulates glycogen in vitro and one that still
possesses enzymatic GAA activity and thereby does not accumulate
glycogen.
In summary, the atypical phenotype for Pompe disease presented by
patient 6 can be explained by a genetic mosaicism for a segment of
chromosome 17 that includes GAA. It is likely that in cardiac cells,
the contribution of homozygous cells to heart tissue is relatively large,
causing a LVH. In skeletal muscle cells, the mixture of homozygous
and heterozygous nuclei in muscle fibers likely causes only mild
pathology.
DISCUSSION
Conventional diagnostic procedures are able to identify and diagnose
most individuals with Pompe disease; however, a number of cases
remain unexplained.4 Here, we emphasize the need to introduce
new methods in the diagnostic validation of Pompe disease in cases
for which conventional procedures prove insufficient. With the use
of extended diagnostic analyses, we identified three new variants in
the GAA gene. With the use of minor adjustments to already-existing
assays, we proved the pathogenicity of the variants and completed the
diagnosis for six cases of Pompe disease derived from four families
(Table 3).
In previous work, the exon-flanking RT-PCR analysis proved useful
to identify novel variants located outside the coding regions, for
example, as shown by the identification of c.2190-345A>G.9 Here,
we showed this assay to be capable of detecting novel deletions and
revealing differential gene expression as a result of GAA variants.
However, the 17kb deletion in patient 2 and thereby other deletions
spanning more than one exon remained undetected, and additional
assays were required. To detect the deletion of exon 18, which is a
common variant in Caucasian patients with Pompe disease, our diag-
nostic center performs a separate PCR reaction.28 However, other
large deletions are not routinely analyzed and will therefore not be
identified. This is supported by the under-representation of gross de-
letions and other types of variants, such as promoter variants in
GAA.10,29,30 As described in the Human Gene Mutation Database
(HGMD), gross deletions represent 7.5% of all disease-associated var-
iants, whereas approximately 1% of all disease-associated variants are
reported to be located in promoter regions genome wide.29 For
Pompe disease, gross deletions constitute only 1.5% of known vari-
ants, and the variants described here in patients 2 and 3 represent
the first reported disease-associated variants located in the promoter
and 50 UTR regions of GAA.10 These regions are critical for the regu-
lation of gene expression, and we recommend these regions to be
included in future diagnostic analyses. The detection of non-coding
variants can be improved with the implementation of techniques
already established in many diagnostic laboratories as a follow-up
to DNA sequencing. SNP array analysis allows for the detection of
large deletions or duplications, whereas aberrant splicing events or se-
vere reductions in gene expression can be detected using whole tran-
scriptome sequencing.18,31 Other existing techniques can also be im-
plemented for specific monogenic disorders and are capable of
detecting smaller aberrations. Multiplex ligation-dependent probe
amplification (MLPA) can detect deletions affecting single exons,
whereas exon-flanking RT-PCR can be performed to detect deletions,
splicing aberrations, and differential gene expression.9,18 A more sys-
tematic approach, as described above, could lead to the identification
of new disease-associated variants and provide a complete DNA diag-
nosis for patients. The implementation of the approaches outlined
here should therefore be considered to improve the genetic analysis
of cases with an unexplained genetic diagnosis.
Patients with an atypical phenotype often represent a challenge when
diagnosing genetic disorders. Patient 6 presented a unique pathological
condition: LVH, a characteristic usually observed only in the classic in-
fantile phenotype, while lacking any sign of muscle weakness after 4
years of age. This phenotype was corroborated by the differences in
Table 3. Novel Variants Identified with Proof of Pathogenicity
Disease-Associated Variant on Allele 1 Disease-Associated Variant/Event on Allele 2 Proof of Pathogenicity for Novel Variant
Patient 1 c.2331+2T>A c.1327-61_1437+171dela
resulting deletion in the transcript is known to
cause a deficiency of GAA
Patient 2 c.-32-13T>G
17 kb deletion, including promoter and
transcription start site of GAAa
no RNA expression originating from the allele
containing the deletion





expression and splicing analysis of variant in
minigene model
Patient 6 c.925G>A mosaicism c.925G>Aa
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GAA activity in the patient’s tissues. With the use of the SNP array
analysis, we detected a chromosomal imbalance on chromosome 17,
which was crucial to identify the genetic mosaicism of Pompe disease.
Genetic mosaicisms are often associatedwith amilder symptomatology
due to the presence of a healthy or less affected cell population.32
The mosaicism in patient 6 appears to be the result of a segmental
UPD. UPDs have been associated with many inherited disorders
and appropriately explain a subset of patients carrying homozygous
disease-associated variants.33 Whole-chromosome UPDs are re-
ported to occur in 1/3,500 births,33 whereas segmental UPDs occur
less frequently and are the result of somatic recombination.34–36
The mosaic nature of the segmental UPD and the high percentage
of affected cells in several of the patient tissues suggest that the recom-
bination event occurred early in the postzygotic stage of embryonal
development.34–36 Tissues of this patient were thereafter comprised
of two cell populations, with the c.925G>A disease-associated variant
being present at either a heterozygous (healthy) or homozygous
(classic infantile) state.
The presence of a population of healthy cells in the patient did not pre-
vent the development of LVH, which normally only occurs in classic
infantile patients. However, at 4 years of age, the patient has not yet
manifested any other symptoms related to Pompe disease. The lack
of muscle weakness in this patient was reflected by mild pathology in
his muscle biopsies. This is likely due to the multinucleation of muscle
fibers, whereby the genetic mosaicism in this patient is offset by the
presence of both affected and unaffected nuclei in individual muscle fi-
bers, which could be sufficient to prevent muscle pathology. A compre-
hensive follow-up of this patient, including CNS magnetic resonance
imaging (MRI) and neuropsychological investigations, will be required
to rule out additional symptoms, such as white matter changes in the
brain, which can manifest in classic infantile Pompe patients.37,38
This study shows the need for the implementation of additional diag-
nostic assays and research as a follow-up when conventional proced-
ures prove insufficient or when a patient’s symptoms or biochemical
characteristics do not match to a disorder. For monogenic disorders,
such as Pompe disease, more specific assays can be implemented for
an improved analysis of a singular gene. The implementation of this
follow-up will likely result in the identification of novel variants and




The patients described here were selected for their clinical and/or
biochemical diagnosis that could be attributed to a deficiency of
GAA. Informed consents were obtained to perform extended diag-
nostic assays to identify GAA variants and explain the presented phe-
notypes. Analysis of the patients analyzed in this study was approved
by the medical ethics committee of the Erasmus MC. Primary fibro-
blasts were not available for patient 4 and 5, assays were performed for
patient 3, and findings were thereafter confirmed in DNA from pa-
tients 4 and 5.
DNA Analysis
GenBank: NM_001079803.2 and NM_0001079803.2 were used as
reference sequences for GAA DNA and mRNA, respectively, where
c.1 represents the first nucleotide of the translation start codon
ATG. NP000143.2 was used as a reference for GAA protein. We
note that in previous annotations, exon 1 comprised 334 nt, whereas
in current annotations, this region is divided into two exons (exon 1A
and 1B) and a 185-nt intron. All SNP arrays analyses were performed
using the Illumina Infinium CytoSNP-850K BeadChip platform.
Analysis of genes related to genetic disorders located within specified
genomic regions was performed using Genomic Oligoarray and SNP
Array Evaluation Tool v3.0.
Histology and Imaging
Acid phosphatase staining was performed on cryosections, as
described.39 PAS staining was performed on sections of glycolme-
thacrylate (GMA)-processed tissue.24 Hematoxylin and eosin
(H&E) stainings were performed on both GMA fixated and cryosec-
tions. A Hamamatsu NanoZoomer 2.0 (Hamamatsu Photonics) was
used for imaging, and images were analyzed with NDP.view
software.
RNA Isolation and cDNA Synthesis
Total RNA was isolated from cultured fibroblasts using the RNeasy
minikit (QIAGEN), including a DNaseI (QIAGEN) treatment. RT-
PCR was performed using the iScript cDNA synthesis kit (Bio-Rad)
in reactions with 300–800 ng RNA input.
PCR and Sanger Sequencing
RT-PCR and qRT-PCR were performed as described.9 Sanger
sequencing of PCR products was performed using a ABI3730XL
DNA analyzer (Thermo Fisher Scientific) and analyzed using ApE
software.
Generation of the Minigene Constructs and Transfection
The minigene model described in Bergsma et al.12 was modified as
follows: with the use of a primer with a XhoI overhang and a SBF1
restriction site, the exon 1a region was amplified and cloned in the
construct. We used the QuikChange II Site-Directed Mutagenesis
Kit (Agilent Technologies) to introduce the c.-113+2T>C variant.
Transfection of the minigene constructs was performed in
HEK293T cells using Lipofectamine 2000 (Invitrogen). RNAwas har-
vested 48 h after transfection.
Enzyme Activity and Glycogen Assay
GAA activity wasmeasured in leukocytes or fibroblasts using 4MU, as
described.9 All 4MU assays were performed in diagnostic settings,
with the exception of Figure 4G. For this experiment, fibroblasts
had been confluent for 3 weeks and starved in glucose-free medium,
24 h before harvest, after which, GAA activity was measured using the
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Figure S1: IVS1-specific RT-PCR.
The forward primer was designed in intron 1b with the last base being c.-32-13G to only amplify 
the IVS1 allele. The reverse primer was located in exon 3. DNA was obtained from patient 2’s 
leukocytes. A control DNA sample was obtained from a healthy individual that did not carry the 
IVS1 variant.
Figure S2: RoH in chromosome 17 of patients 3, 4 and 5 
SNP array analysis visualized for Chr17:77.200.000-81.000.000.  The parental DNA showed a 
normal composition, while patients 3 and 4 showed a RoH ranging from 17q25.3 to the 17qter. 
Patient 5 showed a RoH ranging 3Mb in 17q25.3. 
Figure S3: Skeletal muscle biopsy of patient 6. 
Representative images of histological stainings performed on a muscle biopsy tissue obtained 
from patient 6. (A) Heamatoxylin-eosin staining performed on a cryosection. (B) Acid 
phosphatase staining performed on a cryosection, lysosomes are visible as red dots located 
within the myofibers. (C) Heamatoxylin-eosin staining performed on a GMA fixed tissue 
section. (D) PAS staining performed on a GMA fixed tissue section. Minor glycogen 
accumulation is visible as dark purple patches in the tissue. 
Figure S4: Microsatellite analysis of chromosome 17 in patient 6. 
Microsatellite analysis for chromosome 17 of patient 6. The location of the 15 probes used are 
indicated with arrows. The start of the imbalance is highlighted in red and the details of two 
representative probes are shown: one probe is located in the unaffected segment (left) (17q11.2) 
and one in the imbalanced segment (right) (17q25.3).  
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Table S1: List of genes located in the chromosomal imbalance found in patient 6 and the recessively 
inherited disorders associated with these genes 
 
#   Mapped genes Gene Map Disorder 
1 : GAA(17q25.2-q25.3) Glycogen storage disease II 
2 : SGCA(17q21) Muscular dystrophy, limb-girdle, type 2D 
3 : MEOX1(17q21) Klippel-Feil syndrome 2 
4 : SOST(17q11.2) Craniodiaphyseal dysplasia, autosomal dominant 
5 :   Van Buchem disease 
6 :   Sclerosteosis 1 
7 : NAGS(17q21.31) N-acetylglutamate synthase deficiency 
8 : G6PC3(17q21.31) Neutropenia, severe congenital 4, autosomal recessive 
9 :   Dursun syndrome 
10 : GRN(17q21.32) Frontotemporal lobar degeneration with ubiquitin-positive inclusions 
11 :   Aphasia, primary progressive 
12 :   Ceroid lipofuscinosis, neuronal, 11 
13 : ITGA2B(17q21.32)ITGB3(17q21.32) Bleeding disorder, platelet-type, 16, autosomal dominant 
14 :   Glanzmann thrombasthenia 
15 :   Thrombocytopenia, neonatal alloimmune, BAK antigen related 
16 : CCDC103(17q21.31) Ciliary dyskinesia, primary, 17 
17 : MAPT(17q21.1) Tauopathy and respiratory failure 
18 :   Susceptibility to parkinson disease 
19 :   Pick disease 
20 :   Supranuclear palsy, progressive atypical 
21 :   Dementia, frontotemporal, with or without parkinsonism 
22 :   Supranuclear palsy, progressive 
23 : WNT3(17q21) Tetra-amelia, autosomal recessive 
24 : GOSR2(17q21) Epilepsy, progressive myoclonic 6 
25 : ITGB3(17q21.32) Thrombocytopenia, neonatal alloimmune 
26 :   Myocardial infarction, protection and/or susceptibility 
27 : TBX21(17q21.32) Asthma and nasal polyps 
28 : PNPO(17q21.32) Pyridoxamine 5'-phosphate oxidase deficiency 
29 : HOXB1(17q21.3) Facial paresis, hereditary congenital, 3 
30 : XYLT2(17q21.33) Pseudoxanthoma elasticum 
31 : DGKE(17q22) Nephrotic syndrome, type 7 
32 : EPX(17q23.1) Eosinophil peroxidase deficiency 
33 : MKS1(17q22) Bardet-Biedl syndrome 1-12 
34 :   Meckel syndrome 1 
35 : ACE(17q23.3) MPO(17q23.1) Alzheimer disease 
36 : MPO(17q23.1) Myeloperoxidase deficiency 
37 : RAD51C(17q25.1) Fanconi anemia, complementation group O 
38 :   Susceptibility to breast-ovarian cancer, familial 
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#   Mapped genes Gene Map Disorder 
39 : TRIM37(17q23.2) Mulibrey nanism 
40 : ACE(17q23.3) Renal tubular dysgenesis 
41 :   Microvascular complications of diabetes 3 
42 :   Stroke, hemorrhagic 
43 : TACO1(17q23.3) Mitochondrial complex IV deficiency 
44 : GH1(17q24.2) Growth hormone deficiency 
45 :   Kowarski syndrome 
46 : CD79B(17q23) Agammaglobulinemia 6 
47 : PRKAR1A(17q23-q24) Acrodysostosis 1 
48 :   Carney complex, type 1 
49 :   Thyroid papillary carcinoma 
50 :   Adrenocortical tumor, somatic 
51 :   Myxoma, intracardiac 
52 :   Pigmented nodular adrenocortical disease, primary, 1 
53 : FAM20A(17q24.2) Amelogenesis imperfecta and gingival fibromatosis syndrome 
54 : USH1G(17q25.1) Usher syndrome, type 1G 
55 : SLC25A19(17q25.3) Microcephaly, Amish type 
56 :   Thiamine metabolism dysfunction syndrome 4  
57 : TSEN54(17q25.1) Pontocerebellar hypoplasia 
58 : ITGB4(17q25) Epidermolysis bullosa 
59 : GALK1(17q24) Galactokinase deficiency with cataracts 
60 : ACOX1(17q24-q25|17q25.1) Peroxisomal acyl-CoA oxidase deficiency 
61 : CANT1(17q25.3) Desbuquois dysplasia, 
62 : EIF4A3(17q25.3) Robin sequence with cleft mandible and limb anomalies 
63 : SGSH(17q25.3) Mucopolysaccharidisis type IIIA (Sanfilippo A) 
64 : PDE6G(17q25) Retinitis pigmentosa 57 
65 : ARHGDIA(17q25.3) Nephrotic syndrome, type 8 
66 : PYCR1(17q25.3) Cutis laxa, autosomal recessive, type IIB 
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Abstract
Pompe disease is an inherited disorder caused by disease‐associated variants in the
acid α‐glucosidase gene (GAA). The Pompe disease GAA variant database (http://
www.pompevariantdatabase.nl) is a curated, open‐source, disease‐specific database,
and lists disease‐associated GAA variants, in silico predictions, and clinical pheno-
types reported until 2016. Here, we provide an update to include 226 disease‐
associated variants that were published until 2020. We also listed 148 common GAA
sequence variants that do not cause Pompe disease. GAA variants with unknown
severity that were identified only in newborn screening programs were listed as a
new feature to indicate the reason why phenotypes were still unknown. Expression
studies were performed for common missense variants to predict their severity. The
updated Pompe disease GAA variant database now includes 648 disease‐associated
variants, 26 variants from newborn screening, and 237 variants with unknown se-
verity. Regular updates of the Pompe disease GAA variant database will be required
to improve genetic counseling and the study of genotype–phenotype relationships.
K E YWORD S
database, disease‐associated variants, GAA, NBS, Pompe disease, SNP
1 | INTRODUCTION
Pompe disease (glycogen storage disease type II; MIM #232300) is
an autosomal recessive disorder caused by disease‐associated var-
iants in the acid α‐glucosidase (GAA) gene, resulting in a deficiency of
the GAA enzyme, accumulation of lysosomal glycogen, and
progressive muscle weakness. The clinical spectrum of Pompe dis-
ease is broad (Güngör & Reuser, 2013). The most severe classic in-
fantile phenotype presents shortly after birth with hypertrophic
cardiomyopathy and generalized muscle weakness. These patients
die in the first year of life due to cardiorespiratory insufficiency if left
untreated. The slower progressing phenotype is characterized by
Human Mutation. 2021;42:119–134.
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muscle weakness that can appear at any age from <1 year into
adulthood. These patients are generally spared from cardiac symp-
toms (Kohler et al., 2018; van der Ploeg & Reuser, 2008). Enzyme
replacement therapy (ERT) with intravenously applied recombinant
human GAA is available since 2006. ERT normalizes hypertrophic
cardiomyopathy, improves motor function, and extends survival.
The differences between phenotypes in Pompe disease can, in
part, be attributed to the severity of the disease‐associated variants
present in the GAA gene. Classic infantile patients carry two disease‐
associated variants that completely disrupt the function of GAA (i.e.,
null alleles). This group of patients can be subdivided based on their
cross‐reactive immunological material (CRIM) status, which is de-
fined by the disease‐associated variants involved. When two GAA
variants are present that do not result in GAA protein expression,
the patient is classified as CRIM‐negative. When at least one GAA
variant gives rise to GAA protein expression (in which the GAA
protein can be enzymatically inactive), the patient is classified as
CRIM‐positive. The clinical importance of CRIM status is highlighted
by the fact that CRIM‐negative classic infantile patients have a
poorer prognosis compared with CRIM‐positive classic infantile pa-
tients, possibly due to the formation of high sustained anti‐GAA
antibody titers upon treatment with ERT (Bali et al., 2012; van
Gelder et al., 2015). Patients who do not have the classic infantile
phenotype carry at least one disease‐associated variant that allows
some residual enzymatic activity. These patients are, by definition,
CRIM‐positive (Kroos et al., 2012b; Kulessa et al., 2020).
The “Pompe disease GAA variant database” (http://www.
pompevariantdatabase.nl) is an open‐access database that lists and
classifies all reported variants in the GAA gene. We recently revised this
database to include clinical data from patients collected from the lit-
erature, adapted the classification system for variant severity, and ad-
ded (predicted) CRIM status for disease‐associated variants. The
database included literature up to May 2016, resulting in a total of 561
variants (Niño et al., 2019). In recent years, many new patients and GAA
variants have been reported. These include findings from large patient
populations, such as the French nationwide study (246 patients with
late‐onset Pompe disease) and the Pompe registry (1079 patients from
26 countries; Reuser et al., 2019; Semplicini et al., 2018).
In addition, various countries, including Taiwan, the United
States, Italy, Brazil, and Japan, have implemented newborn screening
(NBS) programs for Pompe disease, resulting in an increase of var-
iants of unknown significance (VUS; Bravo et al., 2017; Burlina
et al., 2018; Chien et al., 2019; Elliott et al., 2016; Momosaki
et al., 2019; Yang et al., 2014). For variants associated with late
onset, the associated phenotypes from NBS cases are still unknown
as symptom onset could, in principle, be delayed until (late) adult-
hood. It will be important to monitor the onset and progress of
symptoms in patients identified via NBS programs closely to de-
termine the severity of the newly identified genetic variants.
Public databases, such as dbSNP (https://www.ncbi.nlm.nih.gov/
snp) and gnomAD (https://gnomad.broadinstitute.org), provide a
source of variants that have been detected in various genome‐wide
studies (Karczewski et al., 2020; Sherry et al., 2001). A large
percentage of these variants represent common sequence variants
that have a minor allele frequency (MAF) ≥ 1%. Several of these
variants have already been reported for the GAA gene and have been
ruled out to cause Pompe disease (Kroos et al., 2007; Labrousse
et al., 2010; Turaça et al., 2015). However, most of the common
sequence variants in these databases are listed as VUSs and may lead
to misinterpretation during molecular diagnostics.
In this study, we provide an update of the Pompe disease GAA
variant database with variants and patients described in the lit-
erature up to January 2020. We included information on novel
GAA variants that were identified via NBS and for which no phe-
notype was yet known. Known common sequence variants in the
GAA gene that do not cause Pompe disease have now also been
added to prevent misdiagnosis. In addition, selected common
missense variants were tested in expression studies and also this
information was added to the updated database. The database
provides a curated up‐to‐date reference source for the molecular
diagnosis of Pompe disease.
2 | METHODS
The Pompe disease GAA variant database is publicly available at
http://www.pompevariantdatabase.nl. The previous version of
the database included literature until 2016; the update described
here contains variants from publications up to January 2020.
Additionally, NBS studies that screened for Pompe disease were
now included if the authors provided the genotypes of the de-
scribed cases. Novel variants were analyzed as described in Niño
et al. (2019). Variants were annotated based on the reference
sequences NM_000152.3 for GAA messenger RNA (mRNA),
LRG_673 genomic sequence for describing variants in intronic
sequences, and NP_000143.2 for GAA protein. Exon annotations
were based on the human genomic build (GRCH37/hg19) for
exons 2–20; however, changes were made to the annotation of
exon 1 to reflect the findings of (GRCH38/hg38). Within this
region, a new 195‐bp intron was identified at positions c.−112
and c.−113. Therefore, the region that was previously annotated
as exon 1 has been split between exons 1A and 1B, which are
separated by intron 1A. Intron 1 has been renamed to intron 1B.
This numbering was made to maintain the same numbering of
subsequent exons compared with existing literature.
Common sequence variants in the GAA gene (hg38
Chr17:80,101,556‐80,119,881) were extracted from gnomAD and
were categorized as “not disease‐associated.” Combined Annotation‐
Dependent Depletion (CADD) in silico predictions were performed
using the CADD (https://cadd.gs.washington.edu) platform, which
compiles different tools for analysis of intronic insertion and deletion
variants (Rentzsch et al., 2019). The MAF and CADD scores were ob-
tained in April 2020. Predictions of effect on pre‐mRNA splicing were
performed using Alamut Visual v.2.15 (Interactive Biosoftware).
Functional studies were performed using site‐directed muta-
genesis (SDM) to generate complementary DNA (cDNA) expression
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TABLE 1 Novel disease‐associated variants added to the Pompe variant database
DNA nomenclature Phenotype combined with a null allele DNA nomenclature Phenotype combined with a null allele
Ch37/hg19 chr17:78,059,821_
78,076,592del
Unknown (disease‐associated) c.1057C>T Unknown (disease‐associated)
c.−113+2T>A Unknown (disease‐associated) c.1057del Unknown (disease‐associated)
c.−32‐17_−32‐10delins(30) Classic infantile c.1099T>G Unknown (disease‐associated)
c.−32‐1G>C Unknown (disease‐associated) c.1106T>A Unknown (disease‐associated)
c.40_47del Classic infantile c.1109G>A Unknown (disease‐associated)
c.104T>C Classic infantile c.1114C>G Unknown (disease‐associated)
c.169C>T Classic infantile c.1114C>T Unknown (disease‐associated)
c.205C>T Unknown (disease‐associated) c.1121G>A Unknown (disease‐associated)
c.258C>A Unknown (disease‐associated) c.1127_1130del Unknown (disease‐associated)
c.265C>T Unknown (disease‐associated) c.1129G>A Unknown (disease‐associated)
c.295_314del Unknown (disease‐associated) c.1153del Unknown (disease‐associated)
c.323G>C Unknown (disease‐associated) c.1192del Unknown (disease‐associated)
c.365del Unknown (disease‐associated) c.1193del Unknown (disease‐associated)
c.380G>A Unknown (disease‐associated) c.1201C>A Unknown (disease‐associated)
c.397T>G Unknown (disease‐associated) c.1209C>A Unknown (disease‐associated)
c.437del Classic infantile c.1211A>C Unknown (disease‐associated)
c.445A>C Unknown (disease‐associated) c.1211A>T Classic infantile
c.484A>C Classic infantile c.1212C>G Unknown (disease‐associated)
c.502C>T Unknown (disease‐associated) c.1216G>A Childhood
c.505C>A Unknown (disease‐associated) c.1219T>C Unknown (disease‐associated)
c.517_519del Childhood c.1221C>A Classic infantile
c.541_545del Classic infantile c.1221del Unknown (disease‐associated)
c.547‐1G>C Unknown (disease‐associated) c.1226_1227insG Classic infantile
c.568C>T Unknown (disease‐associated) c.1231del Unknown (disease‐associated)
c.665T>G Classic infantile c.1240T>C Unknown (disease‐associated)
c.686G>C Unknown (disease‐associated) c.1241del Classic infantile
c.691C>T Unknown (disease‐associated) c.1242C>A Unknown (disease‐associated)
c.692T>C Unknown (disease‐associated) c.1249A>C Unknown (disease‐associated)
c.692+1G>T Unknown (disease‐associated) c.1281G>T Classic infantile
c.693‐2A>C Classic infantile c.1292_1295dup Classic infantile
c.693‐1G>C Unknown (disease‐associated) c.1293_1326+57del Unknown (disease‐associated)
c.715_716del Unknown (disease‐associated) c.1298A>C Classic infantile
c.730C>T Classic infantile c.1311_1312ins(26) Classic infantile
c.736del Unknown (disease‐associated) c.1320_1322del Classic infantile
c.756_757insT Unknown (disease‐associated) c.1327‐54_1437+178del Classic infantile
c.759del Unknown (disease‐associated) c.1358_1361del Classic infantile
c.766_784del Unknown (disease‐associated) c.1378G>T Unknown (disease‐associated)
c.781G>A Classic infantile c.1388_1406del Unknown (disease‐associated)
c.784G>C Unknown (disease‐associated) c.1396dup Unknown (disease‐associated)
(Continues)




DNA nomenclature Phenotype combined with a null allele DNA nomenclature Phenotype combined with a null allele
c.796C>A Childhood c.1402A>T Unknown (disease‐associated)
c.799_803delinsA Unknown (disease‐associated) c.1409A>G Unknown (disease‐associated)
c.837G>C Unknown (disease‐associated) c.1431del Classic infantile
c.841C>T Unknown (disease‐associated) c.1441del Unknown (disease‐associated)
c.876C>G Classic infantile c.1447G>T Unknown (disease‐associated)
c.878G>T Unknown (disease‐associated) c.1456G>T Unknown (disease‐associated)
c.883C>A Unknown (disease‐associated) c.1464dup Classic infantile
c.930_932del Classic infantile c.1470C>A Childhood
c.942C>A Unknown (disease‐associated) c.1477C>T Unknown (disease‐associated)
c.947A>G Classic infantile c.1493G>A Classic infantile
c.950C>T Unknown (disease‐associated) c.1501_1515del Unknown (disease‐associated)
c.955+1G>A Classic infantile c.1507del Classic infantile
c.971dup Classic infantile c.1526A>T Unknown (disease‐associated)
c.982_988del Classic infantile c.1531C>A Unknown (disease‐associated)
c.983T>C Classic infantile c.1537G>A Unknown (disease‐associated)
c.994_995insTT Unknown (disease‐associated) c.1538A>G Classic infantile
c.1000G>T Classic infantile c.1551+3A>T Unknown (disease‐associated)
c.1004_1005dup Unknown (disease‐associated) c.1551+5G>A Unknown (disease‐associated)
c.1047del Unknown (disease‐associated) c.1559A>G Unknown (disease‐associated)
c.1560C>G Unknown (disease‐associated) c.2096T>C Unknown (disease‐associated)
c.1579_1580del Classic infantile c.2109del Unknown (disease‐associated)
c.1583G>C Unknown (disease‐associated) c.2131A>C Classic infantile
c.1594G>A Adult c.2146G>C Unknown (disease‐associated)
c.1597T>G Classic infantile c.2153_2156delinsACGCCG Classic infantile
c.1602_1605delinsAGG Classic infantile c.2182_2183del Unknown (disease‐associated)
c.1610del Unknown (disease‐associated) c.2190‐345A>G Unknown (disease‐associated)
c.1627T>G Unknown (disease‐associated) c.2205dup Classic infantile
c.1629C>G Unknown (disease‐associated) c.2213G>A Classic infantile
c.1636G>C Unknown (disease‐associated) c.2221G>A Classic infantile
c.1636+5G>A Classic infantile c.2222A>T Unknown (disease‐associated)
c.1650del Unknown (disease‐associated) c.2234T>C Classic infantile
c.1657C>T Classic infantile c.2235dup Classic infantile
c.1681_1699dup Unknown (disease‐associated) c.2237G>T Unknown (disease‐associated)
c.1688A>T Unknown (disease‐associated) c.2240G>A Unknown (disease‐associated)
c.1716C>A Classic infantile c.2261dup Unknown (disease‐associated)
c.1721T>C Unknown (disease‐associated) c.2294G>A Classic infantile
c.1753_2799del Classic infantile c.2296T>A Classic infantile
c.1754+1dup Unknown (disease‐associated) c.2297A>C Classic infantile
c.1754+2T>C Unknown (disease‐associated) c.2304del Unknown (disease‐associated)
c.1780C>T Unknown (disease‐associated) c.2320G>A Unknown (disease‐associated)
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constructs containing the missense variant of interest as described
(in 't Groen et al., 2020). The activity of the GAA protein produced by
the constructs was measured using 4‐methylumbelliferyl‐α‐D‐
glucopyranoside (4‐MU) as a substrate in transfected COS‐7 cells, as
described in Kroos et al. (2008). Statistical analysis was performed
using one‐way analysis of variance with Tukey honestly significant
difference post hoc multiple testing corrections. p < .05 was con-
sidered significant.
TABLE 1 (Continued)
DNA nomenclature Phenotype combined with a null allele DNA nomenclature Phenotype combined with a null allele
c.1784C>T Unknown (disease‐associated) c.2331+5G>C Classic infantile
c.1799G>C Unknown (disease‐associated) c.2331+102del Unknown (disease‐associated)
c.1822del Unknown (disease‐associated) c.2334_2335dup Unknown (disease‐associated)
c.1825T>G Unknown (disease‐associated) c.2377_2378insAC Classic infantile
c.1835A>C Unknown (disease‐associated) c.2380dup Unknown (disease‐associated)
c.1835A>G Unknown (disease‐associated) c.2395C>T Unknown (disease‐associated)
c.1837T>G Unknown (disease‐associated) c.2407C>T Unknown (disease‐associated)
c.1839G>C Unknown (disease‐associated) c.2411G>A Classic infantile
c.1844_1846del Unknown (disease‐associated) c.2459_2461del Unknown (disease‐associated)
c.1844G>T Classic infantile c.2460dup Unknown (disease‐associated)
c.1844G>A Classic infantile c.2474C>G Unknown (disease‐associated)
c.1847dup Unknown (disease‐associated) c.2480A>G Unknown (disease‐associated)
c.1859C>A Unknown (disease‐associated) c.2515C>T Unknown (disease‐associated)
c.1879_1881del Classic infantile c.2537C>A Unknown (disease‐associated)
c.1888+2_1888+15del Classic infantile c.2544del Unknown (disease‐associated)
c.1895T>C Unknown (disease‐associated) c.2563G>C Classic infantile
c.1895T>G Classic infantile c.2578G>A Unknown (disease‐associated)
c.1903A>G Unknown (disease‐associated) c.2584G>A Childhood
c.1913G>A Classic infantile c.2585del Classic infantile
c.1944_1950del Unknown (disease‐associated) c.2596del Unknown (disease‐associated)
c.1952dup Unknown (disease‐associated) c.2619C>G Unknown (disease‐associated)
c.1961C>G Unknown (disease‐associated) c.2636T>C Classic infantile
c.2004C>A Unknown (disease‐associated) c.2655_2656del Unknown (disease‐associated)
c.2015G>T Unknown (disease‐associated) c.2716G>A Unknown (disease‐associated)
c.2020C>G Unknown (disease‐associated) c.2720T>C Unknown (disease‐associated)
c.2020C>T Unknown (disease‐associated) c.2725G>A Unknown (disease‐associated)
c.2024A>G Classic infantile c.2740dup Unknown (disease‐associated)
c.2040+2dup Unknown (disease‐associated) c.2742dup Classic infantile
c.2040+29_2190‐270del Classic infantile c.2757del Unknown (disease‐associated)
c.2041‐2A>G Classic infantile c.2799+5G>A Unknown (disease‐associated)
c.2051C>A Unknown (disease‐associated) c.2800‐1G>C Classic infantile
c.2051C>G Unknown (disease‐associated) c.2843dup Classic infantile
c.2051C>T Classic infantile c.2845_2847del Unknown (disease‐associated)
c.2056_2057delinsCC Unknown (disease‐associated)
c.2084dup Unknown (disease‐associated)
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3 | RESULTS AND DISCUSSION
Table 1 provides an overview of the novel variants. We per-
formed a literature search covering the past 4 years and identi-
fied 80 publications (listed in the updated database and Table S1)
that described 350 novel variants, of which 226 were considered
to be disease‐associated (Table 1 and Figure 1a). Seventy‐six
novel variants (33%) were present in combination with a null
allele, which allowed prediction of the clinical severity of these
variants (Table 1 and Figure 1b). In addition, the inclusion of new
patient information allowed us to classify the severity of
55 variants that were already present in the database. This re-
sulted in a new total of 911 GAA variants, of which 648 were
disease‐associated (71%). In total, 336 out of 648 disease‐
associated variants (52%) could be associated with a clinical
phenotype. The geographical or ethnical distribution of reported
patients remained similar to what was described previously. The
majority of patients had a Caucasian background or were of
Caucasian descent (data not shown). This introduces a bias in the
current version of the database and indicates the necessity of
extending the database to patients of other descent. Mapping of




F IGURE 1 Overview of variants, comparing the previous (Niño et al., 2019) and updated version of the Pompe disease GAA variant database
(http://www.pompevariantdatabase.nl). (a) Number of disease‐associated and unknown variants in the previous database (left) and the updated
version of the database (right). (b) Number of disease‐associated variants classified based on the predicted clinical phenotype when combined
with a null allele in the previous database (left) and in the updated version of the database (right). (c) Distribution of disease‐associated
missense variants listed in the updated database, based on the protein domains of GAA and the predicted clinical phenotype when combined
with a null allele. Numbers are corrected for the length of each domain. †Two entries in the previous version of the database were removed as
the variants were described twice using different nomenclatures. ‡For 36 variants listed in the previous version of the database, a
reclassification of the phenotypic severity was performed due to the addition of novel patients included in this update
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TABLE 2 List of common sequence variants located within the boundaries of the GAA gene







Exon 1A, 5ʹ UTR c.−338C>G rs144639114 2% No effect on splicing 6.524
Exon 1A, 5ʹ UTR c.−260G>C rs2304849 16% No effect on splicing 8.996
Exon 1A, 5ʹ UTR c.−178G>A rs77514632 2% No effect on splicing 9.948
Exon 1B, 5ʹ UTR c.−75C>G rs80020206 0.9% (3% in African population) No effect on splicing 9.989
Intron 1B c.−33+219G>C rs4889961 75% No effect on splicing 0.866
Intron 1B c.−33+316C>A rs8077055 20% No effect on splicing 9.079
Intron 1B c.−33+317C>T rs8077056 20% No effect on splicing 8.579
Intron 1B c.−33+671A>C rs55751636 31% No effect on splicing 1.456
Intron 1B c.−33+757G>A rs28413147 5% No effect on splicing 4.974
Intron 1B c.−33+903A>C rs12450199 34% No effect on splicing 8.196
Intron 1B c.−33+1104A>G rs11150841 75% No effect on splicing 6.976
Intron 1B c.−33+1172G>A rs1442315 5% No effect on splicing 0.064
Intron 1B c.−33+1190G>T rs12602593 10% No effect on splicing 1.784
Intron 1B c.−33+1309T>C rs1442314 76% No effect on splicing 1.752
Intron 1B c.−32‐1298G>C rs12602610 33% No effect on splicing 2.604
Intron 1B c.−32‐1124C>T rs58959690 20% No effect on splicing 5.825
Intron 1B c.−32‐884T>C rs145362066 0.9% (3% in African population) No effect on splicing 3.993
Intron 1B c.−32‐793C>G rs55666739 2% No effect on splicing 4.041
Intron 1B c.−32‐721G>C rs75754966 2% Generates a new cryptic
splice accepter site
1.008
Intron 1B c.−32‐686A>G rs147264695 0.3% (1% in Finnish population) No effect on splicing 4.349
Intron 1B c.−32‐640C>T rs12600845 51% No effect on splicing 0.136
Intron 1B c.−32‐521G>T rs115060925 1% Generates a new cryptic
splice donor site
0.639
Intron 1B c.−32‐494C>G rs140325572 2% No effect on splicing 0.036
Intron 1B c.−32‐462G>A rs74003606 5% No effect on splicing 0.226
Exon 2 c.271G>A rs1800299 2% No effect on splicing 0.256
Exon 2 c.324T>C rs1800300 72% No effect on splicing 8.391
Exon 2 c.447G>A rs2289536 0.5% (3% in East Asian
population)
No effect on splicing 1.252
Intron 2 c.546+293G>A rs34746710 20% No effect on splicing 1.899
Intron 2 c.547‐243C>G rs8065426 67% No effect on splicing 2.529
Intron 2 c.547‐238T>C rs12452263 20% No effect on splicing 5.667
Intron 2 c.547‐67C>G rs8069491 67% No effect on splicing 1.337
Intron 2 c.547‐39T>G rs12452721 67% Loss of cryptic splice
donor site
2.78
Intron 2 c.547‐4C>G rs3816256 67% No effect on splicing 4.721
Exon 3 c.596A>G rs1042393 67% No effect on splicing 0.548
Exon 3 c.642C>T rs1800301 18% No effect on splicing 1.805
Exon 3 c.668G>A rs1042395 67% No effect on splicing 1.46
Intron 3 c.692+38C>T rs2304848 3% 5.574
(Continues)











Generates a new cryptic
splice donor site
Intron 3 c.692+144A>G rs2304847 67% No effect on splicing 3.653
Intron 3 c.692+509T>C rs8082405 66% No effect on splicing 3.271
Intron 3 c.692+674G>C rs8078350 67% No effect on splicing 4.501
Intron 3 c.692+751T>C rs8068051 67% No effect on splicing 2.363
Intron 3 c.693‐586G>A rs112308142 3% No effect on splicing 2.71
Intron 3 c.693‐585T>C rs8068555 67% No effect on splicing 4.133
Intron 3 c.693‐559C>T rs12602422 67% No effect on splicing 1.879
Intron 3 c.693‐491G>A rs12948631 67% No effect on splicing 3.629
Intron 3 c.693‐441C>G rs12602440 67% Loss of a cryptic splice
acceptor site
7.559
Intron 3 c.693‐434C>A rs12941269 66% No effect on splicing 4.416
Intron 3 c.693‐414C>G rs12941289 66% Loss of a cryptic splice
acceptor site
0.077
Intron 3 c.693‐413A>G rs12937590 67% Loss of a cryptic splice
acceptor site
1.544
Intron 3 c.693‐216T>A rs11150844 67% No effect on splicing 4.13
Intron 3 c.693‐94C>T rs79849256 0.2% (3% in East Asian
population)
No effect on splicing 9.666
Intron 3 c.693‐78C>T rs74003611 6% No effect on splicing 0.06
Intron 3 c.693‐49C>T rs78855075 7% No effect on splicing 2.374
Exon 4 c.852G>A rs142626724 0.6% (1% in European
population)
No effect on splicing 1.095
Intron 4 c.858+30T>C rs2304845 66% No effect on splicing 0.067
Exon 5 c.921A>T rs1800303 8% No effect on splicing 9.101
Intron 5 c.955+12G>A rs2252455 69% No effect on splicing 0.981
Intron 5 c.955+155C>A rs9901190 5% No effect on splicing 7.196
Intron 5 c.955+167C>T rs77717164 0.7% (6% in East Asian
population)
No effect on splicing 6.348
Intron 5 c.956‐107G>A rs2241888 73% No effect on splicing 5.835
Intron 5 c.956‐84C>T rs2241887 67% No effect on splicing 0.061
Intron 6 c.1075+13C>T rs41292402 1% No effect on splicing 7.496
Exon 8 c.1203G>A rs1800304 67% No effect on splicing 5.972
Exon 8 c.1286A>G rs200294882 0.07% (1% in East Asian
population)
Loss of cryptic splice acceptor
site and generates a new
cryptic splice donor site
0.068
Intron 8 c.1326+132G>A rs894306 67% No effect on splicing 1.999
Intron 8 c.1326+459C>T rs74679377 0.7% (6% in East Asian
population)
No effect on splicing 0.435
Intron 8 c.1326+460G>A rs12150323 2% No effect on splicing 0.322
Intron 8 c.1327‐514G>A rs72850826 5% No effect on splicing 1.914
Intron 8 c.1327‐356G>T rs6565640 73% No effect on splicing 0.258
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Intron 8 c.1327‐321del rs140385114 7% No effect on splicing 0.888
Intron 8 c.1327‐269A>G rs6565641 67% No effect on splicing 4.207
Intron 8 c.1327‐209C>T rs76604157 0.3% (6% in East Asian
population)
No effect on splicing 0.471
Intron 8 c.1327‐179G>A rs2278620 20% No effect on splicing 0.643
Intron 8 c.1327‐118A>G rs74003628 7% No effect on splicing 0.184
Intron 8 c.1327‐18A>G rs2278619 72% No effect on splicing 0.124
Exon 9 c.1374C>T rs1800305 7% No effect on splicing 0.206
Intron 9 c.1438‐220A>G rs2278618 67% No effect on splicing 6.607
Intron 9 c.1438‐108G>A rs12944802 67% No effect on splicing 0.013
Intron 9 c.1438‐19G>C rs2304844 67% No effect on splicing 3.529
Intron 10 c.1551+42G>A rs115427918 0.9% (3% in African population) No effect on splicing 5.792
Intron 10 c.1551+49C>A rs2304843 67% No effect on splicing 7.131
Exon 11 c.1581G>A rs1042396 23% No effect on splicing 6.758
Intron 11 c.1636+43G>T rs2304842 5% Generates a new cryptic
splice accepter site
6.859
Intron 11 c.1636+117del rs199788201 59% No effect on splicing 0.045
Intron 11 c.1636+117C>T rs12945868 11% No effect on splicing 0.181
Intron 11 c.1636+118G>T rs4889817 59% No effect on splicing 3.161
Intron 11 c.1636+205C>T rs79673008 3% No effect on splicing 0.013
Intron 11 c.1636+210G>A rs79487884 5% No effect on splicing 1.463
Intron 11 c.1636+269C>T rs111625854 2% No effect on splicing 3.828
Intron 11 c.1636+284G>C rs111551014 2% No effect on splicing 1.81
Intron 11 c.1636+389C>G rs7221675 63% No effect on splicing 0.573
Intron 11 c.1636+390A>G rs7209921 63% No effect on splicing 1.829
Intron 11 c.1636+404A>G rs4889818 74% No effect on splicing 1.902
Intron 11 c.1637‐185A>G rs12951255 55% No effect on splicing 0.576
Exon 12 c.1726G>A rs1800307 2% Generates a new cryptic
splice acceptor
0.268
Intron 12 c.1754+12G>A rs2304840 6% No effect on splicing 4.325
Intron 12 c.1754+100C>T rs113688685 0.9% (3% in African population) No effect on splicing 8.142
Intron 12 c.1754+104C>G rs2304839 5% No effect on splicing 0.763
Intron 12 c.1754+144C>T rs2304838 61% No effect on splicing 1.787
Intron 12 c.1755‐186A>G rs62075593 2% No effect on splicing 2.032
Intron 13 c.1888+21G>A rs2304837 6% No effect on splicing 3.378
Intron 14 c.2040+20A>G rs2304836 72% No effect on splicing 2.163
Intron 14 c.2040+66C>T rs2304835 7% No effect on splicing 3.54
Intron 14 c.2040+69A>G rs2304834 6% No effect on splicing 0.027
Intron 14 c.2041‐64G>A rs2304833 27% No effect on splicing 0.371
Exon 15 c.2065G>A rs1800309 6% No effect on splicing 1.783
(Continues)











Exon 15 c.2133A>G rs1800310 27% No effect on splicing 1.134
Intron 15 c.2189+95C>T rs72850840 5% No effect on splicing 3,771
Intron 15 c.2189+263G>A rs7221604 66% Generates a new cryptic
splice donor site
0.563
Intron 15 c.2189+510T>G rs4889963 5% No effect on splicing 1.444
Intron 15 c.2189+607G>A rs112710614 7% No effect on splicing 0.189
Intron 15 c.2189+616T>C rs139307163 5% No effect on splicing 1.94
Intron 15 c.2189+723G>A rs4889819 20% No effect on splicing 0.367
Intron 15 c.2189+729A>G rs74737410 5% No effect on splicing 0.498
Intron 15 c.2189+859A>G rs4889964 5% No effect on splicing 1.503
Intron 15 c.2189+884G>A rs4889965 5% No effect on splicing 0.355
Intron 15 c.2189+1153A>G rs72850844 5% No effect on splicing 3.687
Intron 15 c.2189+1201C>A rs72850846 5% No effect on splicing 2.352
Intron 15 c.2189+1208A>G rs72850847 5% No effect on splicing 0.367
Intron 15 c.2189+1263A>G rs74700450 5% No effect on splicing 2.97
Intron 15 c.2189+1290A>G rs74003630 5% No effect on splicing 6.015
Intron 15 c.2189+1600C>T rs60668271 5% No effect on splicing 0.481
Intron 15 c.2190‐1531G>A rs74702528 0.9% (3% in African population) No effect on splicing 0.489
Intron 15 c.2190‐1463G>A rs116416508 0.9% (3% in African population) No effect on splicing 0.328
Intron 15 c.2190‐1139A>G rs184803352 0.7% (2% in African population No effect on splicing 0.095
Intron 15 c.2190‐1005A>G rs4889820 5% No effect on splicing 2.452
Intron 15 c.2190‐686G>A rs12452616 19% No effect on splicing 2.725
Intron 15 c.2190‐647G>A rs59362713 10% No effect on splicing 0.227
Intron 15 c.2190‐536G>A rs60429724 10% No effect on splicing 0.454
Intron 15 c.2190‐490G>A rs111477580 1% No effect on splicing 3.101
Intron 15 c.2190‐444A>G rs4889967 73% No effect on splicing 1.059
Intron 15 c.2190‐336C>T rs76178719 3% No effect on splicing 1.566
Intron 16 c.2331+20G>A rs2304832 75% No effect on splicing 5.346
Intron 16 c.2331+24T>C rs2304831 15% No effect on splicing 0.204
Intron 16 c.2331+151C>T rs111537160 2% No effect on splicing 0.608
Intron 16 c.2332‐198A>T rs2304830 73% No effect on splicing 3.363
Exon 17 c.2338G>A rs1126690 72% No effect on splicing 2.675
Exon 17 c.2446G>A rs1800314 5% No effect on splicing 5.793
Intron 17 c.2482‐132C>T rs113824706 0.9% (3% in African population) No effect on splicing 0.066
Exon 18 c.2553G>A rs1042397 57% Weakens a cryptic splice
donor site
1.241
Intron 18 c.2647‐71G>C rs4889821 5% No effect on splicing 3.473
Exon 19 c.2780C>T rs1800315 2% No effect on splicing 0.222
Intron 19 c.2800‐227C>G rs9890469 66% No effect on splicing 0.661
Intron 19 c.2800‐60G>A rs55662462 0.7% (11% in Latino population) No effect on splicing 2.209
Exon 20, 3ʹ UTR c.*3G>A rs1800317 5% No effect on splicing 0.03
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stronger enrichment in the catalytic core compared with the
mapping we performed previously (Niño et al., 2019; Figure 1c).
We included in the current version of the database common se-
quence variants that have a MAF≥1% and do not cause Pompe disease.
This resulted in a relative increase in the number of nondisease‐
associated variants (Table 2). We decided to include common sequence
variants in response to the misreporting of these variants as the principal
cause of disease in several patients. Examples of this are the c.547‐
67C>G (rs8069491) and 547‐39T>G (rs12452721) variants, which were
reported as the cause of disease while having an allele frequency of 67%
in the global population (Bekircan‐Kurt et al., 2017; Guevara‐Campos
et al., 2019). In total, the database now includes 148 variants with a
MAF≥1%. All variants had a low CADD score (<10; Table 2) and were
classified as “unknown.” We note that while these common sequence
TABLE 2 (Continued)







Exon 20, 3ʹ UTR c.*91G>A rs2229221 12% No effect on splicing 6.887
Exon 20, 3ʹ UTR c.*223C>T rs8132 22% No effect on splicing 3.025
Exon 20, 3ʹ UTR c.*419G>T rs7567 19% No effect on splicing 4.17
Abbreviations: CADD, Combined Annotation‐Dependent Depletion; mRNA, messenger RNA; UTR, untranslated region.
(a)
(b)
F IGURE 2 Expression study of seven disease‐associated missense variants in the GAA gene. (a) Overview of basic information regarding the
pathogenicity of selected variants. (b) Measured GAA activity in both cells and medium of COS‐7 cultures after transfection with the generated
constructs. Findings for the c.1597T>C variants are plotted separately as this was performed in a separate experiment. Data represent means,
error bars represent SD (n = 3 biological replicates), ***p < .001. CADD, Combined Annotation‐Dependent Depletion; mRNA, messenger RNA
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variants do not result in clinical manifestation of Pompe disease, it re-
mains possible that they might modify disease progression when present
in cis with a disease‐associated variant. In Pompe disease, this is the case
for the Asian pseudodeficiency allele (c.[1726G>A (p.Gly576-
Ser);2065G>A (p.Glu689Lys)]) and GAA2 (c.271G>A, (p.Asp91Asn)),
which have a MAF of 14% for c.1726G>A, 23.5% for c.2065G>A (both
East Asian), and 3.2% for GAA2 (European), and can be present in ciswith
known disease‐associated variants (Kroos et al., 2006; Labrousse
et al., 2010). Also, a variant with a low MAF in the general population,
c.510C>T (p.=) (rs564758226), is known to be linked to the late‐onset
variant c.−32‐13T>G (p.[=,0]) (IVS1). c.510C>T has a global MAF of
0.005%, but a MAF of 27.3% in compound heterozygous IVS1 patients
with symptom onset at childhood. It worsens aberrant splicing caused by
IVS1 and causes lower levels of leaky wild‐type splicing and lower GAA
enzyme activity, resulting in accelerated disease onset (Bergsma
et al., 2019).
Figure 2a,b shows the results on the GAA variants we subjected to
a more in‐depth investigation. We selected the common missense
variants c.307T>G (p.Cys103Gly), c.655G>A (p.Gly219Arg), c.670C>T
(p.Arg224Trp), c.1655T>C (p.Leu552Pro), and c.1798C>T (p.Arg600-
Cys) and performed in vitro analysis of their severity using SDM of GAA
cDNA expression constructs. In addition, c.1597T>C (p.Cys533Arg) and
c.309C>G (p.Cys103Trp) were tested due to a request for diagnostic
purposes. All of these variants fully abrogated GAA enzymatic activity
following transfection in COS‐7 cells (Figure 2, compare mutant GAA
with mock transfections). The c.309C>G variant was included because
the patient that harbored this variant in combination with c.525del
p.(Glu176Argfs*45) showed an atypical Pompe disease phenotype
(Mori et al., 2017). This case report described an adult patient with
cardiomyopathy. Molecular analysis of primary skin fibroblasts identi-
fied a reduction in GAA activity, although not at pathogenic levels, and
GAA activity was in the normal range for skeletal muscle tissue (Mori
et al., 2017). We note that the c.309C>G variant was not detected in
DNA from either parent and was described as a de novo variant (Mori
et al., 2017). This variant might have been introduced during embryonic
development, resulting in mosaicism similar to, as described previously
in Labrijn‐Marks et al. (2019) and in 't Groen et al. (2020). This might
explain the “uneven pattern” of glycogen accumulation in histological
sections derived from cardiac tissue (Mori et al., 2017). The in vitro
analysis indicated that the c.309C>G variant is fully deleterious and has
a predicted classic infantile phenotype in combination with a null allele.
A comprehensive genetic analysis would be necessary to confirm this
hypothesis.
Novel variants that have been reported only through NBS studies,
but for which no clinical phenotype has been provided, were classified as
“Unknown (found only in NBS)”. In the current version of the database,
26 variants have been classified as such (Table 3). Seven out of
26 variants were also present in cis with the Asian pseudodeficiency
allele, indicating that additional testing is required because the Asian
pseudodeficiency is known to result in false‐positive outcomes in dried
blood spot‐based assays (Liao et al., 2014; Momosaki et al., 2019). It is
currently unknown at what age symptoms will develop in neonates di-
agnosed with disease‐associated variants that are potentially associated
with a late‐onset phenotype. Symptoms might be delayed until late
adulthood or, for some genetic variants, might not even lead to disease.
In these cases, further research on the effect of the genetic variants is
essential to better inform patients, families, and doctors. As reported, in
these cases, the uncertainty of the diagnosis, the possibility of an
emerging disease, and the doubt on when to start treatment with ERT
could lead to emotional stress (Bodamer et al., 2017). This underscores
the importance of phenotype prediction for disease‐associated variants,
especially in the case of asymptomatic patients identified through NBS
programs.
The sharp increase in reports on patients with Pompe disease
and GAA disease‐associated variants highlights the need for regular
updates of the Pompe disease GAA variant database. Increased
awareness and improved diagnostic technology with exome and
genome sequencing and NBS programs are expected to further in-
crease the number of entries in the database in the coming years. It
will be important to link variants to clinical information and to test
their deleterious effect in vitro using expression and splicing assays.
Curated disease‐specific databases such as the Pompe disease GAA
variant database will be important to provide guidance to clinicians
and clinical geneticists to establish an accurate molecular diagnosis.
ACKNOWLEDGMENTS
We thank the members of the Molecular Stem Cell Biology group for
the critical discussions. This study was funded through Conselho
Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brasil;
grant number: 234407/2014‐0), Sophia Foundation for Medical Re-
search (SSWO; project number: s17‐32); Metakids (project number:
2016‐063), and Departamento Administrativo de Ciencia, Tecnología
e Innovación (Colciencias). The collaboration project is cofunded by
the PPP Allowance made available by Health‐Holland, Top Sector
Life Sciences & Health, to the Prinses Beatrix Spier fonds to stimu-
late public–private partnerships (project number: LSHM19015).
CONFLICT OF INTERESTS
Ans T. van der Ploeg has provided consulting services for various
industries in the field of Pompe disease under an agreement between
these industries and Erasmus MC, Rotterdam, the Netherlands. The
remaining authors declare that there are no conflict of interests.
WEB RESOURCES







The data described in this study is available upon request from the
corresponding authors, and new variants have been added to the
Pompe disease GAA variant database (http://www.pompevariant
database.nl/) and LOVD (http://gaa.lovd.nl/).
84 | Chapter 4
ORCID
Douglas O. S. de Faria https://orcid.org/0000-0001-9525-7260
W. W. M. Pim Pijnappel https://orcid.org/0000-0002-7042-2482
REFERENCES
Bali, D. S., Goldstein, J. L., Banugaria, S., Dai, J., Mackey, J., Rehder, C., &
Kishnani, P. S. (2012). Predicting cross‐reactive immunological
material (CRIM) status in Pompe disease using GAA mutations:
Lessons learned from 10 years of clinical laboratory testing
experience. American Journal of Medical Genetics Part C: Seminars in
Medical Genetics, 160C(1), 40–49. https://doi.org/10.1002/ajmg.c.
31319
Bekircan‐Kurt, C. E., Güneş, H. N., Yildiz, F. G., Saka, E., Tan, E., & Erdem‐
Özdamar, S. (2017). New mutations and genotype–phenotype
correlation in late‐onset Pompe patients. Acta Neurologica Belgica,
117, 269–275. https://doi.org/10.1007/s13760-016-0738-7
Bergsma, A. J., in 't Groen, S. L. M., van den Dorpel, J. J. A.,
van den Hout, H. J. M. P., van der Beek, N. A. M. E., Schoser, B.,
Toscano, A., Musumeci, O., Bembi, B., Dardis, A., Morrone, A.,
Tummolo, A., Pasquini, E., van der Ploeg, A. T., &
Pijnappel, W. W. M. P. (2019). A genetic modifier of symptom onset
in Pompe disease. EBioMedicine, 43, 553–561. https://doi.org/10.
1016/j.ebiom.2019.03.048
Bodamer, O. A., Ronald Scott, C., & Giugliani, R. (2017). Newborn
screening for Pompe disease. Pediatrics, 140, S4–S13. https://doi.
org/10.1542/peds.2016-0280C
Bravo, H., Neto, E. C., Schulte, J., Pereira, J., Filho, C. S., Bittencourt, F.,
Sebastião, F., Bender, F., de Magalhães, A. P. S., Guidobono, R.,
Trapp, F. B., Michelin‐Tirelli, K., Souza, C. F. M., Rojas Málaga, D.,
Pasqualim, G., Brusius‐Facchin, A. C., & Giugliani, R. (2017).
Investigation of newborns with abnormal results in a newborn
screening program for four lysosomal storage diseases in Brazil.
Molecular Genetics and Metabolism Reports, 12, 92–97. https://doi.
org/10.1016/j.ymgmr.2017.06.006
Burlina, A. B., Polo, G., Salviati, L., Duro, G., Zizzo, C., Dardis, A., Bembi, B.,
Cazzorla, C., Rubert, L., Zordan, R., Desnick, R. J., & Burlina, A. P.
(2018). Newborn screening for lysosomal storage disorders by
tandem mass spectrometry in North East Italy. Journal of Inherited
Metabolic Disease, 41, 209–219. https://doi.org/10.1007/s10545-
017-0098-3
Chien, Y.‐H., Hwu, W.‐L., & Lee, N.‐C. (2019). Newborn screening:
Taiwanese experience. Annals of Translational Medicine, 7, 281.
https://doi.org/10.21037/atm.2019.05.47
Chien, Y.‐H., Lee, N.‐C., Huang, H.‐J., Thurberg, B.‐L., Tsai, F.‐J., & Hwu, W.
‐L. (2011). Later‐onset Pompe disease: Early detection and early
treatment initiation enabled by newborn screening. Journal of
Pediatrics, 158(6), 1023–1027. https://doi.org/10.1016/j.jpeds.
2010.11.053
Elliott, S., Buroker, N., Cournoyer, J. J., Potier, A. M., Trometer, J. D.,
Elbin, C., Schermer, M. J., Kantola, J., Boyce, A., Turecek, F.,
Gelb, M. H., & Scott, C. R. (2016). Pilot study of newborn screening
for six lysosomal storage diseases using tandem mass spectrometry.
Molecular Genetics and Metabolism, 118, 304–309. https://doi.org/10.
1016/j.ymgme.2016.05.015
Goina, E., Musco, L., Dardis, A., & Buratti, E. (2019). Assessment of the
functional impact on the pre‐mRNA splicing process of 28
nucleotide variants associated with Pompe disease in GAA exon 2
and their recovery using antisense technology. Human Mutation,
40(11), 2121–2130. https://doi.org/10.1002/humu.23867
Guevara‐Campos, J., González‐Guevara, L., & Cauli, O. (2019). Skeletal
alterations, developmental delay and new mutations in juvenile‐
onset Pompe disease. Neuromuscular Disorders, 29, 192–197. https://
doi.org/10.1016/j.nmd.2018.11.013
Güngör, D., & Reuser, A. J. (2013). How to describe the clinical spectrum
in Pompe disease? American Journal of Medical Genetics, Part A, 161,
399–400. https://doi.org/10.1002/ajmg.a.35662
in't Groen S. L. M., de Faria, D. O. S., Iuliano, A., van den Hout, J. M. P.,
Douben, H., Dijkhuizen, T., Cassiman, D., Witters, P.,
Barba Romero, M.‐Á., de Klein, A., Somers‐Bolman, G. M., Saris, J. J.,
Hoefsloot, L. H., van der Ploeg, A. T., Bergsma, A. J., &
Pijnappel, W. W. M. P. (2020). Novel GAA variants and mosaicism in
Pompe disease identified by extended analyses of patients with an
incomplete DNA diagnosis. Molecular Therapy—Methods & Clinical
Development, 17, 337–348. https://doi.org/10.1016/j.omtm.2019.
12.016
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J.,
Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P.,
Gauthier, L. D., Brand, H., Solomonson, M., Watts, N. A., Rhodes, D.,
Singer‐Berk, M., England, E. M., Seaby, E. G., Kosmicki, J. A., …
MacArthur, D. G. (2020). The mutational constraint spectrum
quantified from variation in 141,456 humans. Nature, 581,
434–443. https://doi.org/10.1038/s41586-020-2308-7
Kohler, L., Puertollano, R., & Raben, N. (2018). Pompe disease: From basic
science to therapy. Neurotherapeutics, 15, 928–942. https://doi.org/
10.1007/s13311-018-0655-y
Kroos, M., Hoogeveen‐Westerveld, M., Michelakakis, H., Pomponio, R.,
van der Ploeg, A., Halley, D., & Reuser, A. (2012a). GAA Database
Consortium. Update of the Pompe disease mutation database with
60 novel GAA sequence variants and additional studies on the
functional effect of 34 previously reported variants. Human
Mutation, 33(8), 1161–1165. https://doi.org/10.1002/humu.22108
Kroos, M., Hoogeveen‐Westerveld, M., van der Ploeg, A., & Reuser, A. J.
(2012b). The genotype‐phenotype correlation in Pompe disease.
American Journal of Medical Genetics Part C: Seminars in Medical
Genetics, 160C, 59–68. https://doi.org/10.1002/ajmg.c.31318
Kroos, M., Manta, P., Mavridou, I., Muntoni, F., Halley, D.,
Van der Helm, R., Zaifeiriou, D., Van der Ploeg, A., Reuser, A. J., &
Michelakakis, H. (2006). Seven cases of Pompe disease from Greece.
Journal of Inherited Metabolic Disease, 29, 556–563. https://doi.org/
10.1007/s10545-006-0280-5
Kroos, M., Pomponio, R. J., van Vliet, L., Palmer, R. E., Phipps, M.,
Van der Helm, R., Halley, D., Reuser, A. J., &
GAA Database Consortium. (2008). Update of the Pompe disease
mutation database with 107 sequence variants and a format for
severity rating. Human Mutation, 29, E13–E26. https://doi.org/10.
1002/humu.20745
Kroos, M. A., Pomponio, R. J., Hagemans, M. L., Keulemans, J. L. M.,
Phipps, M., DeRiso, M., Palmer, R. E., Ausems, M. G. E. M.,
Van der Beek, N. A. M. E., Van Diggelen, O. P., Halley, D. J. J.,
Van der Ploeg, A. T., & Reuser, A. J. J. (2007). Broad spectrum of
Pompe disease in patients with the same c.−32‐13T→G haplotype.
Neurology, 68, 110–115. https://doi.org/10.1212/01.wnl.
0000252798.25690.76
Kulessa, M., Weyer‐Menkhoff, I., Viergutz, L., Kornblum, C., Claeys, K. G.,
Schneider, I., Plöckinger, U., Young, P., Boentert, M., Vielhaber, S.,
Mawrin, C., Bergmann, M., Weis, J., Ziagaki, A., Stenzel, W.,
Deschauer, M., Nolte, D., Hahn, A., Schoser, B., & Schänzer, A.
(2020). An integrative correlation of myopathology, phenotype and
genotype in late onset Pompe disease. Neuropathology and Applied
Neurobiology, 46, 359–374. https://doi.org/10.1111/nan.12580
Labrijn‐Marks, I., Somers‐Bolman, G. M., In't Groen, S. L. M., Hoogeveen‐
Westerveld, M., Kroos, M. A., Ala‐Mello, S., Amaral, O., Miranda, C.,
Mavridou, I., Michelakakis, H., Naess, K., Verheijen, F. W.,
Hoefsloot, L. H., Dijkhuizen, T., Benjamins, M., van den Hout, H. J. M.,
van der Ploeg, A. T., Pijnappel, W. W. M. P., Saris, J. J., & Halley, D. J.
(2019). Segmental and total uniparental isodisomy (UPiD) as a
disease mechanism in autosomal recessive lysosomal disorders:
Update of the Pompe variant database | 85
C
hapter 4
Evidence from SNP arrays. European Journal of Human Genetics, 27,
919–927. https://doi.org/10.1038/s41431-019-0348-y
Labrousse, P., Chien, Y. H., Pomponio, R. J., Keutzer, J., Lee, N. C.,
Akmaev, V. R., Scholl, T., & Hwu, W. L. (2010). Genetic heterozygosity
and pseudodeficiency in the Pompe disease newborn screening pilot
program. Molecular Genetics and Metabolism, 99, 379–383. https://doi.
org/10.1016/j.ymgme.2009.12.014
Liao, H. C., Chiang, C. C., Niu, D. M., Wang, C. H., Kao, S. M., Tsai, F. J.,
Huang, Y. H., Liu, H. C., Huang, C. K., Gao, H. J., Yang, C. F.,
Chan, M. J., Lin, W. D., & Chen, Y. J. (2014). Detecting multiple
lysosomal storage diseases by tandem mass spectrometry—A
national newborn screening program in Taiwan. Clinica Chimica
Acta, 431, 80–86. https://doi.org/10.1016/j.cca.2014.01.030
Momosaki, K., Kido, J., Yoshida, S., Sugawara, K., Miyamoto, T., Inoue, T.,
Okumiya, T., Matsumoto, S., Endo, F., Hirose, S., & Nakamura, K.
(2019). Newborn screening for Pompe disease in Japan: Report and
literature review of mutations in the GAA gene in Japanese and
Asian patients. Journal of Human Genetics, 64, 741–755. https://doi.
org/10.1038/s10038-019-0603-7
Mori, M., Bailey, L. A., Estrada, J., Rehder, C. W., Li, J. S., Rogers, J. G.,
Bali, D. S., Buckley, A. F., & Kishnani, P. S. (2017). Severe
cardiomyopathy as the isolated presenting feature in an adult with
late‐onset Pompe disease: A case report. JIMD Reports, 31, 79–83.
Navarrete‐Martínez, J. I., Limón‐Rojas, A. E., Gaytán‐García, M. J., Reyna‐
Figueroa, J., Wakida‐Kusunoki, G., Delgado‐Calvillo, M. D. R., Cantú‐
Reyna, C., Cruz‐Camino, H., & Cervantes‐Barragán, D. E. (2017).
Newborn screening for six lysosomal storage disorders in a cohort of
Mexican patients: Three‐year findings from a screening program in a
closed Mexican health system. Molecular Genetics and Metabolism,
121(1), 16–21. https://doi.org/10.1016/j.ymgme.2017.03.001
Niño, M. Y., Groen, S. L. M., in't Bergsma, A. J., van der Beek, N. A. M. E.,
Kroos, M., Hoogeveen‐Westerveld, M., van der Ploeg, A. T.,
Pijnappel, W. W. M. P., & (2019). Extension of the Pompe mutation
database by linking disease‐associated variants to clinical severity.
Human Mutation, 40, 1954–1967. https://doi.org/10.1002/humu.
23854
Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J., & Kircher, M. (2019).
CADD: Predicting the deleteriousness of variants throughout the
human genome. Nucleic Acids Research, 47, D886–D894. https://doi.
org/10.1093/nar/gky1016
Reuser, A. J. J., Ploeg, A. T., Chien, Y.‐H., Llerena, J., Abbott, M.‐A.,
Clemens, P. R., Kimonis, V. E., Leslie, N., Maruti, S. S., Sanson, B.‐J.,
Araujo, R., Periquet, M., Toscano, A., Kishnani, P. S., &
on behalf of the Pompe Registry Sites (2019). GAA variants and
phenotypes among 1,079 patients with Pompe disease: Data from
the Pompe Registry. Human Mutation, 40, 2146–2164. https://doi.
org/10.1002/humu.23878
Scott, C. R., Elliott, S., Buroker, N., Thomas, L. I., Keutzer, J., Glass, M.,
Gelb, M. H., & Turecek, F. (2013). Identification of infants at risk for
developing Fabry, Pompe, or mucopolysaccharidosis‐I from newborn
blood spots by tandem mass spectrometry. Journal of Pediatrics, 163(2),
498–503. https://doi.org/10.1016/j.jpeds.2013.01.031
Semplicini, C., Letard, P., De Antonio, M., Taouagh, N., Perniconi, B.,
Bouhour, F., Echaniz‐Laguna, A., Orlikowski, D., Sacconi, S., Salort‐
Campana, E., Solé, G., Zagnoli, F., Hamroun, D., Froissart, R.,
Caillaud, C., & Laforêt, P. (2018). Late‐onset Pompe disease in
France: Molecular features and epidemiology from a nationwide
study. Journal of Inherited Metabolic Disease, 41, 937–946. https://
doi.org/10.1007/s10545-018-0243-7
Sherry, S. T., Ward, M. H., Kholodov, M., Baker, J., Phan, L.,
Smigielski, E. M., & Sirotkin, K. (2001). DbSNP: The NCBI database
of genetic variation. Nucleic Acids Research, 29, 308–311. https://doi.
org/10.1093/nar/29.1.308
Turaça, L. T., Faria, D. O. S., de Kyosen, S. O., Teixeira, V. D., Motta, F. L.,
Pessoa, J. G., Rodrigues e Silva, M., Almeida, S. S., de D'Almeida, V.,
Munoz Rojas, M. V., Martins, A. M., & Pesquero, J. B. (2015). Novel
GAA mutations in patients with Pompe disease. Gene, 561, 124–131.
https://doi.org/10.1016/j.gene.2015.02.023
van der Ploeg, A. T., & Reuser, A. J. (2008). Pompe's disease. Lancet, 372,
1342–1353. https://doi.org/10.1016/S0140-6736(08)61555-X
van Gelder, C.M., Hoogeveen‐Westerveld, M., Kroos, M. A., Plug, I.,
van der Ploeg, A. T., & Reuser, A. J. (2015). Enzyme therapy and
immune response in relation to CRIM status: The Dutch experience
in classic infantile Pompe disease. Journal of Inherited Metabolic
Disease, 8(2), 305–314. https://doi.org/10.1007/s10545-014-
9707-6
Wittmann, J., Karg, E., Turi, S., Legnini, E., Wittmann, G., Giese, A. K.,
Lukas, J., Gölnitz, U., Klingenhäger, M., Bodamer, O., Mühl, A., &
Rolfs, A. (2012). Newborn screening for lysosomal storage disorders
in Hungary. JIMD Reports, 6, 117–125. https://doi.org/10.1007/
8904_2012_130
Yang, C. F., Liu, H. C., Hsu, T. R., Tsai, F. C., Chiang, S. F., Chiang, C. C.,
Ho, H. C., Lai, C. J., Yang, T. F., Chuang, S. Y., Lin, C. Y., & Niu, D. M.
(2014). A large‐scale nationwide newborn screening program for
Pompe disease in Taiwan: Towards effective diagnosis and treatment.
American Journal of Medical Genetics, Part A, 164, 54–61. https://doi.org/
10.1002/ajmg.a.36197
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the
supporting information tab for this article.
How to cite this article: de Faria DOS, in ‘t Groen SLM,
Hoogeveen‐Westerveld M, et al. Update of the Pompe variant
database for the prediction of clinical phenotypes: Novel
disease‐associated variants, common sequence variants, and
results from newborn screening. Human Mutation. 2021;42:
119–134. https://doi.org/10.1002/humu.24148

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Douglas O. S. de Faria
CHAPTER 5
Broad variation in phenotypes for common 
GAA genotypes in Pompe disease
Monica Y. Niño*, Stijn L.M. in ’t Groen*, Douglas O.S. de Faria, Marianne 
Hoogeveen-Westerveld, Hannerieke J.M.P. van den Hout, Ans T. van der 
Ploeg, Atze J. Bergsma, and W.W.M. Pim Pijnappel
*These authors contributed equally to this study
Hum Mutat. 2021 Aug 18. Online ahead of print 
doi: 10.1002/humu.24272
92 | Chapter 5
Human Mutation. 2021;1–12.
Received: 19 June 2021 | Revised: 30 July 2021 | Accepted: 15 August 2021
DOI: 10.1002/humu.24272
R E S E A R CH AR T I C L E
Broad variation in phenotypes for common GAA genotypes
in Pompe disease
Monica Y. Niño1,2,3 | Stijn L. M. in't Groen1,2,3 | Douglas O. S. de Faria1,2,3 |
Marianne Hoogeveen‐Westerveld2 | Hannerieke J. M. P. van den Hout1,3 |
Ans T. van der Ploeg1,3 | Atze J. Bergsma1,2,3 | W. W. M. Pim Pijnappel1,2,3
1Department of Pediatrics, Erasmus University
Medical Center, Rotterdam, The Netherlands
2Department of Clinical Genetics, Erasmus
University Medical Center, Rotterdam,
The Netherlands
3Center for Lysosomal and Metabolic
Diseases, Erasmus University Medical Center,
Rotterdam, The Netherlands
Correspondence
W. W. M. Pim Pijnappel and Atze J. Bergsma,
Department of Pediatrics, Erasmus University





Patients with the common c.‐32‐13T>G/null GAA genotype have a broad variation in
age at symptom onset, ranging from early childhood to late adulthood. Phenotypic
variation for other common GAA genotypes remains largely unexplored. Here, we ana-
lyzed variation in age at symptom onset for the most common GAA genotypes using the
updated and extended Pompe GAA variant database. Patients with the c.2647‐7G>
A/null genotype invariably presented symptoms at adulthood, while the c.‐32‐13T>G/
null, c.546G>T/null, c.1076‐22T>G/null, c.2238G>C/null, and c.2173C>T/null gen-
otypes led to presentations from early childhood up to late adulthood. The c.1309C>T/
null genotype was associated with onset at early to late childhood. Symptom onset
shifted toward higher ages in homozygous patients. These findings indicate that a broad
variation in symptom onset occurs for various common GAA genotypes, suggesting the
presence of modifying factors. We identified three new compound heterozygous c.‐32‐
13T>G/null patients who carried the genetic modifier c.510C>T and who showed
symptom onset at childhood. While c.510C>T acted by lowering GAA enzyme activity,
other putative genetic modifiers did not at the group level, suggesting that these act in
trans on processes downstream of GAA enzyme activity.
K E YWORD S
GAA deficiency, genotype–phenotype, glycogenosis type II, mutation database, Pompe disease
1 | INTRODUCTION
Pompe disease is a monogenic lysosomal storage disorder caused by
disease‐associated variants in the acid α‐glucosidase (GAA) gene
(van der Ploeg & Reuser, 2008). A large number of disease‐associated
GAA variants have been identified and are listed in the recently up-
dated Pompe disease GAA variant database at http://www.
pompevariantdatabase.nl. The database provides GAA genotypes
and phenotypes of all patients in which these were reported (de Faria
et al., 2021; Niño et al., 2019). Two disease‐associated GAA variants,
one per allele, are required to cause Pompe disease.
The clinical spectrum of Pompe disease ranges from a classic in-
fantile form to an adult‐onset form (Gaeta et al., 2015; Gungor &
Reuser, 2013; Herzog et al., 2012; M. A. Kroos et al., 2007; Laforêt
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2021 The Authors. Human Mutation published by Wiley Periodicals LLC
Monica Y. Niño and Stijn L. M. in't Groen contributed equally to this study.
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et al., 2013; Reuser et al., 2018; van der Beek et al., 2009; van der
Ploeg & Reuser, 2008; van der Ploeg et al., 2017). The most severe
classic infantile form of Pompe disease is caused by two very severe
disease‐associated GAA variants that completely abrogate GAA enzy-
matic activity. Classic infantile patients present with generalized ske-
letal muscle weakness and hypertrophic cardiomyopathy shortly after
birth, and die within the first year of life if left untreated (Kishnani
et al., 2006; H. M. van den Hout et al., 2003). Patients with some
residual GAA enzyme activity have a variable onset of symptoms due
to the presence of at least one milder disease‐associated GAA variant.
These patients develop skeletal muscle weakness, leading to impaired
mobility and respiration, resulting in a wheelchair and/or ventilator
dependency at some point in their life (van der Beek et al., 2009,
2012). Cardiac symptoms are usually absent in this patient group.
Treatment of Pompe disease with enzyme replacement therapy
(ERT) is available since 2006. ERT improves survival and is effective in
normalizing cardiac hypertrophy and improving skeletal muscle func-
tion, resulting in increased mobility and stabilization of respiratory
function (Amalfitano et al., 2001; Kishnani et al., 2007; Nicolino et al.,
2009; Strothotte et al., 2010; van Capelle et al., 2010; H. van den Hout
et al., 2000; J. M. van den Hout et al., 2001; van der Ploeg et al., 2010).
The invasive nature of ERT treatment and its high costs are important
factors that need to be taken into account in determining when
treatment of patients with childhood or adulthood onset of symptoms
should be started. Prediction of the phenotype that is associated with
a particular genotype is an important aspect of decision‐making.
While most disease‐associated GAA variants are rare, a number of
variants occur more frequently. Common variants are enriched in
distinct populations, including three variants in the Caucasian popu-
lation: c.‐32‐13T >G (p.[0, p.=]) (also termed IVS1), c.525del
(p.(Glu176Argfs*45)), and c.2481 + 102_2646 + 31del (p.(Gly828_
Asn882del)) (also termed delex18); two variants in the Asian popula-
tion: c.1935C > A (p.(Asp645Glu)) and c.2238G> C (p.(Trp746Cys));
and one variant in patients from African‐American descent:
c.2560C > T (p.(Arg854*)) (Ausems et al., 2001; Becker et al., 1998;
Dagnino et al., 2000; Huie et al., 1994; M. A. Kroos et al., 1995; Laforet
et al., 2000; Lin & Shieh, 1996; Liu et al., 2014; Müller‐Felber et al.,
2007; Pittis & Filocamo, 2007; Reuser et al., 2018; Shieh & Lin, 1998;
Van der Kraan et al., 1994; Wokke et al., 1995). The Caucasian c.‐32‐
13T >G disease‐associated variant is associated with a very broad
range of age at symptom onset (Herzog et al., 2012; M. A. Kroos et al.,
2007; Semplicini et al., 2018). This phenotypic variation is also ob-
served within and between families as is illustrated by a study on 22
families with two or three siblings carrying the c.‐32‐13T >G variant
(Wens et al., 2013). These findings have led to the hypothesis that
modifying factors—genetic, epigenetic, or environmental—may alter
the disease course in patients that carry the c.‐32‐13T >G variant
(Herzog et al., 2012; Huie et al., 1994; Ko et al., 1999; M. Kroos et al.,
2012; M. A. Kroos et al., 2007; Musumeci et al., 2015; Rairikar et al.,
2017; Shieh & Lin, 1998; van der Ploeg & Reuser, 2008; Wens et al.,
2013). It is, however, largely unknown whether phenotypic variation
occurs in groups of patients with specific disease‐associated variants
other than c.‐32‐13T >G. We recently identified the GAA c.510C> T
(p.(=)) variant as a genetic modifier that accelerates symptom onset in
compound heterozygous and homozygous c.‐32‐13T >G patients
(Bergsma et al., 2019), but additional putative variants that alter the
course of Pompe disease remain enigmatic so far.
In the present study, we used the information included in the Pompe
disease GAA variant database to compare variations in symptom onset
for the most common GAA disease‐associated variants in Pompe disease.
We analyzed compound heterozygous and homozygous patients, in-
vestigated the effect of the second GAA allele, and made a prediction
whether additional modifying factors for c.‐32‐13T >G patients may be
present in cis or in trans. The findings on phenotypic variations asso-
ciated with GAA genotypes will be important for diagnosis, genetic
counseling, decision‐making on the start of treatment with ERT, and for
research into the identification of additional modifying factors.
2 | METHODS
2.1 | Patient information
To analyze genotypic variation, we used the most recent version of
the Pompe disease GAA variant database (http://www.
pompevariantdatabase.nl, update January 2020) (de Faria et al.,
2021). References to the publications that contain the original patient
information in this manuscript are listed in Tables S1 and S2. Geo-
graphical origins were indicated or were categorized in the following
four groups: Caucasian (for patients from Europe, North America, and
Australia), Latin American (for patients from Central and South
America), African (for patients from the African continent), and Asian
(for patients from the Asian continent). For the analysis of GAA en-
zyme activity in fibroblasts from patients with the c.‐32‐13T > G
variant and childhood or adulthood onset in the absence or presence
of the modifier c.510C > T, we analyzed the patient cohort that was
described in Bergsma et al. (2019).
2.2 | Nomenclature
Variant annotations and classification conform to recommendations
of the Human Genome Variation Society (HGVS) (den Dunnen et al.,
2016). NM_000152.5 was used as a reference sequence for GAA
mRNA, LRG_673t1.1 was used for intronic regions, and
NP_000143.2 for GAA protein. Position c.1 represents the first
nucleotide of the translation start codon located in GAA exon 2.
2.3 | GAA enzyme activity assay
For the analysis of GAA enzyme activity in fibroblasts from pa-
tients with the c.‐32‐13T > G variant and childhood or adulthood
onset in the absence or presence of the modifier c.510C > T, GAA
enzyme activities were determined by the diagnostic department
of Clinical Genetics of the Erasmus MC in fibroblasts using
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4‐methylumbelliferone‐α‐D‐glucopyranoside (4‐MU) (Sigma‐
Aldrich) as a substrate as previously described (M. A. Kroos
et al., 2007).
3 | RESULTS AND DISCUSSION
3.1 | Phenotypic variation in compound
heterozygous patients
The most frequent compound heterozygous genotypes in the Pompe
disease GAA variant database (http://www.pompevariantdatabase.nl)
were listed from patients in whom a classified disease‐associated GAA
variant was combined with a null allele, which is defined as an allele that
produces no detectable GAA enzyme activity and that occurs in classic
infantile patients that have the most severe form of Pompe disease (Niño
et al., 2019). The ages at symptom onset were plotted for five types of
GAA variants, based on their association with the following groups of
phenotypes: adult, childhood or adult, childhood, classic infantile or
childhood, and classic infantile (Figure 1 and Table 1). It should be noted
that the definition of symptoms can vary between publications, and as a
result could contribute to the variability in age at symptom onset, which is
a limitation of this analysis. A minimum number of four patients per GAA
genotype was required in order for a variant to be included in the analysis.
We note that other frequent compound heterozygous genotypes were
also present in the database; in these cases, the second alleles were not
null alleles. Since the clinical phenotype is the result of the combined
action of two alleles, the absence of a null allele as the second variant
precludes the classification of the variant in question.
In patients with the noncoding splice variant c.2647‐7G >A
(Caucasian), which affects splicing of GAA exon 18 and is associated
with the adult phenotype in combination with a null allele, age at
symptom onset ranged from 35 years to 53 years of age (median,
40 years) (Figure 1 and Table 1). The patients with this variant all
F IGURE 1 Variations in age at symptom onset in compound heterozygous patients. Age at symptom onset is indicated for patients that carry
the most frequently occurring variants at compound heterozygous state in combination with a null allele (minimum of four patients). Clinical
phenotype groups are shown. Median ages at symptom onset are indicated by long vertical lines; ranges by short vertical lines. One exceptional
case was excluded from the figure, this involved an adult patient with two very severe GAA variants (genotype: c.1935C > A/c.2560C > T, age at
symptom onset: 25 years, phenotype: adult), who was considered to be an enigmatic case (Hermans et al., 1993)
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TABLE 1 Information on variants and patients described in Figure 1
aPopulation is reported as indicated in the original publication. In certain cases, only Caucasian origin has been reported.
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came from a single Italian family (Sampaolo et al., 2013). It is inter-
esting that the age at symptom onset can vary greatly even within the
same family. A similar broad range of age at symptom onset has
previously been observed within families with another single GAA
genotype c.‐32‐13T >G/c.525del (Wens et al., 2013). This indicates
that phenotypic variation may occur between members of the same
family with the same GAA genotype.
Five variants that were associated with onset during either child-
hood or adulthood, if combined with a null allele, were subjected to
further study. The combination of the c.‐32‐13T >G variant with a null
allele was encountered most frequently. In total, 312 compound het-
erozygous patients in combination with a null allele and from which age
at symptom onset was described were included from the Pompe disease
GAA variant database. Approximately 90% of Caucasian patients with
childhood or adulthood onset Pompe disease have been reported to
carry this variant (see Bergsma et al., 2019; M. A. Kroos et al., 2007;
Montalvo et al., 2006; Semplicini et al., 2018, and references therein).
The c.‐32‐13T >G variant causes aberrant splicing of GAA exon 2, re-
sulting in at least eight distinct aberrant splice products (Boerkoel et al.,
1995; Huie et al., 1994; van der Wal et al., 2017). It also allows a low
level of normal splicing, resulting in the expression of 10%–15% func-
tional GAA protein compared to average healthy control values. The
median age at symptom onset of compound heterozygous c.‐32‐
13T >G patients combined with a null allele was 30 years, and an ex-
ceptionally broad range between <1 and 71 years of age was found,
similarly as reported previously (Herzog et al., 2012; M. A. Kroos et al.,
2007; Semplicini et al., 2018). We further tested whether there were
sex‐related differences in age at symptom onset within this group of
patients. No significant differences between males and females could be
detected (Figure S1; Kaplan–Meier log‐rank test: p= .3).
The c.546G>T (p.(=)) variant, which is common among Japanese
patients (Fukuhara et al., 2018), also showed a particularly broad range of
age at symptom onset ranging from <1 to 72 years of age (median 17
years, n=9 patients). This variant also causes aberrant splicing of exon 2,
in which some aberrant splicing products are identical to those caused by
the c.‐32‐13T>G variant (leaky wild‐type splicing, complete skipping of
exon 2), while other splicing products are unique to c.546G>T (Bergsma
et al., 2021; Maimaiti et al., 2009).
Patients with the missense variants c.2238G>C (p.(Trp746Cys))
(Asian) and c.2173C>T (p.(Arg725Trp)) (Caucasian) and the splice variant
c.1076‐22T >G (Caucasian) also showed a broad variation in age at
symptom onset from <1 year to 41 years of age (ranges <1–41, 3–22,
and <1–25 years, and medians 22.5, 8.5, and 8 years, respectively). These
data indicate that patients that carry GAA variants that are associated
with childhood or adult onset of the disease show a minimum range in
age at symptom onset of 19 years and a maximum of 72 years, in both
Asian and Caucasian populations. We note that relatively low patient
numbers have been reported to date for these variants, except for c.‐32‐
13T>G, and that it is possible that the inclusion of more patients will
further broaden the range of age at symptom onset.
For only one variant, the missense variant c.1309C > T
(p.(Arg437Cys)) (Asian), sufficient cases were described (n = 9) to
predict that this variant in combination with a null allele is associated
with childhood onset of symptoms. The age at symptom onset ranged
from <1 to 10 years (median 6 years). It remains to be seen in a larger
patient cohort whether this variant is always associated with child-
hood onset or whether it can also occur in adult‐onset patients when
combined with a null allele.
The c.1857C > G (p.(Ser619Arg)) missense variant was found in
combination with a null allele in five Asian patients. The patients
diagnosed with this combination presented either with the classic
infantile form or a slightly milder form (Fukuhara et al., 2018). In
compound heterozygous patients with the c.1857C > G/null geno-
type, there was very little phenotypic variation with symptom onset
<1 year of age in all five patients. However, homozygous patients
showed more variation in symptom onset (see below), indicating that
the c.1857C > G (p.(Ser619Arg)) variant allows for the production of
some residual GAA enzymatic activity, and can thus be classified as a
classic infantile or childhood variant.
By definition, the classic infantile variants c.1935C > A (p.(As-
p645Glu)) (missense), c.525del (frameshift causing deletion),
c.2560C > T (p.(Arg854*)) (nonsense), and c.2481 + 102_2646 + 31del
(in‐frame deletion) were invariably associated with an age at symp-
tom onset of <1 year of age.
3.2 | Phenotypic variation in homozygous patients
Patients with specific homozygous variants can help to provide more
insight into phenotypes of these variants since these can be assessed
for only a single disease‐associated variant without the presence of a
second different GAA disease‐associated variant. A priori, one would
expect that homozygous patients with childhood or adulthood onset
would have a median age at symptom onset that is shifted toward a
higher age relative to their compound heterozygous counterpart in
which the variant is combined with a null allele. This shift is driven by a
higher level of residual GAA enzymatic activity produced from the
second allele compared to activity in compound heterozygous patients
that carry the one copy of the variant combined with a null allele.
One such example is the c.‐32‐13T >G variant. Twenty‐two
symptomatic homozygous c.‐32‐13T > G patients are described in the
database. The median age at symptom onset of these patients was 37
years, which was 7 years older compared to patients with the c.‐32‐
13T > G/null allele GAA genotype (Figure 2 and Table 2). The range of
age at symptom onset was very broad, from <1 year to 58 years of
age, which was comparable to the range of age at symptom onset in
compound heterozygous patients (range <1–71 years).
As asymptomatic individuals (e.g., from newborn screening, or
siblings of patients, or individuals who are homozygous for c.‐32‐
13T > G, see below) were not taken into account in the present
analysis and often remain undiagnosed or are not reported, the
median age at symptom onset in Figure 2 and Table 2 is likely biased
and is in reality higher. The common c.‐32‐13T > G variant leads to a
residual activity of 10%–15% per allele (Boerkoel et al., 1995; Huie
et al., 1994; van der Wal et al., 2017). When present at homozygous
state, patients with the c.‐32‐13T > G variant should have 20%–30%
Broad variation in phenotypes for common GAA genotypes| 97
C
hapter 5
residual enzyme activity, which is just above the disease threshold of
20% (threshold value according to patient ranges used at the Erasmus
MC assessed in fibroblasts with 4MU as substrate). This leads to the
prediction that the majority of homozygous c.‐32‐13T > G patients
remain asymptomatic. Indeed, it was previously noted that the fre-
quency of the common c.‐32‐13T > G variant in the Dutch population
is 1 in 154, which implies the existence of 170 individuals in the
Netherlands that carry c.‐32‐13T > G in a homozygous state (Ausems
et al., 1999). Currently, our center does not see any patients with this
genotype, which suggests that it most often does not lead to a dis-
ease phenotype. Others have drawn similar conclusions (Musumeci
et al., 2015; Rairikar et al., 2017; Semplicini et al., 2018). The broad
range of age at symptom onset in the present analysis formally ex-
cluded the possibility that the second allele was responsible for the
broad range of age at symptom onset in compound heterozygous
c.‐32‐13T > G patients in this study and implies the involvement
of modifying factors that delay or accelerate disease progression in
c.‐32‐13T > G patients, as suggested previously (Herzog et al., 2012;
Ko et al., 1999; M. Kroos et al., 2012; M. A. Kroos et al., 2007;
Musumeci et al., 2015; Rairikar et al., 2017; Semplicini et al.,
2018; Shieh & Lin, 1998; van der Ploeg & Reuser, 2008; Wens et al.,
2013). A previous analysis of homozygous c.‐32‐13T >G patients
showed that the c.510C > T variant acts as such a modifying factor
and is overrepresented in patients with this genotype (Bergsma et al.,
2019). The c.510C > T variant lowers enzymatic activity and can lead
to a residual GAA enzymatic activity below the disease threshold.
Given the spread of homozygous c.‐32‐13T > G patients that develop
symptoms across several European countries, the United States,
Colombia, Algeria, and Turkey (Table 2), it will be interesting to assess
whether genetic modifiers, such as c.510C > T, have a particular
geographical distribution. Because the minor allele frequency of
c.510C > T is too low to be reported, this will require a more ex-
tensive genetic analysis of a larger cohort of patients.
A similar conclusion can be drawn for other variants that were not
associated with the classic infantile phenotype. In the case of
c.546G>T, the median age at symptom onset in homozygous patients
was higher than in compound heterozygous patients in combination
with a null allele (37.5 vs. 17 years, respectively) but the difference in
age between the earliest and latest onset of disease was similar (67.5 vs.
72 years, respectively). The c.‐32‐3C>A splicing variant was associated
with childhood onset when combined with a null allele, but with onset at
adulthood when present at homozygous state (median 35, range
31–43 years). The range of age at symptom onset in patients with
compound heterozygous c.‐32‐3C >A in combination with a null allele
could not be assessed with certainty since there have been insufficient
patients reported with this GAA genotype. Patients with the
c.1857C>G (p.(Ser619Arg)) missense variant had a broad range of age
at symptom onset in homozygous patients that ranged from <1 to
17 years (median 7 years), while it was only found in early childhood
patients (median <1 year, range 2 years) when present at compound
F IGURE 2 Variation in the age of symptom onset in homozygous patients. Age at symptom onset is indicated for patients who carry the
most frequently occurring variants at homozygous state (minimum of four patients). Clinical phenotype groups are shown. Median ages at
symptom onset are indicated by long vertical lines; ranges by short vertical lines
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heterozygous state in combination with a null allele (Fukuhara et al.,
2018). The c.1064T >C (p.(Leu355Pro)) variant was found in six
homozygous patients but the information in compound heterozygous
patients who carried a null allele was lacking; homozygous patients
showed a median age at symptom onset of <1 year (range <1–6 years).
Confirming their classification as null alleles, the variants
c.1935C > A (p.(Asp645Glu)), c.2560C > T (p.(Arg854*)), and
c.2481 + 102_2646 + 31del showed invariable symptom onset before
the age of 1 year when present at the homozygous state or at
compound heterozygous state. In addition, 10 patients were homo-
zygous for the null allele c.1933G > A (p.(Asp645Asn)), and all pa-
tients had an age at symptom onset of <1 year.
We conclude from these analyses that the common GAA variants
examined display phenotypic variation in age at symptom onset of up to
71 years between the youngest and the oldest patient when combined
with a null allele and/or when present at a homozygous state. Broad
phenotypic variation with respect to age at symptom onset and severity
of disease was seen both in patients with splicing variants (c.‐32‐13T>G,
c.546G>T, c.1076‐22T>G, c.‐32‐3C>A) and missense variants
(c.2238G>C (p.(Trp746Cys)), c.2173C>T (p.(Arg725Trp)), c.1309C>T
(p.(Arg437Cys)), c.1857C>G (p.(Ser619Arg)), c.1064T>C (p.(Leu355-
Pro))) and was independent of ethnicity. This suggests that disease‐
associated and potentially variant‐specific modifying factors exist for
Pompe disease that can delay or accelerate the progression of the disease
course.
3.3 | Phenotypic variation in patients with the
c.‐32‐13T > G variant: Effect of c.510C > T and of the
second allele
We previously reported that the GAA c.510C>T variant is a silent variant
that occurs in cis with the c.‐32‐13T>G variant in a subset of c.‐32‐
13T>G patients. The c.510C>T variant was found in 8/136 compound
TABLE 2 Information on variants and patients described in Figure 2
aPopulation is reported as indicated in the original publication. In certain cases, only Caucasian origin has been reported.
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heterozygous c.‐32‐13T>G patients and in 2/4 homozygous c.‐32‐
13T>G patients (Bergsma et al., 2019). Here, we report three additional
c.‐32‐13T>G/null allele patients with Pompe disease who carried
c.510C>T and who developed symptoms at a relatively young age
during childhood at 3, 9, and 12 years of age. GAA enzyme activities in
fibroblasts were determined for two of the three patients and averaged
8.9 nmol/h/mg, which was lower than in fibroblasts from patients with c.‐
32‐13T >G/null GAA genotypes that lacked c.510C>T (12.4 nmol/h/mg)
(Bergsma et al., 2019). Our findings support our earlier conclusion that
the c.510C>T GAA variant is associated with a childhood disease pre-
sentation of symptoms in patients with the c.‐32‐13T >G/null allele
genotype. The updated ages at symptom onset in compound hetero-
zygous c.‐32‐13T>G+c.510C>T patients collected from the Pompe
disease GAA variant database are plotted in Figure 3. Seven of these
patients carried a null allele as the second allele. The median age at
symptom onset of these patients was 3 years (range <1–13), similar to
what was reported previously (Bergsma et al., 2019).
To assess a possible effect of the second allele in the total population
of compound heterozygous c.‐32‐13T>G patients present in the data-
base, we analyzed symptom onset in all patients with the same second
allele (c.525del), any null allele, an unknown (disease‐associated) allele,
and a verified non‐null allele (i.e., an allele that is confirmed to produce at
least some residual enzymatic activity). Importantly and in agreement
with previous reports (Wens et al., 2013), patients with the GAA c.‐32‐
13T>G/c.525del genotype showed a similar median age at symptom
onset and age range (median 30 years for both groups and an age range
of <1–70 and <1–71 years, respectively). This confirmed that phenotypic
variation in either patient group was not caused by differences in severity
of the second allele (Bergsma et al., 2019; Wens et al., 2013). Patients
with the genotype c.‐32‐13T>G/unknown (disease‐associated) also
showed a similar median age at symptom onset (28.5 years) and range
(79 years). This suggested that the majority of unknown (disease‐
associated) variants in the database are null alleles. Identification of classic
infantile patients that carry one of these alleles is required to confirm this.
c.‐32‐13T>G patients in which the second allele was not a null allele
showed a slightly higher median age at symptom onset of 37 years
compared to c.‐32‐13T>G patients with a null allele (age range <1–70)
(Figure 3).
We conclude that the very broad range of age at symptom onset
in patients with the c.‐32‐13T > G variant is not caused by the second
allele, and that most c.‐32‐13T > G patients carry a second null allele.
Furthermore, when the c.510C > T variant occurs in cis with c.‐32‐
13T > G, it acts as a negative modifying factor that is associated with
an onset of symptoms during childhood.
3.4 | In search of additional modifying factors for
c.‐32‐13T > G patients
The c.510C> T variant occurs in a subset of c.‐32‐13T >G patients and
lowers GAA enzyme activity by worsening splicing outcomes. The
presence of the c.510C> T variant predicted symptom onset at child-
hood, but not all patients with childhood onset carried c.510C > T
(Bergsma et al., 2019). This suggested that additional modifying factors
exist that may explain childhood presentation in c.‐32‐13T >G patients
that do not carry c.510C >T. To test whether such putative modifying
factors would act by lowering GAA enzyme activity, like c.510C > T
does, we compared GAA enzyme activities in fibroblasts from com-
pound heterozygous c.‐32‐13T >G patients with childhood onset but
without c.510C > T with compound heterozygous patients with adult-
hood onset without c.510C> T (Figure 4). This showed no difference in
GAA enzyme activity between the two groups. We conclude that pu-
tative modifying factors associated with early onset of symptoms other
than c.510C > T do not lower GAA enzyme activity in fibroblasts at the
group level, suggesting that the majority of such putative modifying
factors likely act in trans, for the following reason. While cis‐acting
F IGURE 3 Effects of the second allele in patients carrying the c.‐32‐13T>G variant. Age range is indicated with a black horizontal line.
Median ages at symptom onset are indicated by long vertical lines; ranges by short vertical lines
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genetic factors could still play a role in patients lacking c.510C> T, such
putative factors, for example, distant enhancers, can be expected to
alter GAA expression, which would be reflected at the level of GAA
enzyme activity. The fact that GAA enzyme activity was not different
between patients with childhood onset that lack c.510C> T and with
adulthood onset that lack c.510C > T led us to conclude that at the
group level, trans‐acting factors that act downstream of regulating GAA
activity, for example, factors that regulate lysosomal or skeletal muscle
homeostasis, seem to be the most likely explanation for the differences
in symptom onset among such patients. This conclusion does not ex-
clude the possibility that for individual patients, cis‐acting factors could
still play a role. In addition, our conclusion relies on the assumption that
enzyme activity in fibroblasts in vitro is a good proxy of enzyme activity
in skeletal muscles in vivo, which remains to be determined. It will be
interesting to verify these results in muscle cells derived from primary
biopsies or patient‐derived induced pluripotent stem cells (van der Wal
et al., 2018) because muscle cells rather than fibroblasts better re-
present the primary affected cell type. Genome‐wide studies using large
patient cohorts will help to identify putative modifying factors, and
advanced in vitro model systems, such as 2D or 3D models, derived
from induced pluripotent stem cells along with gene‐corrected controls
(Iuliano et al., 2020; van der Wal et al., 2018) are required to unequi-
vocally demonstrate their biological effect and to study their mechanism
of action. We speculate that candidate modifying factors may act in
trans and may modulate cellular pathways that are known to be in-
volved in the progression of Pompe disease, such as glucose metabo-
lism, lysosomal biogenesis, autophagy, and skeletal muscle strength and
endurance.
4 | CONCLUSION
Previous work has reported on the large variability in age at symptom
onset of patients with the c.‐32‐13T>G GAA variant. Here, we compared
disease onset of patients carrying the c.‐32‐13T>G variant with patients
carrying other variants and conclude that nine distinct GAA disease‐
associated variants (c.2647‐7G>A; c.546G>T; c.2238G>C
(p.(Trp746Cys)); c.2173C>T (p.(Arg725Trp)); c.1076‐22T>G; c.1309C>
T (p.(Arg437Cys)); c.‐32‐3C>A; c.1857C>G (p.(Ser619Arg)); c.1064T>C
(p.(Leu355Pro))) are associated with a large variation in age at symptom
onset when present at compound heterozygous state in combination
with a null allele and/or at homozygous state. Altogether, these findings
suggest a strong influence of modifying factors that affect the age at
symptom onset in patients with Pompe disease. Furthermore, additional
patients carrying c.510C>T in cis with the c.‐32‐13T>G variant were
reported, confirming that the c.510C>T variant is a disease modifier that
accelerates age at symptom onset when combined with the c.‐32‐
13T>G variant. Importantly, the obtained evidence showed that the
majority of putative additional genetic modifiers besides c.510C>T do
not lower GAA enzyme activity in fibroblasts, suggesting that these pu-
tative modifiers act in trans.
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SUPPLEMENTARY DATA  
Supplementary Figure S1
Supplementary Figure S1: Analysis of sex-related differences in age at symptom onset. The dip test 
indicated that the data was distributed unimodally. The Log-rank test, t-test and Wilcoxon rank sum test 
were performed to determine significance.
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Supplementary Table S1: References to patient information for compound heterozygous 
variants in combination with a null allele 
Variant Pubmed IDs 
c.2647-7G>A 24107549 (Sampaolo, et al., 2013) 
c.-32-13T>G 
16531044 (Kostera-Pruszczyk, et al., 2006), 16838077 (Kroos, et al., 2006), 16917947 (Montalvo, et al., 
2006), 17027861 (Shin, 2006), 17056254 (Palmer, et al., 2007), 17616415 (Gort, et al., 2007), 17643989 
(Muller-Felber, et al., 2007), 17723315 (McCready, et al., 2007), 18607768 (Joshi, et al., 2008), 18757064 
(van der Beek, et al., 2008), 19588081 (Oba-Shinjo, et al., 2009), 20559845 (Sacconi, et al., 2010), 
21550241 (Orlikowski, et al., 2011), 22676651 (Herzog, et al., 2012), 22980766 (Alejaldre, et al., 2012), 
23000108 (Wens, et al., 2012), 23160972 (Schneider, et al., 2013), 23430493 (Nino, et al., 2013), 
23566438 (Spada, et al., 2013), 24245577 (Wens, et al., 2013), 24685124 (Andreassen, et al., 2014), 
25155446 (Horvath, et al., 2015), 25455803 (Vill, et al., 2015), 25526786 (Liu, et al., 2014), 25673129 
(Montagnese, et al., 2015), 25681614 (Turaca, et al., 2015), 25783438 (Musumeci, et al., 2016), 
25786784 (Echaniz-Laguna, et al., 2015), 25835646 (Hobson-Webb, et al., 2015), 25846667 
(Bandyopadhyay, et al., 2015), 26622091 (Tecellioglu and Kamisli, 2015), 26800218 (Angelini, et al., 
2016), 26809617 (Levesque, et al., 2016), 26873529 (Stepien, et al., 2016), 27649523 (Nazari, et al., 
2017), 27862019 (Taisne, et al., 2017), 27927596 (Schanzer, et al., 2017), 28032299 (Bekircan-Kurt, et 
al., 2017), 28380188 (Sixel, et al., 2017), 28694071 (Torrealba-Acosta, et al., 2017), 28763149 (McIntosh, 
et al., 2017), 28838325 (Byrne, et al., 2017), 28856460 (Pichiecchio, et al., 2017), 28951071 (Rairikar, et 
al., 2017), 29122469 (Mori, et al., 2017), 29143201 (Burlina, et al., 2018), 29149851 (Johnson, et al., 
2017), 29181627 (Loscher, et al., 2018), 29742245 (Lorenzoni, et al., 2018), 29880332 (Savarese, et al., 
2018), 30155607 (Semplicini, et al., 2018), 30367637 (Szklanny and Tylki-Szymanska, 2018), 30564623 
(Nallamilli, et al., 2018), 30697769 (Ebert, et al., 2019), 30922962 (Bergsma, et al., 2019), 31125121 
(Jastrzebska, et al., 2019), 31392188 (Alandy-Dy, et al., 2019), 9660056 (Kroos, et al., 1998) 
c.2238G>C 
18458862 (Wan, et al., 2008), 21232767 (Chien, et al., 2011), 25526786 (Liu, et al., 2014), 27692865 
(Chu, et al., 2016), 28433475 (Lee, et al., 2017), 29451150 (Liu, et al., 2018), 30897595 (Lyu, et al., 
2019), 31392188 (Alandy-Dy, et al., 2019) 
c.2173C>T 17616415 (Gort, et al., 2007), 8401535 (Hermans, et al., 1993b), 3865697 (Trend, et al., 1985), 30155607 (Semplicini, et al., 2018) 
c.1076-22T>G 9259196 (Adams, et al., 1997), 17643989 (Muller-Felber, et al., 2007), 25455803 (Vill, et al., 2015), 29181627 (Loscher, et al., 2018) 
c.1309C>T 
25526786 (Liu, et al., 2014), 12601120 (Lam, et al., 2003), 23884227 (Park, et al., 2013), 21940687 (Cho, 
et al., 2012), 24169249 (Liu, et al., 2013), 29124014 (Fukuhara, et al., 2018), 27692865 (Chu, et al., 
2016), 30360039 (Kim, et al., 2019) 
c.546G>T 19609281 (Maimaiti, et al., 2009), 20202878 (Kobayashi, et al., 2010), 25388776 (Park, et al., 2015), 29124014 (Fukuhara, et al., 2018), 28433475 (Lee, et al., 2017) 
c.1857C>G 23884227 (Park, et al., 2013), 21676566 (Ishigaki, et al., 2012), 29124014 (Fukuhara, et al., 2018) 
c.1935C>A 
21039225 (Amarinthnukrowh, et al., 2010), 21232767 (Chien, et al., 2011), 18458862 (Wan, et al., 2008), 
16782080 (Dou, et al., 2006), 25466677 (Chien, et al., 2015), 24243590 (Yang, et al., 2014), 8604985 
(Shieh and Lin, 1996), 24706590 (Chien, et al., 2014), 24269976 (Fu, et al., 2014), 10338092 (Ko, et al., 
1999), 8094613 (Hermans, et al., 1993a), 9554747 (Shieh and Lin, 1998), 11053688 (Tsujino, et al., 
2000), 26685070 (Yang, et al., 2016), 29122469 (Mori, et al., 2017), 28394184 (Chen, et al., 2017), 
31510962 (Ngiwsara, et al., 2019), 31342611 (Reuser, et al., 2019), 19948615 (Chien, et al., 2009) 
c.525del 
8558570 (Kroos, et al., 1995), 9660056 (Kroos, et al., 1998), 10377006 (Huie, et al., 1999), 14695532 
(Hermans, et al., 2004), 15121988 (Van den Hout, et al., 2004), 18429042 (Pittis, et al., 2008), 21687968 
(Manwaring, et al., 2012), 22237443 (Messinger, et al., 2012), 22555271 (Kindel, et al., 2012), 23430912 
(Swarr, et al., 2012), 23825616 (Banugaria, et al., 2013), 29122469 (Mori, et al., 2017), 29422078 (Parini, 
et al., 2018), 30902109 (Poelman, et al., 2019), 31342611 (Reuser, et al., 2019) 
c.2560C>T 
8094613 (Hermans, et al., 1993a), 9529346 (Becker, et al., 1998), 10528311 (Castro-Gago, et al., 1999), 
16860134 (Kishnani, et al., 2006), 17723315 (McCready, et al., 2007), 18535739 (Pereira, et al., 2008), 
19588081 (Oba-Shinjo, et al., 2009), 22237443 (Messinger, et al., 2012), 22658377 (Palermo, et al., 
2012), 23430493 (Nino, et al., 2013), 23601496 (Elder, et al., 2013), 23825616 (Banugaria, et al., 2013), 
24273659 (Alansari, et al., 2013), 29122469 (Mori, et al., 2017), 29390460 (Martinez, et al., 2017), 
29637184 (Elenga, et al., 2018), 31342611 (Reuser, et al., 2019) 
c.2481+102_ 
2646+31del 
7603531 (Raben, et al., 1995), 7717400 (Boerkoel, et al., 1995), 7981676 (Huie, et al., 1994), 8558570 
(Kroos, et al., 1995), 9660056 (Kroos, et al., 1998), 14695532 (Hermans, et al., 2004), 14972326 
(Montalvo, et al., 2004), 15121988 (Van den Hout, et al., 2004), 17616415 (Gort, et al., 2007), 18285536 
(Nascimbeni, et al., 2008), 18429042 (Pittis, et al., 2008), 19588081 (Oba-Shinjo, et al., 2009), 27927596 
(Schanzer, et al., 2017), 28657663 (Tsai, et al., 2017), 29122469 (Mori, et al., 2017), 29422078 (Parini, et 
al., 2018), 30902109 (Poelman, et al., 2019), 31342611 (Reuser, et al., 2019) 
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Supplementary Table S2: References to patient information for homozygous variants 
Homozygous variant Pubmed IDs 
c.-32-13T>G 
11071489 (Laforet, et al., 2000), 15986226 (Sharma, et al., 2005), 17643989 (Muller-Felber, et 
al., 2007), 18285536 (Nascimbeni, et al., 2008), 22676651 (Herzog, et al., 2012), 23430493 
(Nino, et al., 2013), 23430949 (Wittmann, et al., 2012), 23465405 (Scott, et al., 2013), 25455803 
(Vill, et al., 2015), 25677830 (Golden-Grant, et al., 2015), 25786784 (Echaniz-Laguna, et al., 
2015), 26231297 (Musumeci, et al., 2015), 28032299 (Bekircan-Kurt, et al., 2017), 28265479 (Sifi, 
et al., 2017), 28554557 (Almeida, et al., 2017), 28838325 (Byrne, et al., 2017), 28951071 
(Rairikar, et al., 2017), 29326002 (Golsari, et al., 2018), 30093709 (Wasserstein, et al., 2019), 
30155607 (Semplicini, et al., 2018), 31342611 (Reuser, et al., 2019) 
c.546G>T 23465405 (Scott, et al., 2013), 29124014 (Fukuhara, et al., 2018), 30093193 (Hossain, et al., 2018) 
c.-32-3C>A 19588081 (Oba-Shinjo, et al., 2009), 20464284 (Grzesiuk, et al., 2010), 25681614 (Turaca, et al., 2015) 
c.1857C>G 14643388 (Pipo, et al., 2003), 18495398 (Nabatame, et al., 2009), 29124014 (Fukuhara, et al., 2018) 
c.1064T>C 
14972326 (Montalvo, et al., 2004), 16917947 (Montalvo, et al., 2006), 17723315 (McCready, et 
al., 2007), 18429042 (Pittis, et al., 2008), 23430493 (Nino, et al., 2013), 24016645 (Loureiro 
Neves, et al., 2013), (Al-Hassnan, et al., 2018), 31342611 (Reuser, et al., 2019) 
c.2015G>A 9535769 (Huie, et al., 1998), 11053688 (Tsujino, et al., 2000), 28937052 (Quan, et al., 2017), 31342611 (Reuser, et al., 2019) 
c.1933G>A 
16860134 (Kishnani, et al., 2006), 17723315 (McCready, et al., 2007), (Del Rizzo, et al., 2010), 
18285536 (Nascimbeni, et al., 2008), 29122469 (Mori, et al., 2017), 29422078 (Parini, et al., 
2018), 31342611 (Reuser, et al., 2019) 
c.1935C>A 
21039225 (Amarinthnukrowh, et al., 2010), 9554747 (Shieh and Lin, 1998), 11053688 (Tsujino, et 
al., 2000), 18458862 (Wan, et al., 2008), 21232767 (Chien, et al., 2011), 10338092 (Ko, et al., 
1999), 28394184 (Chen, et al., 2017), 31342611 (Reuser, et al., 2019) 
c.2560C>T 
9529346 (Becker, et al., 1998), 17723315 (McCready, et al., 2007), 18535739 (Pereira, et al., 
2008), 19588081 (Oba-Shinjo, et al., 2009), 22237443 (Messinger, et al., 2012), 23601496 (Elder, 
et al., 2013), 24273659 (Alansari, et al., 2013), 29122469 (Mori, et al., 2017), 29390460 
(Martinez, et al., 2017), 29637184 (Elenga, et al., 2018), 31342611 (Reuser, et al., 2019) 
c.525del 8558570 (Kroos, et al., 1995), 18429042 (Pittis, et al., 2008), 15121988 (Van den Hout, et al., 2004), 31342611 (Reuser, et al., 2019), 30902109 (Poelman, et al., 2019) 
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GENERAL DISCUSSION
Since the advancement of technologies for DNA analysis, the field of rare diseases has 
developed substantially. Inherited metabolic disorders represent a vast and heterogeneous 
collection of more than 1000 different rare genetic diseases [1]. Pompe disease is a metabolic 
disorder classified as glycogen storage disease type II, a lysosomal storage disorder. 
Enzyme replacement therapy (ERT) with alglucosidase alfa (Genzyme, Cambridge, USA) 
has been available since 2006 for patients with this disease. The therapy has improved 
the survival rate in classic infantile Pompe disease by several years, beyond the natural 
life expectancy [2], [3]. Additionally, patients with later-onset phenotypes have experienced 
improvement with respect to walking abilities, and stabilisation of respiratory function [4], [5].
POMPE DISEASE EPIDEMIOLOGY AND GEOGRAPHIC 
DISTRIBUTION
The availability of ERT for Pompe disease has stimulated the identification of new patients. 
Worldwide implementation of technologies and facilities for screening symptomatic patients 
by biochemical and molecular analysis has led to increasing numbers of diagnosed patients. 
Differences in prevalence among countries suggest that the number of cases is either 
underestimated and/or determined by genetic background. For example, Pompe disease 
has been reported to be less common in Australia (1:146.000) and Portugal (1:600.000) than 
in the Netherlands (1:40.000) [6]–[8]. The Australian study evaluated diagnosed cases over 
a period of 16 years (1980-1996) and the Portuguese study over 19 years (1982-2001). In 
the Dutch study, conducted in 1999, 3000 random blood spots of newborns were screened, 
and DNA analysis was used for the identification of the three most common variants, c.-
32-13T>G (IVS1), c.525del and c.2481+102_2646+31del (delex 18). The populations in 
these three countries are all of European descent. However, the Dutch study identified more 
patients, suggesting that the applied method using screening of DNA variants brought the 
results closer to today’s reality. 
  A reference study for screening Pompe patients is derived from Taiwan, in which 
newborn screening (NBS) officially started in 1985. The overall incidence of Pompe disease 
in that country is 1:17.000, with an incidence of 1:52.000 for classic infantile disease and 
1:25.000 for late-onset forms [9], [10]. In Taiwan, NBS involves a two-step procedure: the 
measuring of GAA enzyme activity in dried blood spots (DBS) followed by GAA genotyping 
[11]. Recently, an NBS study performed in Pennsylvania, USA, screened 531,139 newborns, 
in which the overall incidence was 1:16.095. The screening algorithm was similar to the one 
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used in Taiwan [12]. Additionally, a recent study that analysed carrier frequency of disease-
associated variants, based on information from several databases, e.g. gnomAD and 
Pompe variant database, predicted the genetic prevalence in seven different populations, 
whereby the prevalence in East Asians and non-Finnish Europeans was highly similar 
(approximately 1:14,000) [13]. Therefore, countries with different genetic backgrounds but 
with similar genetic prevalence’s for Pompe disease, like Taiwan and the USA, point to 
the need for a similar approach in other countries, which may decrease the discrepancies 
among reported prevalence’s.
THE ACTUAL SCENARIO FOR SCREENING POMPE 
PATIENTS 
NBS is a public health initiative with the purpose to detect and identify affected newborns for 
which effective therapy is available [14]. The introduction of NBS in some countries, using 
DBS for first-tier testing, has contributed significantly to the early detection and treatment of 
Pompe disease patients [10], [11], [15]. Most studies performed fluorometry or tandem mass 
spectrometry (MS/MS) to analyse GAA enzyme activity in blood specimens using DBS as 
a sample [16]. However, NBS in Pompe disease using DBS has obstacles due to relatively 
high false-positive and false-negative rates, requiring a second assay for confirmation. 
Chapter 2 showed that 16.7% of the patients came out with false-negative results using 
the DBS assay and needed another method to correct the diagnosis. Measuring a second 
(lysosomal) enzyme activity (e.g. BGAL) is strongly advised for judging the DBS quality. 
At our center, the DBS assay is not used routinely. A leukocyte-based assay is preferred, 
and fibroblasts are used for confirmation using 4MUG as a substrate. The latter is the most 
reliable assay for biochemical diagnosis. The assays using fibroblasts as sample source 
with 4MUG as an artificial substrate reveals distinct residual GAA enzyme activities between 
classic infantile, childhood, and adult forms of Pompe disease.
  The use of leukocytes and fibroblasts is common practice in the Netherlands; 
however, these sample sources can be challenging to obtain in certain countries. Usually, 
the diagnosis of rare diseases such as Pompe disease is done in specialized centers, and 
the shipping of samples over long distances is a limitation in many countries. Taking a skin 
biopsy and the follow up culturing of fibroblasts is time-consuming, and culturing of the 
cells needs a strict procedure. Therefore, the advantage of using DBSs in diagnosis and 
newborn screening is that these samples can be transported safely over long distances, 
they can even be mailed in envelopes because of the stability of enzymes -when dried- 
for months at room temperature [17], [18]. In addition, the ability to block the interfering 
enzyme glucoamylase with acarbose makes the DBS assay a useful method for large scale 
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screening [19]. However, the issue of false-negative and false-positive outcomes, in part 
caused by pseudodeficiency alleles, is a drawback.
   As concluded in Chapter 2,  the analysis of a second lysosomal enzyme as a 
sample control in DBS increases the assay’s reliability. Regarding false-positive cases, a 
study performed in Taiwan analysed a large series of patients’ samples (all phenotypes 
included), carriers and carriers of pseudodeficiency alleles using a fluorometric assay.  This 
method failed to distinguish between infantile and late-onset cases of Pompe disease, and 
carriers of a pseudoallele. However, when performing tandem mass spectrometry, the 
successful distinction between these individuals was claimed [20]. Nevertheless, mass 
spectrometry has high costs, requiring a significant budget for materials and equipment. 
  The most used assay for NBS worldwide is the fluorometric method using DBS but 
differences in the detection of Pompe patients are noticed even within a continent with a 
short geographic distance. For example,  it can be expected to see slight genetic differences 
in European subpopulations that depend on the relative geographic distances, except for 
the Finnish population [21], [22]. However, screening of Danish, Slovenian and Belgian 
myopathic patients has not led to the identification of Pompe patients [23]–[25]. In the Danish 
study, enzyme activity was analyzed in DBSs from 47 patients, but the method applied 
was not clearly described, being either fluorometry or tandem mass spectrometry [23]. 
The Slovenian and Belgium studies analysed 90 and 100 patients, respectively, using the 
fluorometric assay in DBSs. In 5 Belgium patients, low enzyme activity was found, but GAA 
sequencing did not detect deleterious variants [24], [25]. A similar situation was reported 
in Brazil, where the proportion of cases that were diagnosed was much lower than the 
expected incidence at birth, suggesting that many cases could be underdiagnosed [26]. 
  In summary, most screening programs so far relied on measuring the enzyme 
activity in DBS samples using a fluorometric assay as a first-tier test. We conclude that 
the implementation of a protocol that considers false-negatives and false-positives would 
decrease the differences among countries in the number of patients detected by NBS. 
STRATEGIES TO IMPROVE THE EFFICIENCY OF ENZYMATIC 
AND MOLECULAR DIAGNOSIS OF POMPE DISEASE
The immediate concern in the diagnosis of Pompe disease is the early detection of classic 
infantile patients because the time spent to conclude the diagnostic outcome can negatively 
affect the patient’s survival. In a patient with the classic infantile form, symptoms usually 
start shortly after birth and, without ERT, the median age of death is six months [27]. Taking 
Brazil as an example, the diagnosis of rare diseases can take months to years [28]; the 
same may apply to other countries. Several issues can influence the diagnostic process:
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•  General practitioners (GP) are not aware of rare diseases; 
•  The reference centers are usually located in big cities, forcing people to consult a local 
GP. In addition, the GP needs to refer the patient to the right specialist, which can take 
time. The travel from the city of the patient to the city with the reference center is also a 
limitation, especially for patients with a low income;
•  After confirming the diagnosis, receiving ERT may require a judicial process [29].
  For Pompe patients to receive ERT, it is required to be appropriately diagnosed by 
enzymatic and molecular analyses, and the identification of two disease-associated variants 
in the GAA is required in several countries [30]. As mentioned before, the enzymatic diagnosis 
can be a challenge due to potential false-negative or false-positive results. In many cases, 
DNA analysis will be performed after a positive enzymatic result. Routine DNA analysis 
usually focuses on coding regions using PCR and Sanger sequencing. Next-Generation 
sequencing (NGS) is becoming an alternative when disease-associated variants are not 
found. We reported in Chapter 3 the case of a symptomatic patient with low enzyme activity 
but only one disease-associated variant in heterozygosity. By performing an SNP array 
on different tissues, a 39.5MB allele imbalance was detected that was more profound in 
fibroblasts compared to leukocytes. Additional analysis showed genetic mosaicism for a 
segment of Chr 17. This illustrates that extended analysis can resolve inconclusive cases, 
which can be crucial to start or continue ERT.
  Extended analysis may need additional samples such as fibroblasts, and/or require 
RNA for cDNA synthesis. On the other hand, quick results are essential for the survival of 
classic infantile Pompe patients. Most of the samples available in many countries are DBS 
on filter paper or FTA® Cards. In my experience -when I was working on the molecular 
analysis of patients from Latin America in São Paulo, Brazil-  patient’s samples were mostly 
received on filter paper by post. After the Biochemical laboratory had taken a punch from 
the filter paper for enzymatic analysis, the rest of the paper was used to isolate DNA for the 
performance of PCR and Sanger sequencing in case the enzymatic analysis turned out to 
be positive. In a few cases, the sample quality was low, in which case we had to solicit for a 
new one. It was challenging to analyse gross deletions and insertions using samples on filter 
paper because the quality of the DNA might be too low for performing fragment analysis like 
Multiplex probe amplification (MLPA). Some laboratories already developed technologies to 
improve the filter paper quality. For instance, by using CentoCard®, it is possible to perform 
both enzymatic as well as DNA analysis (including MLPA, exome sequencing, genome 
sequencing and biomarker assays). 
  Due to the limited sample source and shipping opportunities, efficient use of filter 
paper samples needs to be implemented. Here, I argue for the implementation of NGS as a 
second-tier assay in NBS, in which delay and misdiagnosis can be avoided [31]–[33].
  NGS technologies include gene panels, such as Motorplex, whereby panels can 
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be pre-designed to screen many different genes [34], to perform whole exome sequencing 
(WES) and whole genome sequencing (WGS). WES has the advantage to screen for rare 
variants, however, intronic variants will be missed. WGS is an alternative to screen the 
entire gene, although the chance to detect variants with a minor allele frequency below 5% 
decreases compared to WES. We have shown in Chapter 4 that the number of listed GAA 
variations in the Pompe variant database has increased by 61% in a period of 4 years. More 
registries are still appearing because of the increased frequency of NBS for Pompe disease 
and the use of NGS. The compilation of data in the Pompe variant database is a useful 
tool to guide medical doctors in how to diagnose and manage Pompe patients, as it links 
disease-associated variants to clinical severities [35]. 
  The treatment with ERT can be influenced by antibodies to the recombinant GAA 
enzyme. For this reason, cross-reactive immunological material (CRIM) negative patients 
receive immunomodulation therapy prior to initiation of ERT. In many instances, the GAA 
genotype can predict the CRIM status pointing to the importance of the Pompe variant 
database and regular updates (Chapter 4).
  NGS can generate a huge collection of uninterpretable variants, known as variants 
of unknown significance (VUS). In Chapter 4 we discussed the issue of VUS in putative 
patients diagnosed by NBS. VUS can lead to underestimation (disease-associated variants 
interpreted as benign) and overestimation (benign variants are misinterpreted as disease-
associated) of Pompe disease. Another issue that became apparent is that asymptomatic 
individuals with a VUS are identified by NBS with  the possibility of an emerging disease and 
doubt on when starting ERT.  Such situation leads to emotional stress [36], [37]. Therefore, 
an up-to-date database, the proper training of GPs, and awareness of rare diseases would 
optimize the diagnostic process. The use of NGS as a routine procedure combined with NBS 
has the potential to prioritize patients at high risk and ensure adequate genetic counselling 
of parents.
A FUTURE PERSPECTIVE ON THE USE OF NGS FOR 
SCREENING POMPE PATIENTS 
We are entering the ‘big data’ era. For example, genomic data from NBS/NGS-based patient 
screening programs are becoming available. Predictions for 2030 see a significant increase 
in human genomics based on NGS since the human genome project was released in 2003 
[38].  This includes: the association of genomic and phenotypic information; the prediction 
of pathogenicity of genomic variants, rendering the designation VUS obsolete; and access 
to our own genomic data via our smartphone [38]. Prices of WES and WGS analyses are 
decreasing every year. Although prices can vary substantially per laboratory depending 
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on whether bioinformatics’ analysis is included, high coverage analysis can be performed 
for a total of 1000 euros per sample. Analysis using artificial intelligence (AI) will decrease 
the price even more, by using an AI algorithm known as deep learning [39]. Recent studies 
suggest how deep learning can revolutionize variant calling for nanopore-based sequencing 
technologies, a sequencing technology that enables real-time analysis of long DNA and 
RNA fragments in a short time [40]. Genotype-phenotype prediction provides diagnoses and 
forecasts future disease risks. The AI-based methods can accurately aid in the diagnosis and 
prediction of disease risks by integrating data. Therefore, for Pompe disease, in the future 
integrating AI with the Pompe variant database (www.pompevariantdatabase.nl) (integrated 
into the LOVD)  may efficiently predict the genotype-phenotype outcome highlighting the 
importance to keep the existing databases updated, as presented in Chapter 4. Additionally, 
the use of NGS as a first-tier test seems a future possibility, turning the diagnostic and 
screening processes into a homogenous and inclusive procedure worldwide.
HOW TO DEAL WITH UNKNOWN MOLECULAR RESULTS?
As stated above, to properly diagnose a Pompe patient the outcomes of the enzymatic 
analysis and the DNA analysis need to be consistent and compatible with the clinical 
diagnosis of Pompe disease. In certain countries, these results need to be available 
before the judicialization process can start that is required for a patient to receive ERT. 
Depending on the country, the costs of ERT can be covered by the health insurance system 
or the government [41], [42].  In Chapter 2, we discussed how to manage and improve the 
enzymatic analysis. However, how to handle in putative case of Pompe disease wherein no 
variants are found by Sanger sequencing?
  The main concern is putative cases of classic infantile Pompe disease, in which 
the survival rate is proportional to an early start of ERT.  In most cases, the only available 
sample will be a DBS. In Figure 1, we depict two possible scenarios when DBS is the only 
available sample. In scenario 1, after the laboratory has received the sample, enzymatic 
and DNA analysis can be performed simultaneously. The first-tier analysis of the enzymatic 
analysis shows low enzyme activity, and with DNA analysis, two disease-associated 
variants are found, of which the (predicted) CRIM status is known. ERT as well as the 
subsequent judicialization process can be initiated. In scenario 2, low enzyme activity is 
found in DBS in the first/second tier; however, Sanger sequencing of the flanking exons 
does not reveal a disease-associated variant. If a VUS is found in the coding or flanking 
region, an in-silico analysis can be performed and used to predict its potential impact. If a 
VUS is not found but when the clinical and enzymatic diagnostic outcomes are indisputable, 
ERT is recommended, the judicialization process is started.
  In many cases, molecular results are still required to continue treatment with ERT. 
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When no variants are found, the next step is to search for large deletions or insertions using, 
for example, MLPA, quantitative qPCR or genome sequencing. Some laboratories have 
already developed techniques to perform this analysis in DBS [43]–[47]. If the results remain 
inconclusive, extended analyses and further investigations are recommended. Chapter 3 
describes six patients in which the molecular diagnosis was successfully performed using 
a generic-splicing assay, minigene analysis, SNP array analysis, and targeted Sanger 
sequencing; however, for these analyses, additional samples such as fibroblasts were 
required.
MODIFYING FACTORS IN POMPE DISEASE
Modifying factors may have an impact on the clinical course of disease severity. For 
example, the variant c.510C>T (p.=), was disregarded for many years because it is silent, 
i.e. it does not change the amino acid. However, recently our group found that in compound 
heterozygous patients - with IVS1 on one allele and another disease-associated variant on 
the other allele - c.510C>T can co-occur on the same allele as  IVS1  and aggravate the 
Potential Classic Pompe patient
Scenario 1 Scenario 2
DBS DBS
Enzymatic Analysis DNA analysis
+ +
1st tier Enzymatic Analysis DNA analysis
+ -
2nd tier Enzymatic Analysis
 (repeat test or 
additional sample)
+
Patient - start ERT
Enzymatic Analysis
 (repeat test or 
additional sample)
VUS                    
+
Potential 
Patient - start ERT










results                    
In-silico 
analyses                   
Judicial process
continue ERT
Figure 1. Two possible scenarios when DBS (Dried blood spot) is the only sample available for a potential 
classic infantile Pompe patient. (+) Results compatible with the diagnosis Pompe disease; (-) Results are 
insufficient/negative to diagnose Pompe disease; (dashed line) in-silico analyses for the prediction of pathogenicity 
and CRIM status. VUS (Variant of unknown significance); ERT (Enzyme replacement therapy).
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extent of aberrant splicing caused by the IVS1 variant. The combination c.510C>T plus IVS1 
was demonstrated to be associated with an early presentation of symptoms [48].  However, 
it is still poorly understood why some patients without c.510C>T manifest symptoms much 
earlier than others, even within families.
  Several publications reported the broad spectrum of symptom onset in patients with 
the IVS1 variant [48]–[51]. In Chapter 5, we analysed the information included in the most 
recent update of the Pompe variant database and found that - besides the IVS1 variant - 
nine other disease-associated variants (c.2647-7G>A; c.546G>T; c. 2238G>C; c.2173C>T; 
c.1076-22T>G; c.1309C>T; c.-32-3C>A; c.1875C>G; c.1064T>C) are associated with 
a broad spectrum of disease onset. This also counted for variants at homozygous state. 
The c.510C>T variant is linked to the IVS1 allele in cis and was shown to be a modifier 
that accelerates the age at symptom onset. However, in the other nine alleles, the variant 
c.510C>T was not found, suggesting an influence of additional modifying factors in disease 
progression. 
  Environmental factors, epigenetic factors, genetic background, and even gut 
microbiota can in theory be involved in the genotype-phenotype relationship. We can 
speculate that factors involved may include differences in muscle fiber types, or up versus 
downregulation of genes involved in relevant pathways such as glucose metabolism, 
‘lysosomal biology’, or muscle function; all areas on which future research can be focused. 
GAA haplotypes can act at another level as modifying factor. A haplotype is an uninterrupted 
series of DNA variations that tend to be inherited together without recombination. A  DNA 
locus that correlates with a quantitative trait variation in the phenotype is named a quantitative 
trait locus (QTL). Furthermore, a DNA locus or a haplotype that influences expression levels 
of mRNA transcripts is known as eQTLs.
  It is already known that eQTLs acting in cis or in trans can influence the expression 
of genes across human tissues [52]–[54] (Figure 2). A large project has been to collect 
samples from almost 1000 postmortem individuals to understand which cis-eQTLs can 
cis-eQTLs trans-eQTLs
Figure 2. Local and distal genetic effects (cis-eQTLs and trans-eQTLs, respectively) influencing gene expression 
(Modified from [58]).
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affect gene expression across 54 different non-diseased tissues. This effort is called the 
Genotype-Tissue Expression (GTEx) project (www.gtexportal.org) and aims to characterise 
genetic effects on the human transcriptome and link regulatory mechanisms to trait and 
disease associations. Interestingly, when we analysed genes involved in glycogen 
metabolism, we found that the GAA is particularly enriched in cis-eQTLs compared to other 
genes (Figure 3). This could explain the broad spectrum of GAA activity found in healthy 
individuals (Chapter 2). By analogy, the broad range in age of onset among patients with 
Pompe disease and the same GAA genotype could be explained by cis-eQTLs in the GAA.
eQTLs  AND HAPLOTYPES INFLUENCE IN GAA EXPRESSION
In Chapter 6, we defined the GAA haplotypes in a general population with Northern and 
Western European genetic ancestry. In short, we found two major haplotypes, one with 
many common variants (MAF ≥ 5%) and another without those variants. IVS1 is present in 
a haplotype without common variants. Therefore, special attention should be given to rare 
variants that are present in cis with IVS1  as these could be modifiers, like we found for 
c.510C>T. In non-IVS1 alleles, the common variants are cis-eQTLs registered in GTEX, and 
they could account for the variability of GAA activity because all those common variants are 
downregulating GAA expression.
  Applying the same effort to another population such as the Asian population, 
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Figure 3. Number of cis-eQTLs present in genes involved in glycogen metabolism, based on 54 different tissues. 
Source: GTEx (www.gtexportal.org , analysis on 27-03-2021).
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pseudodeficiency harbours distinct haplotypes for Pompe patients and unaffected individuals. 
In the Taiwanese population, a haplotype that negatively modulates GAA expression was 
found in 14% of individuals [55]. A more in-depth study of the Asian haplotypes and their 
possible effect on GAA expression is warranted. 
  The IVS1 variant was hypothesized to propagate as a founder variant through 
inheritance and migration [50]. A founder variant usually arises in a tribe or group of people 
that are geographically or culturally isolated. However, the IVS1 variant is widespread in 
people with a European genetic background. This argues against a founder effect as the 
single mechanism, as it would imply that all Europeans are derived from a single founder 
in which IVS1 was present, which is unlikely. Interestingly, the IVS1 variant was found in a 
haplotype with a neutral effect on GAA expression, whereas the great majority of variants 
in common haplotypes had a negative impact on GAA expression. In general, disease-
associated variants are often found in haplotypes that negatively affect the expression of the 
gene in question. This co-occurrence increases the chance that the haplotype incorporating 
the pathogenic variant will be depleted - in the long run - by natural purification selection 
[56]. This phenomenon was indeed seen for most other disease-associated variants for 
Pompe disease (Chapter 6).
  The IVS1 variant has a higher MAF (European non-Finnish MAF-0.5%) than 
other disease-associated variants. Therefore, we speculate that the IVS1 allele could have 
had a beneficial influence during human evolution, being subject to positive selection. 
The IVS1 allele causes leaky splicing that decreases GAA activity. We speculate that 
during human evolution and in episodes of starvation, the presence of IVS1 has been 
advantageous. The presence of IVS1 results in decreased degradation of lysosomal 
glycogen, thereby preserving a glycogen source for the cell. A similar selective advantage 
triggered by ‘protective haplotypes’ has been seen in genes related to type 2 diabetes 
[57]. The protective haplotype dating from the beginning of the Neolithic era did arise by 
purifying selection in response to specific pastoral dietary habits in individuals from Bishkek, 
Kyrgyzstan and Bukhara, Uzbekistan [57]. Thus, haplotypes that had a selective advantage 
in past environments may have become deleterious in the modern world due to changes 
in diet, behaviour, and/or external stimuli, which could explain the high prevalence of 
some polygenic diseases such as diabetes. One may hypothesis that a similar selective 
procedure has operated for the IVS1 variant in Pompe disease, however, its low frequency 
limits further investigation. Efforts to collect data from more IVS1 patients – for instance via 
the European Pompe Consortium - would bring opportunities to perform such analysis and 
to obtain solid evidence.
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CONCLUSIONS
Despite progress in the last 15 years with collecting data from patients and their disease-
associated variants in the GAA, new information is still to come. Patients from certain 
geographic areas are underrepresented in our Pompe variant database, resulting in a lack 
of important information for investigating genotype-phenotype relationships. Advances in 
NGS technology could enable it to become a first-tier test in NBS, making the diagnosis for 
Pompe disease inclusive in many countries. There is increasing evidence for phenotypic 
diversity among patients with the same GAA genotype.  Investigating larger patient cohorts 
will facilitate the search for modifiers, either using a candidate or an unbiased approach in 
genome-wide association analysis and help to understanding how eQTLs in haplotypes can 
influence GAA expression in healthy subjects and in Pompe patients. Further research is 
required to find out whether the pathogenic IVS1 variant is inserted in a protective haplotype 
that has been preserved during evolution, driven by positive selection.
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Pompe disease is a rare, autosomal recessive disorder caused by disease-associated 
variants (mutations) in the gene coding for the enzyme acid-α-glucosidase (GAA). The 
function of GAA is to degrade glycogen to glucose in the lysosome. Deficiency of GAA will 
result in glycogen accumulation in the lysosome causing damage to the cells and tissues, 
leading to loss of function. Complete lack of GAA enzyme activity (0%) causes classic 
infantile Pompe disease, affecting newborns, mainly because of cardiac hypertrophy and 
skeletal muscle wasting. Childhood/adult Pompe patients have a milder phenotype because 
they have a residual enzyme activity (1-20%), leading to progressive muscle weakness, 
mobility problems, and respiratory insufficiency.
  Since 2006 a treatment is available for Pompe disease: enzyme replacement 
therapy (ERT), which consists of intravenously administered human recombinant GAA 
enzyme. The therapy has improved the survival rate for classic infantile patients and showed 
improvements such as better walking abilities and stabilisation of respiratory function in 
children and adult patients. For Pompe patients to receive ERT, an appropriate diagnosis is 
required based on GAA enzyme deficiency, and preferably two disease-associated variants 
should be detected in the GAA gene. A general introduction to Pompe disease and an 
explanation of the process to perform enzymatic and molecular diagnosis is provided in 
Chapter 1. 
  Several methods and samples can be used to determine the enzyme activity for 
GAA. However, enzymatic diagnosis can face some issues such as the existence of false-
positive and false-negative results. Chapter 2 reports methods applied for the enzymatic 
diagnosis of Pompe disease and reviewed the outcome of a series of 2591 assays in 1709 
individuals suspected of having Pompe disease. It shows the results of different types of 
samples and different methods that were used over the past 28 years in the department 
of Clinical Genetics of the Erasmus MC University Medical Center in Rotterdam. In order 
to determine the performance of each assay, GAA activity was measured in white blood 
cells (leukocytes) using glycogen or 4-methylumbelliferyl-α-D-glucopyranoside (4MUG) 
as substrate, dried blood spots (DBS) using 4MUG as substrate, and skin fibroblast using 
4MUG as substrate. Mixed leukocytes provided the fastest diagnostic method, whereby the 
reaction mixture needed to contain acarbose to inhibit glucoamylase. DBS-based assays 
were considered valuable tools for screening, but an additional assay is required to confirm 
the diagnosis to avoid false-negative results. Cultured skin fibroblasts provided the best 
results to differentiate between classic infantile, childhood, and adult Pompe disease forms. 
Glycogen and 4MUG were suitable substrates, but glycogen discriminated best between 
affected and unaffected individuals. The disadvantage of using glycogen is that carriers of 
the GAA2 pseudo deficiency may be misdiagnosed as patients. In such cases, additional 
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use of 4MUG provided the most reliable assay and validated results from leukocytes and/or 
DBS.
  Molecular analysis is also an essential step to conclude the diagnostic procedure 
of a Pompe patient. Traditional Sanger sequencing covering the coding exon flanking 
areas is the most commonly used method, however, in some cases, this method will not 
be enough to conclude a case. In Chapter 3 we showed extended molecular diagnostic 
analyses and identified novel disease-associated variants in patients with Pompe disease 
where conventional analysis was insufficient. Additional assays, such as a generic-splicing 
assay, minigene analysis, SNP array analysis, and targeted Sanger sequencing, allowed 
the identification of an exonic deletion, a promoter deletion, and a novel splicing variant 
located in the 5′ UTR. This extended analysis could also identify an atypical phenotype for 
Pompe disease presented in a patient in which was explained by genetic mosaicism for a 
segment of chromosome 17 that includes GAA.
  We maintain a public database on the understanding of the genotype-phenotype 
correlation in Pompe disease (www.pompevariantdatabase.nl), linking disease-associated 
variants to clinical severity. This database is important to guide clinicians and clinical 
geneticists to establish an accurate molecular diagnosis. In the recent update (Chapter 4), 
the actual database includes 648 disease-associated variants, 26 variants from newborn 
screening and 237 variants with unknown severity. Common sequence variants (minor 
allele frequency ≥ 1%) were added in response to the misreporting of such variants as 
the principal cause of disease in several patients. The data added to the Pompe variant 
database contains important information regarding genotypes and phenotypes from many 
publications on Pompe disease. In Chapter 5, we analysed all data present in the database 
for the most common GAA genotypes to analyse the phenotype-genotype correlation. 
Patients with the common c.-32-13T>G (IVS1)/null GAA genotype have a broad-spectrum 
symptom onset ranging from early childhood to late adulthood. Nine distinct GAA disease-
associated variants (c.2647-7G>A; c.546G>T; c. 2238G>C; c.2173C>T; c.1076-22T>G; 
c.1309C>T; c.-32-3C>A; c.1875C>G; c.1064T>C) also showed considerable variation in 
age at symptom onset when present at compound heterozygous state in combination with 
a null allele or at homozygous state. The silent c.510C>T variant is linked to c.-32-13T>G 
in some cases and is associated with accelerated onset of symptoms. For many patients it 
is still unclear why phenotypic variation happens for these common GAA genotypes, which 
implies the influence of modifying factors.
  Environmental factors, as well as the epigenetic and genetic background, may 
influence the genotype-phenotype correlation. A potential genomic modifier is the haplotype 
configuration. Usually, haplotypes have variants that influence the expression of mRNA 
transcripts, known as eQTLs. To analyse the possible impact of eQTLs on GAA expression, 
in Chapter 6, we analysed the disease-associated genetic environment of GAA. We 
defined European GAA haplotypes, searching for haplotype-based genotype-phenotype 
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correlations and the possible impact on GAA expression. We could see that most disease-
associated variants are present in haplotypes that negatively modulate GAA expression, 
which may increase their penetrance. However, the IVS1 variant was found in a haplotype 
with a neutral effect on GAA expression, possibly suggesting a positive selection scenario.
  We investigated the gene expression profile in fibroblasts to extrapolate our 
understanding of patients with the common IVS1/null GAA genotype (Chapter 7). Our 
analysis pointed to the conclusion that several factors are possibly associated with the 
clinical course of Pompe patients. Comparing the expression profile of two groups of patients, 
one with the onset of first symptoms under the age of 16 years and one with the onset 
of symptoms over the age of 35 years, we could see that three genes stood out (MAOA, 
STC-1 and NRK-1), suggesting that these could be disease-markers. MAOA (Monoamine 
Oxidase Type A) catalyses the oxidation of monoamines, such as dopamine, serotonin and 
adrenalin; STC1 (Stanniocalcin-1) plays a role in regulating renal and intestinal calcium 
and phosphate transport, cell metabolism, or cellular calcium/phosphate homeostasis; and 
NRK (Nik Related Kinase) has been associated with the induction of actin polymerisation 
in late embryogenesis. The overall implication of these genes in biological processes 
includes bone and muscle development, cellular calcium/phosphate homeostasis, cellular 
metabolism, and cellular biogenic amine metabolic process suggesting that these genes 
might be considered potential disease-markers in patients with the IVS1/null genotype.
  Finally, Chapter 8 discusses the main findings, clarifies the methods for enzymatic 
diagnosis, and provides ways to improve the molecular analysis and to increase our 




De ziekte van Pompe is een zeldzame, autosomaal recessieve aandoening die veroorzaakt 
wordt door ziekte geassocieerde varianten (mutaties) in het gen dat codeert voor het enzym 
zure-α-glucosidase (GAA). GAA is verantwoordelijk voor de omzetting van glycogeen naar 
glucose, en een gebrek aan actief GAA zal resulteren in de opstapeling van glycogeen in het 
lysosoom waardoor schade aan de cellen en weefsels kan ontstaan. De vroeg optredende 
(klassiek infantiele) vorm van de ziekte van Pompe, die pasgeborenen treft, ontstaat door een 
volledig gebrek aan GAA enzym activiteit (0%). Deze vorm wordt voornamelijk gekenmerkt 
door hypertrofie van het hart en afname van de functie van de skeletspieren. Kinderen en 
volwassen waarbij de ziekte van Pompe op een later moment tot uiting komt (kindertijd of op 
volwassen leeftijd) hebben mildere symptomen als gevolg van resterende enzymactiviteit 
(1-20%), wat leidt tot langzaam progressieve spierverzwakking, mobiliteitsproblemen en 
ademhalingsproblemen.
  Sinds 2006 is een behandeling beschikbaar voor de ziekte van Pompe: 
enzymvervangingende therapie (ERT), bestaande uit intraveneus toegediend humaan 
recombinant GAA-enzym. Deze behandeling vergroot de overlevingskans voor klassieke 
infantiele patiënten en zorgt voor een verbetering van verschillende symptomen bij 
de later optredende vormen, zoals betere loopvaardigheden en stabilisatie van de 
ademhalingsfunctie. Voordat patiënten met de ziekte van Pompe ERT kunnen ontvangen 
is een diagnose vereist op basis van GAA enzym deficiëntie, en zouden bij voorkeur twee 
ziektegerelateerde varianten moeten worden gedetecteerd in het GAA gen. Een algemene 
inleiding tot de ziekte van Pompe en een uitleg van het proces voor het uitvoeren van de 
enzymatische en moleculaire diagnose is beschreven in hoofdstuk 1.
  Verschillende methoden kunnen gebruikt worden om de enzymactiviteit van GAA 
te bepalen. Echter kan de enzymatische diagnose geconfronteerd worden met enkele 
problemen, zoals het bestaan van vals-positieve en vals-negatieve resultaten. Hoofdstuk 
2 behandelt methoden die toegepast worden voor de enzymatische diagnose van de ziekte 
van Pompe, en bespreekt de uitkomst van een reeks van 2591 assays bij 1709 personen 
die ervan verdacht werden de ziekte van Pompe te hebben. Het toont de resultaten van 
verschillende typen monsters en verschillende methoden om enzymactiviteit te bepalen die 
de afgelopen 28 jaar zijn gebruikt op de afdeling Klinische Genetica van het Erasmus MC 
Medisch Centrum in Rotterdam. Om de prestaties van elke test te bepalen werd GAA-activiteit 
gemeten in witte bloedcellen (leukocyten) met behulp van glycogeen of 4-methylumbelliferyl-
α-D-glucopyranoside (4MUG) als substraat, in gedroogde bloedvlekken (DBS) met 4MUG 
als substraat en in huidfibroblasten met 4MUG als substraat. Gemengde leukocyten bieden 
de snelste diagnostische methode, waarbij het reactiemengsel acarbose moet bevatten om 
glucoamylase te remmen. DBS-gebaseerde assays werden beschouwd als waardevolle 
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instrumenten voor screening, maar aanvullende testen zijn vereist om vals-negatieve 
resultaten te voorkomen en de diagnose te bevestigen. Gekweekte huidfibroblasten 
bieden de beste resolutie om onderscheid te maken tussen de klassiek infantiele, en de 
later optredende vormen van de ziekte. Glycogeen en 4MUG waren geschikte substraten, 
maar glycogeen discrimineert het beste tussen aangedane en niet-aangedane personen. 
Het nadeel van het gebruik van glycogeen is dat dragers van de GAA2 pseudo-deficiëntie 
verkeerd geïdentificeerd kunnen worden als patiënten. In dergelijke gevallen biedt 
aanvullend gebruik van 4MUG in leukocyten en/of DBS de meest betrouwbare resultaten. 
  Naast enzymatische analyse is ook de moleculaire analyse een essentiële stap 
om de ziekte van Pompe te diagnosticeren. De meest gebruikte methode is traditionele 
Sanger-sequencing die de coderende exon flankerende gebieden bestrijkt, maar in 
sommige gevallen zal deze methode niet voldoende zijn om een diagnose vast te stellen. In 
hoofdstuk 3 toonden we uitgebreide moleculaire diagnostische analyses en identificeerden 
we nieuwe ziektegerelateerde varianten bij patiënten met de ziekte van Pompe, waarbij 
de conventionele analyse onvoldoende was. Met behulp van aanvullende assays zoals 
generieke splicing assays, minigen analyse, SNP array analyse, en gerichte Sanger 
sequencing, werden zowel een exonische deletie, een promotor verwijdering, en een 
nieuwe splicing variant gelegen in de 5′ UTR geïndentificeerd. Deze uitgebreide analyse 
kon ook een atypisch fenotype voor de ziekte van Pompe bij een patiënt identificeren, wat 
verklaard kan worden door een genetisch mozaïek voor een segment van chromosoom 17 
dat GAA omvat.
  We houden een openbare database bij over het begrip van de genotype-fenotype 
correlatie bij de ziekte van Pompe (www.pompevariantdatabase.nl), waarbij ziekte 
geassocieerde varianten worden gekoppeld aan het fenotype van de patiënten. Deze 
database is belangrijk om clinici en klinisch genetici te begeleiden bij het vaststellen van een 
nauwkeurige en accurate diagnose. In de recente update (hoofdstuk 4) bevat de database 
648 ziektegerelateerde varianten, 26 varianten van newborn screening en 237 varianten van 
onbekende mate van ernst. Veel voorkomende sequentievarianten (minor allele frequency 
≥ 1%) werden toegevoegd als reactie op het onjuist rapporteren van zulke varianten als de 
de voornaamste oorzaak van de ziekte bij verschillende patiënten. De gegevens die zijn 
toegevoegd aan de Pompe variant database bevatten belangrijke informatie over genotypen 
en fenotypen uit vele publicaties. In hoofdstuk 5 analyseerden we alle gegevens in de 
database voor de meest voorkomende GAA-genotypen om de fenotype-genotype correlatie 
te bekijken. Patiënten met het gemeenschappelijke c.-32-13T>G (IVS1)/null GAA-genotype 
hebben een breed spectrum van het moment van ontstaan van de ziekte, variërend van 
de kindertijd tot op latere volwassen leeftijd. Negen verschillende GAA-ziektegerelateerde 
varianten (c.2647-7G>A; c.546G>T; c. 2238G>C; c.2173C>T; c.1076-22T>G; c.1309C>T; 
c.-32-3C>A; c.1875C>G; c.1064T>C) vertoonden ook een aanzienlijke variatie in de leeftijd 
waarop de symptomen begonnen, wanneer deze heterozygoot voorkwamen in combinatie 
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met een nul-allel of wanneer deze homozygoot aanwezig waren. De stille c.510C>T 
variant is in sommige gevallen gekoppeld aan c.-32-13T>G en wordt geassocieerd met 
een versneld begin van de symptomen. Voor veel patiënten is het nog steeds onduidelijk 
waarom een variatie in het fenotype optreedt voor deze veel voorkomende GAA-genotypen, 
wat impliceert dat er modificerende factoren moeten zijn.
  Omgevingsfactoren en de epigenetische en genetische achtergrond van de 
patiënt kunnen de correlatie tussen genotype en fenotype beïnvloeden. Een potentiële 
genomische modificator is de haplotype configuratie. Meestal hebben haplotypen varianten 
die de expressie van mRNA-transcripties beïnvloeden, beter bekend als eQTL’s. Om de 
mogelijke impact van eQTL’s op de GAA-expressie te analyseren hebben we in hoofdstuk 
6 de ziekte gerelateerde genetische omgeving van GAA geanalyseerd. We definieerden 
Europese GAA-haplotypes die een mogelijke impact hebben op de GAA-expressie. De 
meeste ziekte geassocieerde varianten zijn aanwezig in haplotypes die de GAA-expressie 
negatief kunnen beïnvloeden, wat hun penetrantie kan verhogen. De IVS1-variant werd 
echter gevonden in een haplotype met een neutraal effect op de GAA-expressie, wat een 
positief selectie scenario suggereert.
  We onderzochten het genexpressieprofiel in fibroblasten om ons begrip van 
patiënten met het gemeenschappelijke IVS1/null GAA-genotype te vergroten (hoofdstuk 
7). Onze analyse suggereert dat verschillende factoren mogelijk verband houden met 
het klinische verloop van Pompe-patiënten. Door het expressieprofiel van twee groepen 
patiënten te vergelijken, één met het begin van de eerste symptomen onder de leeftijd 
van 16 jaar en één met het begin van symptomen ouder dan 35 jaar, kwamen drie genen 
naar boven (MAOA, STC-1 en NRK-1), wat suggereert dat dit potentiële ziekte-markers 
kunnen zijn. MAOA (Monoamine Oxidase Type A) katalyseert de oxidatie van monoamines, 
zoals dopamine, serotonine en adrenaline; STC1 (Stanniocalcine-1) speelt een rol bij het 
reguleren van het renale en intestinale calcium- en fosfaattransport, het cel metabolisme 
of de cellulaire calcium/fosfaathomeostase; en NRK (Nik Related Kinase) is geassocieerd 
met de inductie van actinepolymerisatie bij late embryogenese. De algehele implicatie van 
deze genen in biologische processen omvat bot- en spierontwikkeling, cellulaire calcium/
fosfaathomeostase, cellulair metabolisme en het cellulair biogene aminemetabolische 
proces, wat aangeeft dat deze genen mogelijk kunnen worden beschouwd als potentiële 
ziekte-markers bij patiënten met het IVS1/null genotype.
  Ten slotte bespreekt hoofdstuk 8 de belangrijkste bevindingen, verduidelijkt 
het de methoden voor enzymatische diagnose en biedt het manieren om de moleculaire 
analyse te verbeteren en onze kennis over de correlatie tussen genotype en fenotype bij de 
ziekte van Pompe te verhogen.
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RESUMO
A doença de Pompe é uma doença autossômica recessiva rara, causada por mutações 
no gene que codifica a enzima α-glucosidase ácida (GAA). A função da enzima GAA é 
degradar o glicogênio em glicose no lisossomo. Sua deficiência resulta no acúmulo de 
glicogênio no lisossomo, causando danos às células e tecidos, levando à perda de função 
celular. A ausência completa da atividade da enzima GAA causa doença de Pompe infantil 
(forma clássica), afetando recém-nascidos, levando principalmente a hipertrofia cardíaca e 
perda de músculo esquelético. Pacientes infantis ou adultos com Pompe têm um fenótipo 
mais brando porque apresentam uma atividade enzimática residual (1-20%), causando 
fraqueza muscular progressiva, problemas de mobilidade e insuficiência respiratória.
  A terapia de reposição enzimática (TRE) é utilizada como tratamento para esses 
pacientes e está disponível desde 2006 e consiste na administração intravenosa da enzima 
GAA recombinante humana. Quando tratados, pacientes com a formas infantil apresentam 
aumentos substanciais nas taxas de sobrevivência. Crianças e pacientes adultos também 
se beneficiam melhorando suas habilidades de caminhada e estabilização da função 
respiratória. Entretanto, para que os pacientes com a doença de Pompe recebam TRE, 
é necessário um diagnóstico apropriado com base na deficiência da enzima GAA e, 
preferivelmente, que sejam detectadas duas variantes associadas à doença no gene GAA. 
O Capítulo 1 da presente tese apresenta uma introdução geral à doença de Pompe bem 
como uma explicação do processo para realizar o diagnóstico enzimático e molecular.
  Atualmente, diferentes métodos e amostras podem ser utilizados na determinação 
da atividade enzimática da GAA. No entanto, o diagnóstico enzimático enfrenta algumas 
limitações, como a existência de resultados falso-positivos e falso-negativos confiáveis. 
Assim, é objetivo do Capítulo 2, relatar os métodos atualmente utilizados no diagnóstico 
enzimático da doença de Pompe e revisar o resultado de uma série de 2.591 ensaios em 
1.709 indivíduos com suspeita de ter a doença. Este capítulo apresenta os resultados nos 
quais diferentes tipos de amostras bem como diferentes métodos que foram utilizados 
nos últimos 28 anos no departamento de Genética Clínica do Erasmus Medical Center em 
Rotterdam. A fim de determinar o desempenho de cada ensaio, a atividade enzimática para 
GAA foi medida em glóbulos brancos (leucócitos) usando glicogênio ou 4-metilumbeliferil-
α-D-glucopiranosídeo (4MUG) como substrato, gotas de sangue secas (DBS) usando 
4MUG como substrato, e de fibroblastos obtidos de biópsia de pele usando 4MUG como 
substrato. As amostras de leucócitos apresentaram o método de diagnóstico mais rápido, 
em que a mistura de reação precisa conter acarbose para a inibição da glucoamilase. 
Os ensaios baseados em DBS foram considerados ferramentas valiosas para a triagem, 
mas um ensaio adicional, como por exemplo análise em leucocitos é necessário para 
confirmar o diagnóstico e evitar resultados falso-negativos. Fibroblastos de pele cultivados 
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apresentaram os melhores resultados na diferenciação entre a forma infantil, a forma juvenil 
e a forma adulta da doença de Pompe. Glicogênio e 4MUG são substratos adequados, 
mas o glicogênio é capaz de discriminar melhor indivíduos afetados de não afetados. A 
desvantagem de usar glicogênio é que os portadores da pseudo deficiência GAA2 podem 
ser diagnosticados erroneamente como pacientes de Pompe. Nesses casos, o uso adicional 
de 4MUG resultou em uma abordagem mais confiável e os resultados foram validados em 
leucócitos e / ou DBS.
  A análise genética-molecular também é uma etapa essencial para concluir o 
diagnóstico de um paciente Pompe com maior precisão. O sequenciamento Sanger 
tradicional cobrindo as áreas flanqueadoras do exon de codificação é o método mais 
comumente usado, no entanto, em alguns casos, esse método não se mostra suficiente 
para concluir o diagnóstico. No Capítulo 3, apresentamos análises aprofundadas de 
diagnóstico molecular e identificamos novas variantes genéticas associadas à doença em 
pacientes com doença de Pompe, onde a análise convencional era insuficiente. Ensaios 
adicionais, como um ensaio padrão de splicing, análise por minigene, análise de SNP array 
e sequenciamento Sanger direcionado, permitiram a identificação de uma deleção exônica, 
uma deleção do promotor bem como uma nova variante de splicing localizada na região 
5 ‘UTR do gene. Esta análise mais detalhada também é capaz de identificar um fenótipo 
atípico para a doença de Pompe detectado em um paciente no qual pôde ser explicado por 
mosaicismo genético de um segmento do cromossomo 17 que inclui GAA.
  Nosso laboratório mantém um importante banco de dados público sobre 
a compreensão da correlação genótipo-fenótipo na doença de Pompe (www.
pompevariantdatabase.nl), relacionando as variantes associadas à doença à gravidade 
clínica. Este banco de dados é fundamental para orientar os médicos e geneticistas 
clínicos a estabelecer um diagnóstico molecular preciso. Na atualização recente (Capítulo 
4), o banco de dados inclui 648 variantes associadas à doença, 26 variantes da triagem 
neonatal e 237 variantes com gravidade desconhecida. Variantes comuns (frequência do 
alelo menor(MAF) ≥ 1%) foram adicionadas em resposta a interpretação incorreta de tais 
variantes como a principal causa da doença em vários pacientes. Os dados adicionados ao 
banco de dados de variantes de Pompe contêm informações importantes sobre genótipos 
e fenótipos de diversas publicações científicas sobre a doença de Pompe. No Capítulo 5, 
apresentamos a análise de todos os dados presentes no banco para os diferentes genótipos 
GAA mais comuns com o intuito de avaliar a correlação fenótipo-genótipo. Pacientes com 
o genótipo comum c.-32-13T> G (IVS1) / GAA nulo apresentam o início de sintomas em um 
amplo espectro que varia desde a primeira infância até a idade adulta tardia. Nove variantes 
GAA distintas associadas à doença (c.2647-7G> A; c.546G> T; c. 2238G> C; c.2173C> T; 
c.1076-22T> G; c.1309C> T; c. -32-3C> A; c.1875C> G; c.1064T> C) também mostraram 
variação considerável na idade no início dos sintomas quando presente em heterozigose 
composta em combinação com um alelo nulo ou em homozigose. A variante silenciosa 
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c.510C> T está associada a c.-32-13T> G em alguns casos e está relacionada ao início 
acelerado dos sintomas. Porém, para muitos pacientes ainda não está claro por que a 
variação fenotípica ocorre para esses genótipos GAA comuns, o que sugere a influência de 
fatores modificadores.
  Fatores ambientais, bem como modificações epigenéticas e antecedentes 
genéticos podem influenciar a correlação genótipo-fenótipo. Um potencial modificador 
genômico é a configuração do haplótipo. Normalmente, os haplótipos possuem variantes 
que influenciam a expressão de transcritos de mRNA, conhecidos como eQTLs. Para 
analisar o possível impacto dos eQTLs na expressão de GAA analisamos o ambiente 
genético GAA de variantes associadas à doença, apresentado no Capítulo 6. Ao identificar 
correlações genótipo-fenótipo baseadas em haplótipos fomos capazes de definir haplótipos 
GAA mais frequentes em indivíduos europeus bem como um possível impacto na expressão 
de GAA. Apresentamos evidências de que a maioria das variantes associadas à doença 
estão presentes em haplótipos que modulam negativamente a expressão de GAA, o que 
pode levar ao aumento da sua penetrância. No entanto, a variante IVS1 foi encontrada em 
um haplótipo com efeito neutro na expressão de GAA, possivelmente sugerindo um cenário 
de seleção positiva.
  Investigamos o perfil de expressão gênica em fibroblastos para extrapolar nossa 
compreensão genética de pacientes com o genótipo comum IVS1 / GAA nulo (Capítulo 
7). Nossa análise apontou para a conclusão de que vários fatores estão possivelmente 
associados ao curso clínico dos pacientes com Pompe. Comparando o perfil de expressão 
de dois grupos de pacientes, um com início dos primeiros sintomas abaixo dos 16 anos 
e outro com início dos sintomas acima dos 35 anos, pudemos observar que três genes 
se destacaram (MAOA, STC-1 e NRK-1), sugerindo que estes podem ser marcadores de 
doença. MAOA (Monoamina Oxidase Tipo A) catalisa a oxidação de monoaminas, como 
dopamina, serotonina e adrenalina; STC1 (Stanniocalcina-1) desempenha um papel na 
regulação renal e intestinal de cálcio e transporte de fosfato, metabolismo celular ou 
homeostase celular de cálcio / fosfato; e NRK (Nik Related Kinase) está associado à 
indução da polimerização da actina em estágios tardios da embriogênese. 
  Por estarem de um modo geral associados a processos biológicos que incluem 
desenvolvimento ósseo e muscular, homeostase celular de cálcio / fosfato, metabolismo 
celular e processo metabólico de amina biogênica celular, o padrão de expressão destes 
três genes pode ser considerado como marcadores para o diagnóstico da doença doença 
de Pompe possível para pacientes com o genótipo IVS1 / nulo.
  Finalmente, o Capítulo 8 discute as principais descobertas apresentadas nesta 
tese, esclarece os métodos de diagnóstico enzimático e fornece maneiras de melhorar a 
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